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Abstract 
Title: Strategies for characterisation of the unexplored human phosphoproteome 
Author: Gemma Elizabeth Hardman 
Post-translational modification of proteins by addition of a phosphate group serves as a 
means of rapidly regulating protein function, and thus has vital roles in all aspects of cell 
biology. Phosphorylation of serine, threonine and tyrosine are the focus of the vast 
majority of studies aimed at elucidating the function of such modification in human cells. 
However, there is growing evidence that phosphohistidine (pHis) may also have a role in 
diverse cellular processes in mammalian systems.  
Characterisation of pHis is compromised by the inherent instability of the acid-labile 
phosphoramidate bond, meaning there is a severe lack of suitable experimental strategies 
to pinpoint the presence of pHis in proteins. The acidic conditions integral to current 
phosphoproteomics workflows are incompatible with analysis of acid-labile pHis. 
In this work, chemical phosphorylation was used to generate a set of model pHis-
containing peptides, for which stability of the histidine phosphorylation across a range of 
pH values and at elevated temperature was assessed. The pHis-containing peptides were 
further used to evaluate various existing enrichment strategies for their suitability for pHis. 
None of the enrichment methods tested for this work that had previously been used for 
enrichment of serine/threonine phosphopeptides enabled recovery of pHis peptides. 
Subsequently, a strong anion exchange fractionation method has been developed, which 
permits separation of pHis-containing peptides from non-phosphorylated equivalents with 
salt gradient elution at non-acidic pH. Fractions at the end of the gradient are significantly 
enriched for phosphopeptides. Crucially, the unbiased phosphopeptide enrichment by 
strong anion exchange (UPAX) method enabled recovery of pHis-peptides from complex 
cell lysates. 
The UPAX method with characterisation by LC-MS/MS has revealed extensive 
phosphorylation of histidine, lysine, arginine, aspartate and glutamate in human cell 
extract, including 310 pHis sites and over 1000 sites of lysine phosphorylation. Remarkably, 
the extent of non-canonical phosphorylation far exceeds that of phosphotyrosine, exposing 
the previously underappreciated diversity of the human phosphoproteome. 
The results of this work highlight possible roles for pHis and other sites of non-canonical 
phosphorylation in human cells. Identification of pHis at a conserved residue within the 
catalytic domain of eukaryotic protein kinases, suggests histidine phosphorylation may act 
as a general mechanism for kinase regulation. Application of the UPAX strategy for 
unbiased phosphoproteomics analysis has opened up diverse avenues for exploring roles 
and regulation of non-canonical phosphorylation sites in any proteome.  
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1. Introduction 
 
1.1. Protein Phosphorylation 
 
Protein phosphorylation is a vital post-translational modification (PTM) for the control of 
cellular processes and adaptation of cells to their environment. Reversible protein 
phosphorylation is involved in many cellular processes including carbohydrate and lipid 
metabolism, DNA transcription and replication, memory, cell migration, muscle contraction 
and cell proliferation and differentiation1. Phosphorylation of proteins was first identified in 
19062, although it was not until 1954 that the first enzymatic phosphorylation was 
discovered3. Since then it has been estimated that one-third of all proteins in eukaryotic 
cells are phosphorylated at any given time4. The most widely studied phosphorylated 
amino acids are serine (Ser), threonine (Thr) and tyrosine (Tyr), the structures of which are 
shown in Figure 1.1.  
 
Figure 1.1. Structures of phosphoserine, phosphothreonine and phosphotyrosine 
 
Reversible protein phosphorylation is regulated by kinases and phosphatases. Kinases 
enable the transfer of a phosphate group from adenosine triphosphate (ATP) to a specific 
amino acid in a substrate protein, whilst phosphatases are responsible for the removal of 
phosphate groups from proteins. The addition of a phosphate group to a protein can cause 
significant conformational changes, thus changing the activity of the protein. Changes in 
localised charge, and electrostatic and hydrophobic interactions can also be conferred by 
the addition (or removal) of a phosphate group. Thus, protein phosphorylation modulates 
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inter- and intra-cellular signalling, and can also regulate protein stability, protein binding 
and sub-cellular localisation.  The site and stoichiometry at which phosphorylation occurs 
has a direct impact on protein function, therefore identifying sites of phosphorylation is 
vital for understanding how complex networks of phosphorylation events modulate cellular 
activity. Abnormal phosphorylation is implicated in a variety of diseases, such as cancer, 
diabetes and rheumatoid arthritis, further highlighting the importance of studying protein 
phosphorylation in human systems. 
 
As well as Ser, Thr and Tyr a number of other amino acids can be phosphorylated, including 
histidine (His), arginine (Arg), lysine (Lys), aspartate (Asp), glutamate (Glu) and cysteine 
(Cys)5.  Whilst there are reports of these modifications and/or related kinase activity 
occurring in mammalian systems, the extent of this non-canonical phosphorylation on 
human proteins and the possible functions they may have are still largely unknown6-8.   The 
characterisation of pHis in human cells is the primary focus of this work. 
 
1.1.1 Phosphohistidine 
Histidine can be phosphorylated in either the 1- or 3- positions, resulting in two biologically 
relevant pHis isomers (Figure 1.2).  
Figure 1.2 Structures of 1- and 3-phosphohistidine 
 
The function of pHis in prokaryotes, fungi and plants is well documented in the context of 
the two-component system of intracellular signalling, but there is no evidence for two-
component signalling in mammalian systems. It has however been  estimated that histidine 
phosphorylation accounts for ~6% of the total phosphorylation in nuclear extracts of model 
eukaryotes9, meaning this modification may be more extensive than pTyr, although the 
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abundance of pHis in the cytoplasm is yet to be assessed. There is little doubt about the 
presence of histidine phosphorylation in mammalian systems which was first reported in 
human cells over 50 years ago10, and there is growing evidence for the roles pHis may have 
in cellular signalling in these systems. However, widespread characterisation of histidine 
phosphorylation and its functions in human cells is still lacking. 
 
Two-component systems 
The two-component system is a widespread and fundamental mechanism of signal 
transduction in prokaryotes. Based on the phosphotransfer reaction between His and Asp 
residues, the two-component system is responsible for conversion of extracellular signal 
recognition to a cellular response, i.e. via transcriptional regulation. Although eukaryotic 
signalling is dominated by Ser, Thr and Tyr phosphorylation, the two-component system 
has been reported in a number of lower eukaryotes including yeast, fungi and plants11, 12. 
 
The two-component system consists of a sensor histidine kinase and a response regulator 
(Figure 1.3). Functional histidine kinases in the two-component system are homodimeric. 
When the sensor domain of the histidine kinase receives an appropriate stimulus (e.g. 
ligand binding), a conformational change occurs. This brings the kinase domain of one 
subunit close to the His phosphorylation site of the other subunit, enabling 
phosphorylation on this His residue to occur. Phosphotransfer from a His to an Asp residue 
located in the receiver domain of the response regulator then ensues. This Asp 
phosphorylation event relieves inhibition of the output domain which enables the 
downstream function, usually transcriptional activation, to be performed. In eukaryotic 
systems sensor histidine kinases are almost exclusively hybrid kinases, whereby the 
histidine kinase also contains a response regulator domain. 
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Figure 1.3 Schematic of the two-component system. Phosphorylation of a His in the 
dimerization domain of a sensor histidine kinase by the histidine kinase domain of the 
other subunit in the homodimer occurs in response to binding of an external stimulus to 
the sensor domain. This phosphoryl group is transferred to an Asp residue in the receiver 
domain of the response regulator which initiates a cellular response (adapted from Besant 
et al.13) 
 
The typical two-component system is exemplified by the osmoregulatory system in E. coli. 
The mechanism of His-Asp phosphotransfer between the sensor histidine kinase EnvZ and 
response regulator OmpR enables detection of extracellular osmotic conditions and a 
resulting transcriptional response to regulate expression of outer membrane proteins 
OmpF and OmpC14.  In eukaryotes two-component systems typically consist of more than 
two proteins. A His-containing phosphotransfer factor can acquire and transfer a 
phosphoryl group from and to a receiver domain to form a sequential His-Asp-His-Asp 
phosphotransfer pathway, known as a “multistep phosphorelay”. For example, in the 
fission yeast S. pombe, phosphorelay signalling  between three hybrid histidine kinases 
(Phk1/Mak2, Phk2/Mak3 and Phk3/Mak1), a His-containing phosphotransfer (Spy1) and 
two downstream response regulators (Mcs4 and Prr1) are implicated in oxidative stress 
responses, mitotic control and sexual development15. This type of phosphorelay 
mechanism also extends to signalling in plants. The first histidine kinase identified in plants 
was an ethylene sensor ETR1, discovered in Arabidopsis thaliana. Further identification of 
histidine kinases, His-containing phosphotransfer factors and responses regulators indicate 
a role for the two-component system in ethylene and cytokinin signalling. These plant-
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specific hormones regulate almost all aspects of a plants life cycle, including seed 
germination, fruit ripening and flower development16. 
 
pHis in mammalian systems 
In mammalian systems, transmembrane Tyr kinase receptors initiate similar responses to 
external stimuli that are performed by two-component systems in prokaryotes and lower 
eukaryotes. Sequence comparisons indicate the existence of a few proteins in higher 
eukaryotes with His kinase or response regulator motifs analogous to those in two-
component systems, but there is no strong evidence for their wide-spread existence or 
functional role in mammalian systems17. The presence of pHis in mammalian systems has 
however been known for some time, with growing evidence for its involvement in 
mammalian signalling. Phosphorylated His residues are known to function as catalytic 
intermediates in phosphotransfer reactions18-20, an example being phosphorylation of a 
conserved His residue within the catalytic core of the histidine tyrosine phosphatase, TULA-
2. Thus, pHis has been implicated in glycoprotein VI signalling in platelets and bone 
remodelling21, 22. His phosphorylation also functions as a mechanism for reversible 
regulation of protein function. Phosphorylation of His has been implicated in the 
differentiation of PC12 neuronal cells, with nerve growth factor inducing a 3-fold increase 
in levels of histidine kinase activity against an exogenous substrate23. Moreover, Ras-
dependent His phosphorylation of a 38 kDa protein from rat liver plasma is differentially 
regulated during cell division24.  The kinases and phosphatases involved in pHis regulation 
are however still largely unknown. 
 
The only mammalian histidine kinases reported to data are NME1 and NME2 (also known 
as nucleoside diphosphate kinases A and B; NDPK-A and NDPK-B), both of which are 
implicated in cancer and tumour metastasis25-27. With respect to histidine kinase activity a 
handful of NME1/2 substrates are currently known, including the β-subunit of 
heterotrimeric G-proteins, the metabolic enzyme adenosine 5-triphosphate-citrate lyase 
(ACL), the Ca2+ activated K+ channel KCa3.1 and the epithelial Ca2+ channel TRPV528-31. 
Regulation of His phosphorylation of these proteins is further achieved by activity of 
phosphohistidine phosphatase 1 (PHPT1). This is an evolutionarily conserved 14 kDa 
protein which until very recently was the only known example of a His phosphatase in 
mammalian systems32, 33. PHPT1 has been shown to directly bind to and inhibit KCa3.1 by 
dephosphorylating His358, a His residue which is phosphorylated by NME234, thus 
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indicating a role for pHis in T-cell signalling. Phosphoglycerate mutase 5 (PGAM5) has also 
been shown to demonstrate His phosphatase activity, specifically against NME2, resulting 
in inhibition of NME2 mediated His phosphorylation of KCa3.135.  Interestingly, it seems as 
though PHPT1 and PGAM5 dephosphorylate different isomers of pHis, at least in this 
example. 
 
A number of other proteins have been identified as containing pHis, including P-selectin36, 
annexin-I37 and histone H438, although the kinases responsible for their phosphorylation are 
yet to be discovered. In the case of histone H4, kinase activity was first reported in nuclei of 
rat liver cells and Walker-256 carcinoma cells in the 1970s39, 40, but despite similar activity 
being observed in a number of tissues and cell types, purification and identification of the 
kinase has not yet been achieved. Histone H4 kinase activity appears to be associated with 
proliferating cells; there is a large increase in activity preceding proliferation of 
hepatocytes, and high histone H4 kinase activity is observed in hepatocellular carcinoma 
cells whilst activity in surrounding tissues is low41-43.  
 
The slow progress in studying pHis, particularly on a proteome wide scale, stems from the 
technical difficulties associated with analysis of this labile modification. The inherent 
instability of His phosphorylation under acidic conditions and at elevated temperature 
means that typical biochemical techniques and proteomics workflows, such as gel 
electrophoresis and acidic liquid chromatography (LC) conditions, are not necessarily suited 
to analysis of pHis (as discussed further in section 1.5). Consequently, there is still much to 
be uncovered about the roles of this modification in mammalian systems. 
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1.2 Proteomics 
 
Proteomics is the study of the complete protein complement expressed by a genome44. A 
proteome is a dynamic population of proteins, defined by a given cell at a specific time, 
with consideration required for protein isoforms and modifications45. The field of 
proteomics as a whole covers the determination of protein structure, protein-protein 
interactions, expression levels and localisation of modifications. Techniques for proteomics 
analysis include array-based systems, structural and imaging tools, and mass spectrometry 
(MS), with the latter being the focus of this work.  
 
Proteomics was originally focused on the use of 2D gel electrophoresis, however this was 
not without its limitations, including difficultly analysing hydrophobic and large molecular 
weight proteins, a limited dynamic range, problems with visualisation methods and issues 
with reproducibility46, 47. Although for a time 2D gel electrophoresis was used alongside MS 
techniques, more recent advances have seen a move away from the use of 2D gels. Modern 
MS approaches enable in depth proteomics analysis of a variety of biological systems 
through the use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
experiments. It is arguably the vast developments in MS that have driven the field of 
proteomics forwards so rapidly in the last 20 years. 
 
1.2.1 Mass spectrometry 
A general schematic of a mass spectrometer is shown in Figure 1.4, consisting of four main 
elements: ionisation source, mass analyser, detector and a data system. The ionisation 
source generates ions and introduces them into the mass spectrometer. From here ions are 
guided to a mass analyser where they are separated based on their mass to charge (m/z) 
ratio. Ions are detected and information recorded to generate a mass spectrum; m/z is 
plotted against the ion intensity. Typically, for proteomics experiments tandem MS analysis 
will be performed. The first stage (MS1) is the recording of a full mass spectrum, i.e. 
detection of all ions across a designated m/z range at a given time. Ions of a desired m/z 
are then isolated and undergo fragmentation, with the resulting product ions recorded in a 
second stage of mass analysis (MS2). A number of fragmentation techniques are available 
for the purpose of generating product ions, such as collision induced dissociation (CID) and 
electron transfer dissociation (ETD), which are discussed in more detail in section 1.2.1.3. 
Tandem MS analysis can be performed either in time, i.e. all stages of MS analysis are 
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performed sequentially in the same mass analyser, or in space whereby MS1 and MS2 are 
conducted in different mass analysers within the mass spectrometer. In a TopN approach 
to tandem MS analysis, the ‘n’ most abundant precursor ions are selected to undergo MS2 
analysis. Typically, a ‘dynamic exclusion’ time window is set, during which ions with an m/z 
that has already been fragmented will not be selected for fragmentation again.  
 
Many modern mass spectrometers are hybrid instruments, which incorporate various 
combinations of mass analysers. The Bruker Amazon mass spectrometer used in this work 
consists of just one 3D ion trap, whilst the Thermo Orbitrap Fusion mass spectrometer 
incorporates a quadrupole mass filter, linear ion trap and an Orbitrap. 
 
 
 
 
Figure 1.4 Schematic of a typical mass spectrometer. Sample is introduced into the 
instrument via a (nano-)electrospray emitter. Gaseous ions are produced at the source and 
are resolved based on m/z in the mass analyser. Tandem MS experiments can be 
performed in a single mass analyser or more than one analyser may be used (either of the 
same or a different type). Ions are detected and this information recorded by a data 
system. The blue box indicates parts of the mass spectrometer operated under high 
vacuum. 
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1.2.1.1 Electrospray ionisation 
The first stage of MS analysis is the generation of ions, with the requirement for “soft” 
ionisation techniques being critical for non-destructive ionisation of large biomolecules, 
such as peptides. Electrospray ionisation (ESI) is one such “soft” ionisation technique, first 
demonstrated for the transfer of large molecules onto the gas phase by Fenn et al. in the 
1980s, and for which he was awarded the Nobel Prize48, 49. Further development of the 
technique allowed much lower flow rates to be used, whilst providing increased 
desolvation and ionisation efficiency, so called nano-ESI50, 51. ESI is performed under 
atmospheric pressure, with the application of a strong electric field and high temperature 
to a capillary from which the liquid sample is sprayed resulting in the formation of ions in 
the gas-phase. ESI results in the formation of multiply charged ions in the form of 
protonated adducts [M+H]+, [M+2H]2+, M+nH]n+. There are two models used to describe the 
generation of these gas-phase ions from sprayed droplets: the ion evaporation model and 
the charge residue model (Figure 1.5). 
 
 
Figure 1.5 Gaseous ion formation by electrospray ionisation (ESI), described by either the 
ion evaporation model or charge residue model. Grey circles represent peptides, with blue 
outlines indicating droplets formed during ESI. 
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In the ion evaporation model droplets shrink by evaporation as a result of heat or a flow of 
gas. As a droplet shrinks, electrostatic repulsion increases up to the point at which the 
repulsion exceeds the surface tension of the droplet. At this point, known as the Rayleigh 
limit, solvated ions are expelled from the droplet52, 53 . In the charge residue model, a highly 
charged droplet shrinks by evaporation until a characteristic Taylor Cone shape is formed. 
From the tip of the Taylor Cone, smaller highly charged droplets are emitted, with this 
process repeating itself until a droplet containing only one analyte ion is formed. This 
analyte ion is transferred to the gas phase by further solvent evaporation and 
declustering50, 54. The current consensus regarding these two models is that larger 
molecular ions (>1000 Da) are generated in line with the charge reside model, whilst 
smaller ions are more likely to be generated according to the ion evaporation model55. 
 
1.2.1.2 Mass analysers 
Once gaseous ions enter the mass spectrometer they are guided to a mass analyser, 
whereby their m/z is determined. There are many different types of mass analyser, each 
performing m/z separation in a different way, although generally using a magnetic or 
electric field, or both. The two types of analyser found in the MS instrumentation used in 
this work are the ion trap and the Orbitrap, which are discussed in more detail below. 
 
Ion trap 
An ion trap mass analyser uses an oscillating electric field to store ions. There are two types 
of ion trap: the 3D (or Paul) ion trap, and the 2D (or linear) ion trap (Figure 1.6). First 
described in 196056, a 3D ion trap consists of a circular electrode with two ellipsoid 
electrodes at the top and bottom. Application of an RF voltage to the ring electrode whilst 
the end-cap electrodes are held at ground potential results in generation of a 3D 
quadrupolar field, which traps ions in a 3D trajectory, similar to a figure of eight. Helium 
gas in the trap removes excess energy from the ions meaning they oscillate at the centre of 
the trap where the quadrupolar field is more homogeneous, therefore giving a more 
uniform ejection process and improved performance57, 58.  
 
To perform mass analysis using an ion trap, all ions across the desired mass range are 
simultaneously trapped then sequentially ejected in order of mass by ramping the RF 
voltage applied to the ring electrode. Increasing the RF voltage causes the trajectory of ions 
to become unstable meaning they are expelled from the trap through the end cap 
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electrode to the detector. One problem with performing mass analysis in this way is that as 
the trajectories become unstable, some ions will be closer to the end cap than others, 
meaning ions with the same m/z may leave the trap at different times. To overcome this, 
mass analysis can instead by performed by resonant ejection. Here, the end-cap electrodes 
are supplied with an RF voltage which matches the frequency of oscillation for ions of a 
given m/z. This resonant excitation increases the amplitude of the oscillations causing the 
ions to be ejected. All ions of a given m/z will oscillate as a group so are ejected 
simultaneously when the resonant frequency is applied. By this principle ions of a desired 
m/z can also be selected to remain in the trap, whilst all others are ejected. If the 
frequencies applied to the end-cap electrodes are resonant with all ions not required, they 
will all be ejected leaving the ions with the desired m/z in the trap where they can undergo 
fragmentation for MS/MS analysis.  
 
A linear ion trap consists of four quadrupoles with lenses at either end, meaning ions are 
confined in the radial dimension by a quadrupolar field and the axial direction by an electric 
field. Ions fly along the trap between the end electrodes, whilst oscillating due to the RF 
potential applied to the rods. As with the 3D trap, helium gas is used for cooling. Mass 
analysis is also performed in the same way as the 3D ion trap, either by increasing the 
voltage to cause ions to become unstable and be ejected from the trap, or by resonant 
ejection. Again, ions with a single m/z can be isolated in a linear ion trap to undergo 
fragmentation. When ions are ejected from a linear ion trap they leave via slots in two 
opposite rods. A detector at each of these slots means that all ions that leave the trap are 
analysed59, 60. Linear ion traps also have a higher ion storage capacity than 3D ions traps as 
a result of having a larger volume, and ions being focused along a line rather than a single 
point. Ion capacity is important as too many ions in the trap can cause space-charging 
effects, whereby ions nearer the edges of the trap act a shield and modify the field acting 
on the ions towards the centre, thus leading to decreased resolution and errors in mass 
measurement. In both types of ion trap this can be overcome by setting the automatic gain 
control (AGC) which is the maximum abundance of ions allowed in the trap61. 
 
Fragmentation reactions, by CID or ETD can be performed in both 3D and linear ion traps. 
By applying a frequency that is resonant with the isolated ions, only these ions undergo 
fragmentation, i.e. product ions do not fragment further as they are not in resonance. 
Product ions of interest can be isolated to perform additional rounds of fragmentation; 
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known as MSn analysis. One limitation of performing fragmentation in an ion trap is known 
as ‘the one-third rule’. This states that product ions with m/z less than one-third of the 
isolated precursor will have unstable trajectories and hence will be ejected before they are 
detected/analysed. 
 
 
 
Figure 1.6 Ion trap mass analysers. a) 3D (or Paul) ion trap whereby application of an RF 
voltage to the ring electrode whilst the end-cap electrodes are held at ground potential 
results in generation of a 3D quadrupolar field, trapping ions in a 3D trajectory. b) 2D (or 
linear) ion trap whereby ions fly along the trap between the end electrodes, whilst 
oscillating in the radial dimension due to the RF potential applied to the four quadrupoles.  
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Orbitrap 
The Orbitrap mass analyser was developed by Makarov in the 1990s62, 63. It consists of an 
outer ‘barrel-shaped’ electrode cut into two equal parts, and an inner electrode shaped like 
a spindle (Figure 1.7). Ions are injected as short packets into the Orbitrap, from the ‘C-trap’, 
at a position offset from its equator and perpendicular to its z-axis, which runs along the 
spindle electrode. Each ion packet contains ions of a single m/z, which immediately start 
coherent axial oscillations without the need for additional excitation. Stable ion trajectories 
in the Orbitrap involve an orbiting motion around the central electrode and simultaneous 
oscillations in the z-direction, along the length of the inner electrode. The frequency of 
oscillation along the z-axis is directly linked to the m/z of an ion, and is independent of the 
ions initial position or energy. The current induced by these oscillating ions is detected on 
the outer electrodes, a process termed image current detection. This time-domain signal is 
converted using a Fourier Transform into a mass spectrum. The main advantages of an 
Orbitrap mass analysers are the high resolution and high mass accuracy that can be 
achieved, plus a larger trapping volume compared to a 3D ion trap. The latest commercial 
Orbitrap instruments can deliver resolution of up to 1,000,000 FWHM at m/z 200, with 
sub-1 ppm mass accuracy. 
 
Figure 1.7 Orbitrap mass analyser. Ions oscillate around the inner electrode and axially 
along the length of it, with the frequency of these axial oscillations being dependent on 
m/z. The outer electrodes measure the current induced by oscillating ions, and a Fourier 
Transform converts the signal to a mass spectrum 
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1.2.1.3 Fragmentation 
As previously discussed, tandem MS analysis is typically used for proteomics experiments. 
All ions across a designated m/z range are detected (MS1), and then precursor ions are 
isolated and fragmented to produce product ions which are recorded in a second stage of 
mass analysis (MS2). A number of different fragmentation techniques can be used to 
fragment the precursor ions, each with its own benefits and potential shortcomings for a 
particular type of experiment. 
 
Collision-induced dissociation (CID) 
CID is a generally considered as a two-step process. Firstly, ions are excited by collisions 
with an inert gas which results in transfer of kinetic energy into internal energy. In the 
second stage of the process this activated ion undergoes dissociation. As the activation 
time is much faster than the dissociation time, energy is distributed throughout the 
molecule prior to fragmentation, resulting in preferential cleavage of the weakest bonds. 
Peptide fragmentation by CID generally occurs via charge-directed pathways, i.e. 
fragmentation involves a proton at the cleavage site, which can be further described by the 
‘mobile proton model’64-66. This model states that whilst protonation of a peptide will occur 
at the most basic sites, activation of the peptide will allow a proton to move to other less 
basic sites along the peptide backbone, thereby directing cleavage of the C-N bond at these 
positions. Fragmentation of peptides by CID generally results in b- and y-type ions, arising 
from cleavage of the amide bond with the charge retained by either the amino-terminal 
fragment (b-ions) or carboxy-terminal fragment (y-ions). Nomenclature associated with 
peptide fragmentation is shown in Figure 1.867, 68.  
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Figure 1.8 Peptide fragmentation nomenclature. Ions are labelled consecutively from the 
amino terminus an, bn and cn, and from the carboxy terminus xn, yn and zn, where n is the 
number of amino acid R groups the ion contains. Cleavage of amide bonds results in b-ions 
when the charge is retained by the amino terminal fragment and y-ions when it is retained 
by the carboxy terminal fragment. Cleavage of the N-Cα bond results in c-ions when the 
charge is retained by the amino terminal fragment and z-ions when it is retained by the 
carboxy terminal fragment. A loss of C=O from a b-ion can account for the occurrence of a-
ions. Double backbone cleavage, usually a result of a combination of b- and y-type cleavage 
produces internal fragment ions. A combination of a-type and y-type cleavage results in 
formation of an immonium ion. 
 
Higher-energy collisional dissociation (HCD) 
Whilst traditional CID is typically associated with lower resolution ion-trap based 
instruments, HCD was developed to be used alongside high resolution Orbitrap detection69. 
HCD fragmentation occurs in a collision cell containing an inert gas that is supplied with a 
high RF voltage. Compared to CID, the higher energy dissociations associated with HCD 
result in a wider range of fragmentation pathways. The generation and detection of 
immonium ions and other secondary fragments can aid in sequence determination and 
detection of post-translation modifications. HCD is considered to be similar to ‘beam-type’ 
collisional activation, producing similar spectra to those generated by CID in triple 
quadrupole and Q-TOF instruments. Fragmentation spectra of this type are generally 
dominated by y-ions, with b-ions further fragmenting to a-ions or smaller species70. 
 
Electron transfer dissociation (ETD) 
ETD was developed in 2004 as a way to access the alternative fragmentation mechanisms 
of electron capture dissociation (ECD), for which an FT-ICR mass spectrometer is required71. 
Dissociation mediated by electrons (ETD and ECD) is generally thought to be a non-ergodic 
process, meaning that the activation occurs on a rapid timescale so bond dissociation 
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occurs without prior randomisation of internal energy. Therefore, fragmentation is not 
driven by proton localisation or bond strength, making it particularly attractive for the 
analysis of peptides with post-translational modifications, as the labile covalent 
modification remains attached to the original modified amino acid residue.  
 
ETD is achieved by first generating reagent anions by chemical ionisation (CI). An inert gas is 
bombarded with 70 eV electrons to generate positively charged ions plus a population of 
electrons with near-thermal kinetic energy. These electrons are captured by the reagent 
gas, typically fluoranthene, to produce radical anions. Electron transfer occurs from the 
radical anion reagent to protonated peptide ions. ETD induces cleavage of the N-Cα bond, 
with the product ions formed termed c- and z∙- type ions; the charge can be retained by 
either the amino-terminal fragment (c-ions) or carboxy-terminal fragment (z∙-ions). 
 
ETD is widely considered to be a complementary technique to CID72-75. For peptides with 
charge states greater than 2+, ETD can outperform both CID and HCD in terms of sequence 
coverage and thus peptide ion scores. A potential problem with ETD fragmentation is the 
occurrence of non-dissociative electron transfer, i.e. non-covalent interactions bind c- and 
z-ions together and thus they are not observed as ETD product ions in the mass spectrum. 
However, this lack of ETD product ion dissociation can be overcome by the use of 
supplemental activation, where low energy CID is applied following the ETD reaction, 
thereby breaking apart these non-dissociated ion pairs. This technique (termed ETcaD) 
results in a significant improvement over ETD fragmentation alone, especially for doubly 
charged peptides76. A further development of ETcsD is the integration of both ETD and HCD 
fragmentation to produce a mixed spectrum of b/y and c/z ions for a given precursor. The 
application of HCD following ETD results in fragmentation of the unreacted and charge 
reduced precursor ions to produce information rich fragment ion spectra77. Higher 
sequence coverage and improved phosphosite localisation are achieved with this method 
(termed EThcD) compared to HCD alone78 with many benefits demonstrated in using this 
technique for analysis of peptide and protein post-translational modifications79-81.  
 
 
1.2.1.4 Thermo Orbitrap Fusion  
The Thermo Orbitrap Fusion mass spectrometer used in this work offers an extremely 
flexible arrangement of mass analyser and fragmentation techniques82, 83, with a number of 
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features able to be exploited to perform high quality phosphoproteomics analysis. The 
tribrid Orbitrap Fusion incorporates a quadrupole mass filter, linear ion trap and Orbitrap, 
as shown in Figure 1.9. As one of the most advanced mass spectrometers currently 
available for proteomics, the Orbitrap Fusions is capable of achieving 500,000 resolving 
power at m/z 200. 
 
Operation of the Orbitrap and ion trap mass analysers can be parallelized to maximise the 
time available for MS1 and MS2 analysis. Isolation can be performed with the quadrupole 
mass filter or the ion trap mass analyser. Fragmentation can be performed using HCD, CID, 
ETD, ETcaD and EThcD, with these available for any level of MSn analysis. The precursor and 
fragment ions can subsequently be detected using either the Orbitrap or ion trap mass 
analysers, representing the first time detection of HCD fragment ions by ion trap has been 
possible in a commercial instrument. Additionally, rather than a traditional TopN approach 
typically used for bottom-up proteomics, the ‘TopSpeed’ mode implements a defined cycle 
time during which the maximum number of MS/MS scans are performed. There are a vast 
number of combinatorial possibilities for tandem MS available on the Orbitrap Fusion 
platform. This large degree of flexibility allows for many variations in experimental design 
to suit a particular type of experiment.  
 
 
 
Figure 1.9 Thermo Orbitrap Fusion mass spectrometer. Includes a quadrupole mass filter, 
linear ion trap and Orbitrap for sensitive, rapid and flexible analysis 
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1.2.2 Mass spectrometry-based proteomics 
MS-based proteomics is used to reveal a wealth of information about a huge variety of 
biological systems, from yeast to bacteria, from plants to humans84-87. MS-based 
proteomics is able to answer questions about protein structure88, protein-protein 
interactions89, 90, spatial distribution of proteins within different tissues and localization to 
subcellular organelles91, 92, and post-translational modifications93-95. Additionally, in-depth 
analysis of whole proteomes provides valuable information for systems biology. 
 
In a ‘bottom-up’ approach to proteomics, as illustrated in Figure 1.10, proteins are 
extracted from the cells, tissue or bodily fluid of interest. These proteins are then reacted 
with a reducing agent (e.g. dithiothreitol, DTT) to break disulphide bridges, and an 
alkylating agent (e.g. iodoacetamide) to prevent cysteine residues from reforming disulfide 
bonds, before being digested using a protease to generate a mixture of peptides. The most 
commonly used protease is trypsin which selectively cleaves at the C-terminus of arginine 
and lysine residues (except if followed by proline). At this point an enrichment step can be 
conducted if required, to isolate peptides of interest (e.g. phosphopeptides), or 
fractionation strategies, such as ion exchange or high pH reversed phase chromatography, 
may be carried out to increase depth of proteome coverage.  The resulting peptide mixture 
is then subjected to liquid chromatography (LC), where peptides are separated on the basis 
of their hydrophobicity. Typically, peptides bound to a C18 column are eluted by increasing 
the concentration of acetonitrile. The LC system is coupled in-line with a mass 
spectrometer via ESI, and the peptide ions are analysed by tandem MS as they elute from 
the LC column. Tandem mass spectra are searched against a database of all possible 
protein sequences in the sample with specially designed algorithms, to infer peptide 
identities and consequently the presence of an expressed gene product (protein identity). 
Further details regarding analysis tandem MS data can be found in section1.4.1. In the 
alternative ‘top-down approach’, intact proteins are analysed rather than their constituent 
peptides. Unlike ‘bottom-up’, ‘top-down’ proteomics reveals information about different 
protein isoforms, including phosphoforms, which is inevitably lost using the ‘bottom-up’ 
approach96-99. 
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Figure 1.10 Bottom up proteomics workflow. Following extraction from the sample of 
interest, proteins are digested into peptides before undergoing LC-MS/MS analysis. 
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Bottom-up proteomics experiments can be further divided into quantitative or qualitative 
analysis. Qualitative experiments are designed to reveal the identity of the proteins in a 
biological system, which may include any PTMs the proteins have, whilst in a quantitative 
proteomics experiment the purpose is to determine the levels of protein expression and 
how they change over time or space, in various cellular states or in response to external 
stimuli.  
 
Absolute quantification reports an absolute value for a given protein, for example in 
protein copies per cell, whilst relative quantification defines the degree of change for an 
individual protein between two or more conditions. Furthermore, quantitative experiments 
can be performed using either isotope labelling (labelled) or label-free approaches. Label 
free approaches arguably offer greater flexibility in experimental design, with comparison 
possible across many samples simultaneous without the requirement for extra 
experimental steps, although the can suffer from greater experimental error as samples 
must be processed independently. Label free quantification can be achieved by spectral 
counting, which is based on the observation that more abundant peptides will produce a 
higher number of MS/MS spectra100 or by using peak area as a measure of peptide 
abundance101. An alternative approach termed ‘Hi3’ allows for absolute label-free 
quantification using the fact that the average abundance of the three most intense tryptic 
peptides is proportional to protein amount102. 
 
Labelling for quantitative proteomics experiments can be metabolic, for example using 
SILAC (stable isotope labelling by amino acids in cell culture)103, or by chemical methods 
such as iTRAQ (isotope tags for relative and absolute quantification) or TMT (tandem mass 
tags)104, 105.  Briefly, for a SILAC experiment cells are grown in a medium containing either 
‘heavy’ or ‘light’ amino acids. For the ‘heavy’ culture the 13C6/
15N7 stable isotope-labelled 
versions of arginine and/or lysine are often used, whilst the ‘light’ culture will contain 
naturally occurring isotopes. The samples can be mixed immediately after harvesting of the 
cells which means any variability in the workflow applies equally to both samples. The 
‘heavy’ and ‘light’ peptides will co-elute from the LC, but will demonstrate a mass shift in 
the mass spectrometer as a result of the labelled arginine/lysine residue. The ratios 
between the ‘heavy’ and ‘light’ peptides reflect the relative changes in abundance between 
the samples. Chemical incorporation of isotope tags, either by iTRAQ or TMT, is typically 
performed at the peptide level. Peptides from different samples are labelled with the 
Chapter 1. Introduction 
 
21 
 
isobaric stable isotope tags, which consist of a reporter, balance and reactive region, and 
the samples are then mixed. In the MS1 spectra peptides appear a single precursor, but 
upon fragmentation the reporter ions are released from the tag, each of which has a 
distinct m/z value due to different combinations of 13C and 15N isotopes. The abundance of 
each reporter ion provides quantitative information regarding the peptide (and 
subsequently protein) abundance between samples. The TMT technology, alongside high-
resolution mass spectrometry is able to provide up to 11-plex multiplexing of samples.  
 
Using data dependent acquisition (DDA) methods, whereby precursor ions are sequentially 
selected for tandem MS can prove problematic for quantitative proteomics. These methods 
are somewhat stochastic, meaning the same peptide may not always be selected for 
MS/MS across multiple runs and thus ‘missing values’ can impede quantification of all 
peptides/proteins of interest in a sample. As an alternative approach data independent 
acquisition (DIA) methods are available. Here, all precursor ions at a given moment in time 
are simultaneously fragmented and the resulting mass spectrum containing all fragment 
ions from all precursor species is recorded. Such a method can be implemented on Waters 
TOF instruments, and is termed MSE 106. Alternatively, rather than fragmenting the entire 
mass range smaller mass windows (e.g. 25 Da) can be isolated and fragmented in a 
sequential manner until the whole mass range in covered. This technique is called SWATH, 
and is implemented on Sciex TripleTOF and Q-TOF instruments107. 
 
Defining protein PTMs, whether in a qualitative or quantitative approach, is an important 
area of MS based proteomics research. There are more than 300 different types of PTM, 
including phosphorylation, glycosylation, acetylation, ubiquitination and many more108. Any 
given gene product can be present in several modified forms, with different combinations 
of sub-stoichiometric modifications giving rise to a high degree of heterogeneity within the 
proteome. This makes comprehensive characterisation of post-translationally modified 
proteins particularly challenging. 
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1.3 Phosphoproteomics 
Phosphoproteomics is a branch of proteomics specifically concerned with examining the 
phosphorylation state of proteins. Early phosphoproteomics was low throughput, usually 
only able to study the phosphorylation of one protein at a time. Some of the first MS-based 
phosphoproteomics experiments used a technique known as differential peptide mass 
mapping. Enzymatic dephosphorylation of peptides was monitored by MS, with a mass 
shift of 80 Da between peptides signals before and after treatment with alkaline 
phosphatase indicative of a peptide having previously contained a phosphorylated 
residue109, 110. To study even tens of phosphoproteins from a single experiment typically 
required 2D gel separation of proteins followed by individual mapping of phosphopeptides 
from each spot111.  
 
Identification of phosphopeptides from fairly complex mixtures could be performed with 
tandem quadrupole mass spectrometers.  Using a “neutral loss scanning” method a mass 
offset of 98 Da between two quadrupole mass analysers means that only ions which lose 
H3PO4 reach the detector, and hence these phosphopeptides are selected for further 
sequence determination112. The “precursor ion scanning” method works in negative ion 
mode; ions with m/z 79 formed by release of PO3
- from phosphopeptides are detected, 
with the corresponding precursor ion subsequently selected for MS/MS in positive ion 
mode113, 114. The low abundance of phosphopeptides in complex mixtures meant large 
quantities of sample were required for such analyses, and even then identification of the 
modified site remained a challenge. 
 
Early improvements in LC-MS/MS based proteomics strategies also increased throughput of 
phosphoproteomics experiments, but even in the early 2000s only a few hundred modified 
peptides could be identified from a single sample, despite extensive pre-fractionation or 
phosphopeptide enrichment115, 116. In recent years, further development of protocols to 
enrich phosphopeptides from complex mixtures and advances in MS instrumentation and 
methods to enable faster, higher resolution analysis and more efficient identification of 
phosphopeptides, have driven the field towards high-throughput analysis. Current 
phosphoproteomics experiments report identification of up to tens of thousands of 
phosphosites from whole cell types, tissues or organisms92, 94. Crucially, phosphoproteomics 
is able to answer important questions about complex biological systems.  Temporal profiles 
of phosphorylation have been studied in a number of systems, revealing the dynamic 
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nature of phosphorylation in response to external stimuli117, 118. Additionally, 
phosphoproteomics can be used to reveal e.g. aspects of tumour biology governed by 
phosphorylation mediated signalling, whilst both the direct and off-target effects of drugs 
to treat diseases such as cancer through inhibition of kinase activity can also be studied 
using phosphoproteomics approaches119. Comprehensive analysis of the phosphoproteome 
is thus vital for understanding human health and disease. 
 
1.3.1 Phosphopeptide enrichment 
Protein phosphorylation often occurs at sub-stoichiometric levels which means that 
detection of phosphorylated peptides amongst an excess of non-phosphorylated peptides 
is particularly challenging. Compounded by the fact that ionisation of phosphorylated 
peptides is reported to be suppressed by the presence of non-phosphorylated peptides, a 
phosphopeptide enrichment step is an essential stage of any phosphoproteomics 
experiment. An additional consideration for large-scale phosphoproteomics is the possible 
requirement to further reduce sample complexity and thereby increase depth of 
phosphoproteome coverage through the use of a fractionation strategy. 
 
There are a number of strategies available for selective analysis of phosphopeptides from a 
complex mixture. The general principle of such strategies is to bind phosphopeptides to a 
solid support, allowing non-phosphorylated peptides to be discarded. A sample enriched 
for phosphopeptides is thus obtained, making downstream analysis of these peptides more 
effective. 
 
Immobilized metal ion affinity chromatography (IMAC) 
IMAC is one of the most extensively used phosphopeptide enrichment techniques. This 
method is based on the affinity of the negatively charged phosphate group for metal ions, 
such as Fe3+ or Ga3+, which are chelated to a solid support120, 121. Phosphopeptide 
enrichment by IMAC can suffer from interference from acidic non-phosphorylated 
peptides, due to binding of the carboxyl groups to the metal ions. The very low pH required 
to fully protonate these residues can result in leaching of the metal from the IMAC 
material122. One proposed alternative is to perform an esterification reaction to convert 
carboxyl groups to methyl esters, but sample loss due to extensive lyophilisation and 
increased sample complexity as a result of incomplete reaction and unwanted side 
reactions can be problematic116, 123. Another issue with IMAC is the low tolerance for many 
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buffers that are typically used for preparation of biological samples, with the added 
limitation that IMAC in the presence of biological buffers shows a stronger selectivity for 
multiply phosphorylated peptides124. 
 
IMAC is often combined with a pre-fractionation step to reduce sample complexity prior to 
phosphopeptide enrichment. The use of hydrophilic interaction chromatography (HILIC) for 
fractionation prior to IMAC enrichment demonstrated 99% selectivity for phosphopeptides, 
resulting in identification of over 1000 unique phosphorylation sites from HeLa cell 
lysate125. Additionally, a combined strong cation exchange (SCX) and IMAC strategy has 
been used to identify ~1000 phosphopeptides in postsynaptic density samples, a significant 
improvement compared to using either of the techniques alone126, whilst a similar two-step 
procedure consisting of SCX and IMAC resulted in identification of over 5000 
phosphorylation sites from mouse liver127. 
 
Metal oxide affinity chromatography (MOAC) 
MOAC uses immobilised metal oxide ions to selectively enrich phosphopeptides. A wide 
variety of metal oxides have been demonstrated to be suitable for this purpose including 
ZrO2, Al2O3, Nb2O5, SnO2, and CeO2
128-132, but TiO2 is by the far the most widely used. The 
use of TiO2 for phosphopeptide enrichment was first described in 2004
133-135, with further 
developments to improve selectivity described in subsequent years136, 137. 
 
Selective binding of phosphopeptides to metal oxides is achieved by the affinity of the 
oxygen in the phosphate group for metal atoms. Performing the binding stages of the 
process at acidic pH minimises unwanted binding of peptides containing acidic residues; at 
low pH acidic residues will remain protonated. To further decrease binding of acidic no-
phosphorylated peptides and thus increase selectivity, additives can be used during the 
binding step. A phosphate group and carboxylic acid group do not interact with TiO2 via the 
same type of binding interaction (Fig 1.11). Adsorption of the phosphate group to the TiO2 
surface is via a bridging bidentate interaction, whilst carboxylic acids bind via a chelating 
bidentate interaction. These non-equivalent binding sites mean that additives can be 
chosen that will target sites that are preferred by carboxyl groups but will provide no 
competition for the interaction with phosphate groups. Examples of suitable additives to 
achieve this include 2,5-dihydroxybenzoic acid, glutamic acid, lactic acid and glycerol136, 138-
140. 
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Figure 1.11 Adsorption of carboxylic acid group and phosphate onto TiO2 by different 
modes 
 
Other attempts to improve TiO2 enrichment focus on the material used for the solid 
support. For example, nanoparticles have been shown to have a higher enrichment 
capacity than micro-particles, due to the larger surface area available for binding141, whilst 
mesoporous aerogels are reported to increase the surface area further142. TiO2 has been 
coated onto monolithic capillary columns143, and also used to functionalize magnetic 
particles, which has the added advantage of increasing the ease with which the enrichment 
protocol can be carried out144. As an alternative approach, methods to enable on-target 
TiO2 enrichment prior to matrix-assisted laser desorption ionisation (MALDI)-MS analysis 
have also been reported145, 146. 
 
TiO2 for phosphopeptide enrichment has also been used alongside additional enrichment 
or fractionation steps to enable large scale phosphoproteomics analysis. For example, a 
combination of IMAC, HILIC and TiO2 enrichment enables identification of ~4700 
phosphopeptides from epidermal growth factor (EGF) stimulated HeLa cells, with 
quantitative analysis revealing >600 EGF regulated phosphosites147. An alternative 
approach which proposes TiO2 as the first stage of enrichment prior to strong anion 
exchange (SAX) and SCX fractionation allowed for identification of ~5000 phosphosites in 
HeLa cells, including multiply phosphorylated peptides148. Additionally, an electrostatic 
repulsion-hydrophilic interaction chromatography (ERLIC) strategy for fractionation with 
subsequent IMAC and TiO2 enrichment provides comprehensive analysis of 
phosphorylation in platelet derived growth factor (PDGF) stimulated NIH 3T3 cells, allowing 
for characterisation of kinase substrate phosphorylation motifs149.  
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Hydroxyapatite 
Hydroxyapatite is a crystalline form of calcium phosphate, Ca10(PO4)6(OH)2, which was 
originally utilised for the separation of proteins and nucleic acids150, 151, and is still routinely 
used for purification of monoclonal antibodies152.  Phosphorylated proteins exhibit stronger 
binding to hydroxyapatite than non-phosphorylated proteins153, 154, and this trend has been 
shown to be applicable to peptides, driving the development of hydroxyapatite as a solid 
support for phosphopeptide enrichment155, 156. 
 
Hydroxyapatite interacts with proteins and peptides through both positively charged Ca2+ 
ions which complex with carboxyl groups, and negatively charged phosphates (PO4
2-) which 
interact with positively charged residues. The Ca2+ ions additionally bind to phosphoryl 
groups, and indeed do so with a stronger affinity than is observed for carboxyl moieties. 
This explains the observation that phosphorylated proteins and peptides exhibit tighter 
binding to hydroxyapatite than their non-phosphorylated counterparts. Hydroxyapatite 
enrichment routinely enables recovery of multiply phosphorylated peptides, with one 
proposed method enabling separation of singly, doubly and multiply phosphorylated 
peptides by elution from hydroxyapatite at increasing phosphate concentrations155. 
Recovery of multiply phosphorylated peptides using hydroxyapatite is particularly 
advantageous when compared to titanium dioxide based methods which generally favour 
enrichment of singly phosphorylated peptides. 
 
The use of hydroxyapatite for phosphopeptide enrichment from relatively simple peptide 
mixtures has been demonstrated in a variety of formats including direct analysis of 
phosphopeptides by MALDI-MS without elution from the hydroxyapatite microgranules156, 
incorporation of hydroxyapatite nanoparticles into monolithic pipette tips157 and the use of 
magnetic hydroxyapatite clusters for a quicker and simpler enrichment protocol158. 
Additionally, hydroxyapatite has been used for phosphopeptide enrichment from complex 
samples in combination with MudPIT (multidimensional protein identification technology). 
Identification and quantification of approximately 1000 phosphopeptides was achieved 
from whole cell lysate, whilst the method also enabled identification of up to 4000 
phosphopeptides from the amygdala region of mouse brain159. 
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Calcium Phosphate Precipitation 
Phosphopeptides have been found to co-precipitate with calcium phosphate at neutral pH, 
allowing for their separation from non-phosphorylated peptides which do not precipitate 
under these conditions. This technique has been applied to the analysis of complex 
phosphoproteomes, for example from rice160 and brain tissue161, either alone or in 
combination with an additional enrichment a step such as IMAC. More recently, trivalent 
lanthanide salts have been used to perform selective co-precipitation of phosphopeptides, 
with lanthanide cations forming strong ionic bonds with phosphate anions162. These 
precipitation methods are proposed to offer increased selectively over other affinity based 
methods primarily due to the fact that the precipitate can be stringently washed to remove 
non-phosphorylated peptides. 
 
Immunoprecipitation 
Phosphorylation of Tyr occurs at a much lower abundance than Ser and Thr 
phosphorylation and hence with typical phosphopeptide enrichment strategies pSer and 
pThr largely dominate the identified phosphosites. For this reason, pTyr is often more likely 
to be enriched by immunoprecipitation, with pTyr antibodies offering a more targeted 
enrichment strategy. Immunoprecipitation at the protein level initially suffered from an 
inability to identify sites of Tyr phosphorylation within pTyr proteins163. Additional 
purification of phosphopeptides by the IMAC method following precipitation of pTyr 
proteins improved analysis but still less than 100 pTyr sites could be identified in a single 
experiment164, 165.  In 2005, a method for enrichment at the peptide level with pTyr 
antibodies was first described, enabling identification of over 600 pTyr sites in a cancer cell 
line, around 70% of which were novel166. Application of this method for enrichment of pTyr 
from a panel of cancer cell lines and tumours enabled identification of 4500 pTyr sites on 
over 2700 proteins167. Antibodies against pSer/pThr are not generally used for 
immunoprecipitation based enrichment on a phosphoproteome wide scale; they are 
targeted against a phosphoamino acid in the context of the surrounding residues and thus 
don’t bind to all pSer/pThr sites with the same efficiency. In order to detect all pSer/pThr 
phosphosites by immunoprecipitation multiple antibodies would be required168. 
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1.3.2 Fractionation 
A variety of fractionation approaches have been employed to increase the depth of 
coverage in proteomics experiments. A greater overall degree of separation of peptides is 
achieved if two orthogonal chromatographic steps are utilised prior to MS/MS analysis, 
compared to a single low pH reversed phase chromatographic separation, therefore vastly 
increasing the number of peptide (and protein) identifications obtained for analysis of a 
single sample84, 169, 170. In phosphoproteomics experiments the combination of a pre-
fractionation approach and subsequent phosphopeptide enrichment has been reported to 
improve the degree of enrichment and thus more comprehensive analysis of the 
phosphoproteome is achieved126, 147, 159. A number of chromatographic approaches have 
been exploited for both proteomics and phosphoproteomics experiments.  
 
High pH reversed phase 
Reversed phase (RP) chromatography separates peptides based on hydrophobicity; the 
most hydrophilic peptides elute first with peptides of increasing hydrophobicity eluting 
from a C18 column as the percentage of organic solvent in the mobile phase is increased. 
Whilst low pH RP chromatography is used as a means of peptide separation prior to MS/MS 
analysis, high pH RP offers an orthogonal approach that can be exploited for sample 
fractionation. At high pH carboxylic groups and ammonium groups will be deprotonated, 
changing the charge distribution and hydrophobic properties of peptides when compared 
to low pH where such groups will be protonated171, 172. Orthogonality of separation 
between high and low pH RP can be further increased using a concatenation approach to 
fraction collection; rather than adjacent fractions being combined, fractions from the start, 
middle and end of the gradient are combined, e.g. fractions 1, 13 and 25, and 2, 14 and 26 
would be mixed together173. Concatenation of high pH RP fractions followed by TiO2 
enrichment resulted in comprehensive coverage of the phosphoproteome of NIH 3T3 cells, 
including identification of a high number of pTyr and multiply phosphorylated peptides174. 
 
Ion exchange 
Ion exchange chromatography separates peptides based on differences in charge. Strong 
cation exchange (SCX) utilises a negatively charged stationary phase, such that peptides 
with greatest net positive charge are most strongly retained by the column. SCX has been 
used for effective pre-fractionation in analyses of the total proteome84, 169. 
Phosphopeptides are poorly retained by SCX, due to electrostatic repulsion of negatively 
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charged phosphate groups, meaning the majority of phosphopeptides elute at the start of 
the gradient. Nevertheless, when used either alone or in combination with an additional 
stage of fractionation or phosphopeptide enrichment SCX has proven to be an effective 
strategy for global phosphoproteomics experiments127, 175, 176.  
 
Strong anion exchange (SAX) facilitates peptide separation via electrostatic interactions 
with a positively charged stationary phase. Elution from the SAX column can be elicited by 
either a decreasing pH gradient177, 178, or increasing salt concentration at a constant pH179. If 
loading of the sample onto the SAX column is performed at low pH, the negative charge of 
a single phosphate group is often not sufficient to overcome the electrostatic repulsion 
conferred by the N-terminus and the side chain of the C-terminal amino acid, resulting in 
poor retention of singly phosphorylated peptides. However, above pH 6 a second negative 
charge is acquired, making SAX fractionation of phosphopeptides a feasible strategy when 
high pH sample loading is employed180. 
 
Hydrophilic interaction chromatography (HILIC) 
In HILIC, peptides interact with a neutral, hydrophilic stationary phase via hydrogen 
bonding. A high starting concentration of organic solvent is used in the mobile phase, with 
elution of peptides in order of increasing hydrophilicity elicited by increasing the polarity of 
the mobile phase181. HILIC has a high degree of orthogonality compared to reversed phase 
LC, making it a desirable fractionation strategy prior to standard LC-MS/MS analysis of 
peptides171. Phosphopeptides are more strongly retained by HILIC compared to non-
phosphorylated peptides, with the effectiveness of HILIC for phosphoproteomics 
demonstrated both alone and in combination with an IMAC enrichment step125. 
 
Electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) 
ERLIC is performed using anion exchange columns with mobile phases that contain at least 
60% organic solvent, leading to an additional hydrophilic interaction superimposed on the 
electrostatic effects182. The combination of these two effects results in highly effective 
separation of phosphopeptides from unmodified peptides183, 184. As is true of all 
electrostatic based separation methods (e.g. TiO2, IMAC, SAX), ERLIC can suffer from co-
elution of acidic peptides with phosphorylated peptides, although performing the 
chromatography around pH 2 is fairly effective at overcoming this problem180, 185.  
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Overall, there are many strategies available for enrichment and fractionation of 
phosphopeptides, with a combination of approaches often offering the most in-depth 
coverage of the phosphoproteome. Many of these techniques rely on acidic conditions to 
elicit phosphopeptide enrichment and/or peptide fractionation, and therefore they are not 
necessarily suitable for analysis of acid-labile phosphorylation, such as pHis. Further 
developments of these methods are therefore required to access this unexplored area of 
the phosphoproteome, represented by acid-labile modifications. 
 
1.3.1 Fragmentation of phosphopeptides for identification by tandem MS 
Even once phosphopeptide samples are effectively enriched and/or fractionated, the MS 
stage of a phosphoproteomics experiment can still provide considerable challenges. The 
fragment ions detected following tandem MS must not only be able to provide peptide 
sequence information but also allow for the site of phosphorylation within the peptide to 
be determined. If the phosphate group is lost during the fragmentation reaction (a process 
termed neutral loss) then the resulting fragment ion spectrum may be too poor to allow for 
identification of the peptide sequence and/or there will be insufficient fragment ion 
evidence to localise the site of phosphorylation to a specific residue within the peptide. The 
phosphate group neutral loss can be occur as loss of HPO3, corresponding to 80 Da or loss 
of H3PO4, corresponding to a mass of 98 Da. Concomitant loss of water (H2O, 16 Da) 
alongside loss of H3PO4 will result in an observed neutral loss of 116 Da. 
 
Analysis of phosphopeptides using CID fragmentation is known to result in extensive 
neutral loss, where the predominant ion in the tandem mass spectrum is the peptide 
sequence without the phosphate group. For pSer and pThr peptides this neutral loss is 
characterized by loss of H3PO4, corresponding to a mass of 98 Da. The most likely 
mechanism for neutral loss is a charge directed intramolecular nucleophilic substitution 
(Figure 1.12)186, 187. The reaction is initiated by protonation of the phosphate group, with 
the hydrogen either coming from the mobile proton, or via a protonated neighbouring 
amino acid. Nucleophilic attack of the β-carbon on the side chain of the phosphorylated 
amino acid by the amide carbonyl group results in formation of a cyclic, five membered 
oxazoline structure and release of H3PO4. The extent of this neutral loss is dependent on 
the charge state of the peptide and the number of basic residues (Arg, Lys, His) it contains. 
If the charge state is less than the number of basic residues then a low proton mobility 
environment exists, meaning lower energy pathways, such as neutral loss, are favoured 
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over backbone fragmentation. Under a mobile proton environment, where the charge state 
is greater than the number of basic residues, relocation of the mobile proton(s) across 
several amide nitrogen atoms directs C-N bond cleavage and balances backbone 
fragmentation with elimination of H3PO4. 
 
Figure 1.12 Mechanism of neutral loss from pSer/pThr peptides. Intramolecular 
nucleophilic substitution reaction results in formation of cyclic five-membered oxazoline 
structure and loss of H3PO4. 
 
The aromatic ring of pTyr residues prevents loss of H3PO4 via the previously described 
mechanism. Within the C-O-P structure of a pTyr residue the C-O bond is stronger than the 
same bond of phosphorylated aliphatic amino acids due to stabilisation by the aromatic 
ring. This weakens the O-P bond, therefore favouring loss of HPO3, corresponding to 80 Da. 
The exact mechanism by which the loss occurs is yet to be fully established, but it is 
suggested that a basic moiety may be involved. The observation of a 98 Da loss from pTyr 
peptides can be attributed to simultaneous or consecutive loss of HPO3 from the pTyr 
residue and water (18 Da) from another amino acid. Neutral loss from pTyr peptides is 
generally observed to a lesser extent than from pSer/pThr peptides. 
 
Extensive neutral loss from phosphorylated peptides, and the associated reduction in 
backbone cleavage, results in poor peptide sequence coverage and an inability to localise 
the phosphorylation to a specific amino acid187, 188. Attempts to improve phosphosite 
localization by CID have been reported, including gas-phase boron derivatisation189 and 
enzymatic removal of the basic C-terminal residue, which promotes backbone cleavage 
over neutral loss of the phosphate group186. 
 
In order to improve the sequence information obtained from peptides that undergo 
extensive neutral loss following activation by CID, an additional round of activation can be 
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performed. In an MS3 experiment, the formation of a neutral loss ion in the MS2 stage of 
analysis triggers a further round of activation, whereby the neutral loss ion is isolated and 
fragmented to produce sequence specific backbone fragments. However, this results in an 
increased duty cycle due to the considerable increase in analysis time per peptide. To 
overcome this, the MS2 and MS3 stages can be combined in a multistage activation (MSA) 
experiment190. Alongside activation of the precursor ion, additional activation at the m/z 
corresponding to the neutral loss ion is performed. This results in a spectrum which 
contains MS2 fragment ions plus additional fragment ions from the neutral loss species, i.e. 
b- and y- ions minus 98 Da.  There is contradictory evidence over the usefulness of these 
strategies for improved phosphopeptide analysis, with the effect on phosphosite 
localization found to be limited191, 192.  Although suited to some experimental approaches it 
is likely that the capabilities of high mass accuracy MS instrumentation negate the need for 
CID-based MS3 and MSA techniques for high-throughput phosphoproteomics 
experiments187.  
 
HCD has proven to be useful for phosphoproteomics experiments193, 194, including 
quantitative analysis using the iTRAQ technology195. However, whilst detection of HCD 
fragment ions in the Orbitrap allows for high resolution analysis, and detection of ions in 
the low mass range, acquisition times are slower compared to an ion trap. This has been 
suggested to have possible negative implications for in-depth phosphoproteomics where 
rapid CID-ion trap analysis may outweigh the benefits of HCD with Orbitrap detection196, 197. 
 
For modified peptides ETD is particularly useful, although the slower reaction time 
compared to CID/HCD can impact on the overall number of MS/MS spectra acquired and 
therefore peptides identified in a complex mixture. Strategies combining fragmentation 
techniques for phosphopeptide analysis are fairly common, with one example being to 
perform alternating CID and ETD scans for each precursor ion74, 118, 198, a technique 
employed with the Bruker AmaZon mass spectrometer used in this work. 
 
The Thermo Orbitrap Fusion mass spectrometer used in this works offers a great degree of 
flexibility in terms of possible fragmentation strategies available for effective identification 
of phosphopeptides. Phosphoproteomics experiments can be performed with CID, HCD, 
ETD or a combination of fragmentation types to aid in identification199, 200.  A particularly 
attractive method for this work is a neutral loss triggered workflow whereby detection of a 
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98 Da neutral loss (indicative of a phosphorylated peptide) in the MS2 spectrum triggers 
the precursor ion to undergo an additional round of fragmentation, typically using an ETD-
based method. Although neutral loss triggering methods can be slow due the extra stage of 
MS analysis, for the purposes of this work a HCD with neutral loss triggered EThcD method 
is believed to provide the ideal balance between number of identifications and phosphosite 
confidence. Such a technique is expected to be of particular advantage for analysis of 
samples containing a high number of non-phosphorylated peptides, which will not 
necessarily benefit from EThcD fragmentation. 
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1.4 Data Analysis 
 
1.4.1 MASCOT: database search engine 
A vast amount of data is generated in a single LC-MS/MS experiment. From this data, both 
MS1 and MS2 level information are used to infer the identity of the peptides (and 
subsequently the proteins) in a sample. High throughput peptide/protein identification is 
typically performed using a search engine tool, which in the case of this work was 
MASCOT201. The basic principle of a search engine such as MASCOT is to compare the 
experimental masses of MS1 precursor ions and MS2 fragment ions to calculated values 
obtained by in silico digestion (and subsequent MS/MS fragmentation) of a sequence 
database using rules that match the experimental conditions. For example, all sequences in 
a database of human proteins are digested according to trypsin cleavage rules, with 
fragmentation of peptide ions reflecting HCD (b- and y-ions generated).  
 
MASCOT uses a probability based scoring algorithm to enable the peptide sequence that 
best matches the experimental data to be identified. Essentially, the probability that the 
observed match between the experimental data and the sequence database occurs by 
chance is calculated, with a lower probability of chance being reflected by a higher score.  
 
Current guidelines to improve reliability of protein identification data published based on 
database search results require the false discovery rate (FDR) to be determined202. 
Calculation of FDR is generally achieved using the target-decoy strategy203. According to 
this approach, the search is repeated with the exact same parameters except the database 
used is one of reversed or randomised sequences, such that there should be no matches 
between the experimental data set and this false (or “decoy”) database. The number of 
matches obtained against this database is essentially an estimation of the number of false 
positives that are present in the results for the real (or “target”) database search. FDR is 
thus reported as the number of false positive matches in the decoy database divided by the 
total number of matches in the target database. 
 
1.4.2 Phosphosite localisation tools 
The development of more sophisticated strategies for generating and analysing MS data is 
undoubtedly facilitating improved (phospho)peptide identification. However, for 
phosphopeptide identification it is equally important to have confidence in both the 
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sequence and the site of modification. If only one site within a peptide can be 
phosphorylated the site localisation is of course unambiguous, but determining with 
confidence the position of modification when there is more than one possibility is slightly 
more challenging. It is therefore beneficial to apply a localisation score to indicate 
confidence in a given site of modification, and indeed publication of phosphoproteomics 
data typically requires an assessment of such site localisation confidence. 
 
A few search engines have an integrated method by which site localisation scores can be 
determined but there are also a variety of other post-search engine tools available. In 
general, site localisation scores can be determined in two ways. One method is to assess 
the chance of a given peak that allows for site determination having been matched at 
random, an approach which is employed by tools such as A-score204, PTM-score 
(Andromeda)117, SLoMo205, and PhosphoRS206. The alternative strategy calculates the 
difference in search engine scores for peptide identifications with different site 
localisations, examples of which include MASCOT Delta score207 and SLIP score (Protein 
Prospector)208. 
 
For the large-scale phosphopeptide analysis conducted in this project the localisation tool 
ptmRS was used, which is the latest version of PhosphoRS and is available as an integrated 
node of the Proteome Discover data analysis software206. The output of ptmRS is a site 
confidence probability for each potential site of modification within the peptide sequence. 
Assignment of a localisation score to each possible phosphosite is preferable to the 
approach taken by tools such as A-score and MASCOT Delta which report just one 
localisation score for an entire peptide with a given modified residue or combination of 
residues. A novel aspect of ptmRS is the dynamic approach to peak depth determination. 
Tools such as PTM-score and A-score search the ‘n’ most intense peaks within a bin of 100 
m/z to identify the site determining product ions, whilst ptmRS considers the total number 
of extracted peaks across the entire mass range of the MS2 spectrum, whilst also taking 
into account the fragment ion mass tolerance. This allows ptmRS to overcome potential 
issues arising from uneven peak distribution in m/z bins. It also means ptmRS is better to 
suited to high-resolution data sets200, 209. Indeed, ptmRS was designed to be suitable for use 
with both high and low-resolution data, whilst both A-score and PTM-score use unit mass 
resolution which makes them only really suitable for low-resolution MS2 data.  
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Unlike FDR for peptide identifications, there is no way to readily calculate the false 
localisation rate (FLR) for phosphosite localisation results. Decoy sequences do not provide 
an accurate assessment of error as peptide identifications with incorrect site localisations 
are very similar to the correct matches. One possible approach is to use a synthetic library 
of phosphopeptides with known sites of modification, from which an FLR can be calculated 
and the appropriate score thresholds applied to subsequent experimental data sets. 
Although this strategy relies on the assumption that scores have consistent meanings when 
transferred from the standard data set to the experimental data set, it has nevertheless 
proven useful in the absence of an alternative method for calculating FLR directly from 
experimental data200, 206, 209.  
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1.5 Challenges of phosphohistidine analysis 
 
The study of pHis as a post-translational modification is far behind that of phosphorylated 
Ser, Thr and Tyr. As well as the many challenges already highlighted for phosphoproteomics 
experiments, the analysis of pHis presents an additional challenge. The phosphoramidate 
bond of pHis is acid-labile meaning the phosphate group can be lost under many of the 
conditions used in phosphoproteomics workflows. Hydrolysis of pHis occurs much more 
readily than phosphohydroxyamino acids due to the phosphoramidate bond having a -ΔG 
value of -12 to -14 kcal mol-1 compared to approximately -6.5 to -9.5 kcal mol-1 for a 
phosphoester bond210. Hydrolysis of both isomers of free pHis is reported to be extremely 
rapid under both heat and acidic conditions, typically on the time-scale of a few minutes211, 
212. 
  
As a result of pHis instability, strategies available to study this modification in proteins are 
thus far fairly limited. Characterization on a protein-by-protein basis has been achieved 
using a membrane based method for detection of alkali-stable protein phosphorylation213 
or via a 31P-NMR strategy214. MS-driven strategies, which have been invaluable for 
characterization of pSer, pThr and pTyr, would be extremely beneficial for proteome wide 
analysis of pHis. As already discussed, a key stage in any phosphoproteomics workflow is 
the enrichment of phosphopeptides from a background consisting of a large excess of non-
phosphorylated peptides. Most of the currently available approaches rely on acidic 
conditions to elicit effective phosphopeptide enrichment, which of course is not suitable 
for pHis. The application of a modified IMAC approach, using Cu2+, rather than the more 
commonly employed Fe3+, has been demonstrated for enrichment of pHis peptides. 
However, this experiment was performed with peptides from digestion of just one protein 
(histidine-containing phosphocarrier protein) and is yet to be utilised for global pHis 
analysis215. 
 
For LC-MS/MS analysis, which typically employs acidic buffers for chromatographic 
separation of peptides, the use of shorter gradients has been investigated in an attempt to 
limit acid induced hydrolysis of pHis peptides216. Implementation of such a method will 
however be limited by sample complexity. Despite reports of neutral and basic buffers 
reducing chromatographic resolution and causing a decrease in MS signal intensity217, 
Lapek et al.218 describe the successful application of an LC-MS/MS based strategy for 
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analysis of acid-labile pHis and pAsp using ammonium bicarbonate containing buffers at pH 
5. Utilising this strategy they are able to identify 20 pHis containing proteins, including the 
site of phosphorylation, from prostate cancer cell lines. The use of MS analysis in negative 
mode has also been explored, whereby reduced neutral loss in negative ion MALDI-MS 
analysis resulted in increased likelihood of site identification for synthetic pHis-containing 
peptides219. 
 
A further approach for pHis protein characterization is through the use of antibodies, which 
would permit a variety of biochemical experiments, as well as providing a strategy for pHis 
specific enrichment prior to LC-MS/MS analysis analogous to pTyr phosphoproteomics 
studies. One major problem in the development of such antibodies is that hydrolysis of 
pHis occurs much too quickly to elicit an immune response. To overcome this issue a 
number of stable analogues of pHis have been generated, for both the 1- and 3-pHis 
isomers220, 221. Several groups focused on the use of phosphoryl-triazolylalanine (pTza) as a 
stable pHis analogue222, 223, with incorporation of such analogues into synthetic peptides 
enabling generation of sequence specific pHis polyclonal antibodies towards pHis18 in 
histone H4224. Further to this, first and second generation “pan-pHis” polyclonal antibodies 
against 3-pHis have been reported. Generated using either phosphoryl-triazolylethylamine 
(pTze) or phosphono-pyrazolylethylamine (pPye) as the hapten, these antibodies showed 
high affinity for a range of pHis proteins, but were limited by their cross-reactivity with 
pTyr225, 226. Most recently Fuhs et al.227 incorporated the pHis analogue pTza into 
degenerate peptide libraries, which were subsequently used to immunize rabbits and thus 
the first monoclonal 1- and 3-pHis antibodies were developed. These antibodies are 
reported to be sequence independent with no cross-reactivity with pTyr, and their use has 
been demonstrated in a variety of immunological assays. 
 
The application of monoclonal 1- and 3-pHis antibodies to an immunoprecipitation based 
protein enrichment, allowed over 700 pHis containing proteins to be identified by LC-
MS/MS, with marked differences in proteins isolated by immunoprecipitation with each of 
the phosphoisomer specific antibodies. Despite this being the largest exploration of the 
pHis proteome to date, pHis-containing peptides were not identified, meaning that the site 
of phosphorylation within these proteins is still unknown. Although the development of 
these antibodies is a huge leap forward for the field of pHis research, there are still further 
advances to be made to enable confident identification and localisation of pHis sites across 
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the proteome. It is clear that development of new biochemical tools and novel strategies 
will be necessary to allow the field to determine the extent and understand the roles of His 
phosphorylation in mammalian systems.  
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1.6 Aims and objectives 
 
The aim of this work is to develop analytical strategies for the separation and 
characterization of pHis-containing peptides from complex mixtures, with a view to 
understanding the extent of this modification in human cells. A comprehensive strategy 
including sample preparation, phosphopeptide enrichment, MS analysis and data 
processing will be established, with the aim of investigating pHis and other acid-labile 
phosphorylation in a human cell line. This work will endeavour to reveal the extent of the 
unexplored human phosphoproteome, thus gaining insight into the possible roles these 
modifications may play in mammalian systems. 
 
The aims of this project will be met though the following objectives: 
 
 Generation and characterisation of a pHis protein standard for evaluation of 
experimental strategies 
 Assessment of existing phosphopeptide enrichment strategies for their suitability 
to pHis analysis 
 Development of a strong anion exchange fractionation method for 
phosphopeptides at non-acidic pH 
 Assessment of neutral-loss patterns during peptide fragmentation for improved 
localisation of pHis  
 Application of a novel strong anion exchange strategy to HeLa cells having 
undergone knockdown of a known histidine phosphatase, PHPT1. 
 Extensive data analysis to identify novel sites of phosphorylation on unexplored 
residues, with insights gained through functional annotation and motif analysis into 
the potential biological relevance of pHis and other non-canonical sites of 
phosphorylation in a human system. 
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Chapter 2. Materials and Methods 
 
2.1 Sample generation 
 
2.1.1 Preparation of histidine phosphorylated myoglobin standard 
Potassium phosphoramidate was synthesised from phosphoryl chloride and ammonia 
according to the procedure described by Wei and Matthews213. In brief, phosphoryl 
chloride was reacted with ammonium hydroxide for 15 minutes on ice to produce 
ammonium hydroxide phosphate, which was subsequently reacted with potassium 
hydroxide at 50 °C for 10 minutes. The resulting potassium phosphoramidate salt was 
precipitated with ethanol and collected by vacuum filtration. Equine myoglobin (Sigma 
Aldrich) was phosphorylated by dissolution in 1 M aqueous potassium phosphoramidate 
(150 nmol/mL) overnight at room temperature. The resulting sample was buffer exchanged 
into 20 mM ammonium acetate using a molecular weight (10 kDa) cut-off spin filter. Briefly, 
sample was added to the filter, centrifuged at 10000 x g for 10 minutes then 500 μL 20 mM 
ammonium acetate added to the top of the filter before being centrifuged again. This was 
repeated twice more and then the concentrated sample obtained by inversion of the filter 
and centrifugation at 1000 x g for 2 minutes. 
 
2.1.2 U2OS cell culture 
U2OS cells were maintained in DMEM supplemented with 10% (v/v) fetal bovine serum, 
penicillin (100 U/mL), streptomycin (100 U/mL), and L-glutamine (2 mM) at 37 °C, 5% CO2. 
Once 80% confluence was reached, cells were washed with phosphate buffered saline 
(PBS) and released with trypsin (0.05% (v/v)). Cells were centrifuged at 220 x g for 5 
minutes, washed with PBS and lysed with 100 μL lysis buffer (8 M urea, 50 mM ammonium 
bicarbonate (AmBic), 1 protease inhibitor tablet (cOmplete Mini EDTA free, Roche) per 10 
mL). The lysate was sonicated briefly and centrifuged at maximum speed for 20 min. 
Protein concentration was determined by Bradford assay. 
 
2.1.3 HeLa cell culture and siRNA knockdown of PHPT1 
HeLa cells were maintained in DMEM (Sigma-Aldrich, Dulbecco’s Modified Eagle’s Medium-
high glucose, 4500 mg/L glucose with sodium bicarbonate, without L-glutamine and sodium 
pyruvate) supplemented with 10% fetal bovine serum, penicillin (100 U/mL) and 
streptomycin (100 U/mL) at 37 °C, 5% CO2. To split cells, the medium was aspirated and 
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cells were washed with warm PBS prior to incubation with 1 mL trypsin (0.05% (v/v)) for 1 
minute at 37 °C. Reaction was quenched with 1 mL supplemented DMEM. For siRNA 
knockdown T75 flasks at ~50% confluency were exchanged to antibiotic-free medium 
(DMEM supplemented with 10% fetal bovine serum). siRNA for PHPT1 (SMARTpool: ON-
TARGETplus), Lamin A/C (siGENOME control) and a non-targeting pool (ON-TARGETplus 
Non-targeting Pool) were purchased from Dharmacon. For each flask 1 nM siRNA (1.1 μL of 
a 20 μM stock prepared in RNAse free water (Thermo Fisher)) and 40 μL INTERFERin 
(Polyplus transfection) was prepared in 4 mL Opti-mem reduced serum medium (Thermo 
Fisher). After incubation for 10 minutes at room temperature, the siRNA reaction mixture 
was added to the flasks. Cells were incubated for 48 hours at 37 °C, 5% CO2 then trypsinized 
and lysed. For cell lysis, trypsinized cells were centrifuged at 220 x g for 5 minutes, washed 
with PBS and lysed with 100 μL lysis buffer (8 M urea, 50 mM AmBic, 1 protease inhibitor 
tablet (cOmplete Mini EDTA free, Roche) per 10 mL). Lysate was sonicated at low amplitude 
for 3 X 10 seconds with 1 minute in between. Protein concentration was determined by 
Bradford assay. 
 
2.2 Protein analysis 
 
2.2.1 SDS-PAGE  
Cell lysates from PHPT1, Non-targeting and Lamin experiments were diluted 1:1 with 2 X 
sample loading buffer (0.06 M Tris-HCl (pH 6.8), 10% (v/v) glycerol, 10% (w/v) SDS, 0.005% 
(v/v) bromophenol blue, 0.1 M DTT), with the volume loaded for each sample resulting in 
equal protein loading. Samples were boiled for 5 minutes and loaded on a SDS-PAGE gel, 
which was run at 200 V for approximately 45 minutes. Gels were immediately used for 
western blotting. 
 
2.2.2 Western blotting  
Proteins were transferred to nitrocellulose membrane at 100 V for 1 hour in transfer buffer 
(25 mM Tris, 192 mM glycine, 20% (v/v) MeOH). The membrane was blocked for 1 hour at 
room temperature (5% milk in TBS-T) washed with TBS-T (1 X TBS, 0.1% Tween-20; 3 X 10 
minutes) and incubated with the appropriate primary antibody (PHPT1 (Santa Cruz 
Biotechnology, sc130229, 1:200 dilution); Lamin (Santa Cruz Biotechnology, sc6215, 1:200 
dilution); GAPDH (proteintech, 1:5000 dilution)) in blocking buffer overnight at 4 °C. 
Membranes were then washed with TBS-T (3 X 10 minutes), incubated with the 
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appropriate secondary antibodies in blocking buffer for 1 hour at room temperature, 
washed with TBS-T (3 X 10 minutes) and developed with SuperSignal West Pico PLUS 
chemiluminescent substrate (Thermo Fisher) according to the supplier’s protocol using 
X-Ray film. 
 
2.3 Tryptic digestion and peptide desalting 
 
2.3.1 In-solution tryptic digestion 
His-phosphorylated myoglobin (200 µg) and α-/β-casein (Sigma Aldrich, Gillingham, Dorset, 
UK; 100 µg of each), were dissolved in 25 mM AmBic to 2 μg/μL. Cell lysates were prepared 
in lysis buffer, as previously described. Proteins were reduced with 3 mM DTT (in 50 mM 
AmBic) for 20 minutes at 30 °C, and, after cooling, free Cys residues were alkylated with 
14 mM iodoacetamide (in 50 mM AmBic) for 45 minutes at room temperature in the dark. 
The reaction was quenched by addition of DTT to final concentration of 7 mM. The urea 
concentration in cell lysates was reduced to 2M by addition of 50 mM Ambic. Proteins were 
digested using 2% (w/w) trypsin (sequencing grade modified trypsin, Promega) at 30 °C 
overnight. 
 
2.3.2 C18 StageTip desalting 
StageTips were prepared with 3 discs of C18 material (EmporeTM Octadecyl C18, 47 mm) in 
a 200 μL pipette tip. Tips were conditioned by sequential addition of 100 μL MeOH, 100 μL 
H2O:ACN (50:50) and 100 μL H2O, with centrifugation for 2 minutes at 2000 x g to pass the 
liquid through the tip each time. A portion of sample (100 μL) was loaded onto the tip, 
centrifuged, then the flow through added to the tip and centrifuged again. The tip was 
washed with 100 μL H2O and peptides were then eluted by addition of 50 μL H2O:ACN 
(50:50). Eluents were dried to completion by vacuum centrifugation then resolubilised in 
H2O:ACN (97:3) prior to LC-MS/MS analysis. 
 
2.4 Phosphohistidine peptide characterisation 
 
2.4.1 pH stability of pHis myoglobin peptides 
Myoglobin peptides (1 nmol) were diluted to 100 μL in either 0.5% TFA (pH 1) or 20 mM 
ammonium acetate (pH 4, pH 6 or pH 9). Samples were incubated at 25 °C with shaking at 
600 rpm. At timed intervals (15 minutes, 30 minutes, 1 hour and 2 hours) 5 μL of sample 
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was removed, neutralised (e.g. by addition of 5 μL ammonium hydroxide to samples at pH 
1) and diluted to 500 fmol/μL with H2O:ACN (97:3) for LC-MS/MS analysis with the Bruker 
AmaZon instrument. This experiment was performed in triplicate for each pH. 
 
2.4.2 Heat stability of pHis myoglobin peptides 
Myoglobin peptides (300 pmol) were diluted to 75 μL in 50 mM AmBic (pH 7). Samples 
were heated at 80 °C and 95 °C with shaking at 600 rpm. At timed intervals (30 minutes, 1 
hour, 2 hours and 4 hours) 1 μL of sample was removed and diluted to 250 fmol/μL with 
H2O:ACN (97:3) for LC-MS/MS analysis with the Bruker AmaZon instrument. 
 
2.4.3 Reaction of pHis myoglobin peptides with hydroxylamine 
Myoglobin peptides (600 pmol) were diluted to 20 µL with 50 mM AmBic (pH 7), and 
incubated with an equal volume of 500 mM hydroxylamine for 1 hour at room 
temperature. The sample was diluted to 500 fmol/μL with H2O:ACN (97:3) for LC-MS/MS 
analysis with the Bruker AmaZon instrument. 
 
2.4.4 Chemical modification of His-containing peptides 
Tryptic peptides of myoglobin (900 pmol in 30 μL AmBic) were reacted with 30 μL of either 
10 mM diethylpyrocarbonate (DEPC) in acetonitrile at room temperature or 2 mM 
4-hydroxynonenal (HNE) in 10 mM sodium phosphate (pH 7.2) at 37 °C. After 1 hour an 
aliquot of the reaction mixture was diluted to 500 fmol/μL with H2O:ACN (97:3) for 
LC-MS/MS analysis with the Bruker AmaZon instrument. 
 
2.5 Enrichment strategies 
 
2.5.1 Titanium dioxide enrichment 
Titanium dioxide enrichment of α-/β-casein and His-phosphorylated myoglobin peptides 
(200 pmol) was performed using 200 µL spin tips (Protea Biosciences). For standard TiO2 
enrichment, tips were prepared by addition of 200 µL binding buffer (65% ACN, 2% TFA, 
saturated with glutamic acid, pH 2) and centrifuged at 2000 x g for 1 minute. Peptides in 
200 µL binding buffer were added to the tip, centrifuged, re-loaded and centrifuged again. 
The resulting flow through (unbound material) was collected for analysis. Tips were washed 
with 200 µL each of binding buffer and two wash buffers (65% ACN, 0.5% TFA and 65% 
ACN, 0.1% TFA), with each fractionation collected by centrifugation. Bound peptides were 
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eluted by addition of 100 µL of each elution buffer (300 mM NH3, 50% ACN and 500 mM 
NH3, 60% ACN). All fractions were dried by vacuum centrifugation and reconstituted in 
H2O:ACN (97:3) for LC-MS/MS analysis with the Bruker AmaZon instrument. The non-
enriched peptides (“start material”) were diluted to a concentration of 500 fmol/µL for LC-
MS/MS analysis. Alternative binding, washing and elution buffers were also tested, as 
discussed further in Chapter 3. Results I (Table 3.2). 
 
2.5.2 Hydroxyapatite enrichment 
Hydroxyapatite (HAP) resin (5 mg; Bio-Gel HTP, Bio-Rad) was suspended in 200 µL loading 
buffer (20 mM Tris-HCl (pH 7.2)) and added to a Pierce spin column (Thermo Scientific). The 
spin column was centrifuged at 3000 x g for 1 minute to remove the buffer and washed 
with a further 50 µL loading buffer, and again centrifuged. Centrifugation of the spin 
column at 3000 x g for 1 minute was used to collect all subsequent fractions. Tryptic 
peptides of α-/β-casein and His-phosphorylated myoglobin (40 pmol) in 50 µL of loading 
buffer was added to the resin in the spin column and incubated with gentle rotation at 
room temperature for 30-45 minutes. The flow-through was collected and the resin 
washed twice with 200 µL of loading buffer, which was also collected. The resin was then 
washed twice with 200 µL of wash buffer (20 mM Tris-HCl (pH 7.2), 20% (v/v) ACN) which 
was again collected. To recover the phosphopeptides, the resin was incubated twice with 
100 µL elution buffer (1.0 M K2HPO4 at pH 7.8, pH 7.0 or pH 6.0), rotating for 15 minutes at 
room temperature each time, before collecting and combining the eluent fractions. All 
fractions were dried by vacuum centrifugation and reconstituted in H2O:ACN (97:3) for LC-
MS/MS analysis with the Bruker AmaZon instrument.  
 
2.5.3 Calcium phosphate precipitation 
Tryptic peptides of α-/β-casein and His-phosphorylated myoglobin (50 pmol) were diluted 
to 50 μL in H2O. Sodium phosphate (2 µL of 0.5 M) and ammonia water (2 µL of 2 M) were 
added, and the pH of the resulting solution determined to be approximately pH 10 using 
universal indicator paper. CaCl2 (2 µL of 2 M) was added and the sample mixed using a 
vortex mixer for 5 minutes, followed by centrifugation at 12000 x g for 15 minutes. The 
resulting supernatant was transferred to a clean low bind sample tube. CaCl2 (100 µL of 
80 mM) was added to the precipitate which was briefly mixed and then centrifuged as 
before. The resulting supernatant was combined with that of the previous step, and the 
wash step repeated with a further 100 µL of 80 mM CaCl2, again combining the supernatant 
Chapter 2. Materials and Methods 
 
46 
 
fractions. The precipitate was resolubilised in 10 µL of either 5% (v/v) or 0.1% (v/v) TFA and 
immediately transferred to a C18 StageTip for sample desalting. 
 
2.5.4 Subtractive approaches for pHis peptide enrichment 
Tryptic peptides of α-/β-casein and His-phosphorylated myoglobin (20 pmol) in 50 µL of 
loading buffer (20 mM Tris-HCl (pH 7.2)) were added to HAP resin (5 mg; Bio-Gel HTP, 
Bio-Rad) and washed as described above (section 2.5.2). The resin was then washed with 
100 μL of H2O and incubated with 500 mM hydroxylamine (50 μL) for 1 hour at 37 °C or 
without hydroxylamine at 95 °C for 45 minutes. The eluates were collected, dried to 
completion and reconstituted in H2O:ACN (97:3) for LC-MS/MS analysis with the Bruker 
AmaZon instrument. 
Tryptic peptides of α-/β-casein and His-phosphorylated myoglobin (200 pmol) in 200 µL 
binding buffer (65 mM NH4OAc, 5% MeCN, (pH 7.5)) were added to a TiO2 spin tip (Protea 
Biosciences), centrifuged (2000 x g for 1 minute), re-loaded and centrifuged again. The tip 
was then washed with 100 μL of binding buffer, followed by addition of 50 μL 5% (v/v) TFA. 
The tip was incubated with the acid for 30 minutes then the eluate collected by 
centrifugation. Bound phosphopeptides were eluted with 100 μL each of 300 mM NH3, 50% 
MeCN and 500 mM NH3, 60% MeCN. All eluates were dried to completion and 
reconstituted in H2O:ACN (97:3) for LC-MS/MS analysis with the Bruker AmaZon 
instrument. 
 
2.5.5 Immunoprecipitation 
Crosslinking of 1- and 3-pHis antibodies (2 μg) to 25 μL protein A/G magnetic beads with 
DSS was conducted using the Pierce Crosslink Magnetic IP kit (Thermo Scientific). U2OS cell 
lysate (500 μg) was diluted to 500 μL with wash/binding buffer (50 mM Tris, 30 mM sodium 
carbonate, pH 8) and a pre-clearing step performed by incubating the lysate with 25 μL 
protein A/G magnetic beads for 1 hour at room temperature. Pre-cleared lysate was then 
incubated with 1- and 3-pHis antibody crosslinked magnetic beads at 4 °C overnight. Beads 
were washed with 3 X 200 µL wash/binding buffer and once with 500 µL H2O prior to 
elution with 3 X 100 μL elution buffer (100 mM trimethylamine, pH 11).   Eluted proteins 
were dried to completion by vacuum centrifugation and re-solubilised in 25 mM AmBic for 
tryptic digestion. 
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2.6 Fractionation 
 
2.6.1 SAX chromatography  
SAX was performed using a Dionex U3000 HPLC instrument equipped with a fraction 
collector. Peptides from phosphorylated protein standards (25 µg each α-/β- casein and 
His-phosphorylated myoglobin) or digested cell lysate (2 mg) were chromatographed using 
a PolySAX LP column (PolyLC; 4.6 mm × 200 mm, 5 μm particle size, 300 Å) with a binary 
solvent system of solvent A (20 mM ammonium acetate, 10% ACN) and solvent B (300 mM 
triethylammonium phosphate, 10% ACN) at pH 6.0, pH 6.8 or pH 8.0. Solvent was delivered 
at 1 mL/min according to the following gradient: 5 minutes at 100% solvent A, then 43 
minutes to 100% solvent B, and then 5 minutes at 100% solvent B before equilibration to 
start conditions. Fractions were collected every minute for 48 minutes, with every 3 pooled 
and the volume reduced by drying under vacuum to give 16 fractions in total.  
 
2.6.2 High pH RP chromatography 
High pH RP fractionation was performed using a Dionex U3000 HPLC instrument equipped 
with a fraction collector. Peptides from phosphorylated protein standards (25 µg each α-/β- 
casein and His-phosphorylated myoglobin) were separated by RP-HPLC on an Extend-C18 
column (3.5 µm packing material, 3 mm x 150 mm; Agilent Technologies Ltd., Stockport, 
UK) using a binary solvent system of solvent A (20 mM ammonium hydroxide, pH 10) and 
solvent B (20 mM ammonium hydroxide in ACN:H2O 90:10).  Solvent was delivered at 
500 µL/min according to the following gradient: 5 minutes at 5.5% solvent B, then 31 
minutes to 34% solvent B, 6 minutes to 45% solvent B, a further 6 minutes to 100% solvent 
B, then 5 minutes at 100% solvent B before equilibration to start conditions. Fractions were 
collected every minute for 48 minutes, with every 3 pooled and the volume reduced by 
drying under vacuum to give 16 fractions in total. 
 
2.6.3 SAX fractionation using StageTips 
SAX buffers for step elution were prepared by mixing Buffer A (20 mM ammonium acetate, 
10% ACN, pH 6.8) and Buffer B (300 mM triethylammonium phosphate, 10% ACN, pH 6.8) 
as follows: ‘SAX1’ 100:0 (A:B); ‘SAX2’ 95:5; ‘SAX3’ 90:10; ‘SAX4’ 80:20; ‘SAX 5’ 70:30; 
‘SAX6’ 60:40; ‘SAX7’ 50:50 ‘SAX8’ 30:70. StageTips were prepared with 2 discs of anion 
exchange material (Empore Anion Exchange, 47 mm) followed by 1 SDB disc (Empore 
styrenedivinylbenzene-XC, 47 mm) in a 200 μL pipette tip. Tips were conditioned by 
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sequential addition of 20 μL MeOH, 20 μL Buffer 2 (20 mM ammonium acetate, 80% ACN), 
20 μL Buffer 1 (20 mM ammonium acetate, pH 6.8), 20 μL buffer ‘SAX8’ and 20 μL Buffer 1, 
with centrifugation at 500 x g for 2 minutes each time. Tryptic peptides of α-/β-casein and 
His-phosphorylated myoglobin (20 µg of each) were added to the tip in 50 µL of Buffer 1 
and centrifuged as before, then the tip was washed with 20 μL Buffer 1 and the flow 
through discarded. Buffer 2 (20 μL) and 2 X 20 μL buffer ‘SAX1’ were sequentially passed 
through the tip, with the flow through combined as Fraction 1. Sequential addition of 2 X 
20 μL of each buffer ‘SAX2’ to ‘SAX 8’ with centrifugation to collect the flow through was 
performed to obtain Fractions 2-8. All SAX fractions were made up to 100 μL with H2O prior 
to desalting with C18 StageTips. 
 
2.7 Mass spectrometry 
 
2.7.1 Intact protein MS analysis 
Analysis of intact phosphorylated myoglobin was conducted using a Waters Synapt G2-Si 
instrument. Phosphorylated myoglobin (5 μM in 20 mM ammonium acetate:ACN 50:50) 
was analysed using borosilicate emitters (Thermo ES 387). Spraying voltage was adjusted to 
1.5 kV, sampling cone was 50 V.  The time-of-flight mass analyser was set to Resolution 
Mode. Data was processed using Mass Lynx V4.1, with deconvolution performed using 
MaxEnt 1.  
 
2.7.2 LC-MS/MS 
Bruker Amazon ETD 
LC-MS/MS analysis of simple peptide mixtures was performed using the AmaZon ETD ion 
trap mass spectrometer (Bruker Daltonics, Bremen, Germany) arranged in-line with a 
nanoAcquity n-UHPLC system (Waters Ltd., Elstree, UK). Peptides were loaded from an 
autosampler onto a Symmetry C18 trapping column (5 µm packing material, 180 µm x 
20 mm) (Waters Ltd., Elstree, UK) at a flow rate of 5 µL/min of solvent A (0.1% (v/v) formic 
acid in H2O), trapped for 3 minutes and then resolved on a nanoACQUITY C18 analytical 
column (1.8 µm packing material, 75 µm x 150 mm) (Waters Ltd., Elstree, UK) using a 
gradient of 97% A, 3% B (0.1% (v/v) formic acid in ACN) to 60% A, 40% B over 60 minutes at 
300 nL/min. The column effluent was introduced into the AmaZon ETD ion trap mass 
spectrometer via a nano-ESI source with capillary voltage of 2.5 kV. Full scan ESI-MS spectra 
were acquired over 150-2000 m/z, with the three most abundant ions being selected for 
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isolation and sequential activation by CID or ETD. A 1 min dynamic exclusion window was 
incorporated to avoid repeated isolation and fragmentation of the same precursor ion. CID 
was performed with helium as the target gas, with the MS/MS fragmentation amplitude set 
at 1.20 V, and ramped from 30 to 300% of the set value.  For ETD, peptides were incubated 
with fluoranthene anions (ICC target 100000, max ETD reagent accumulation time 10 ms, 
ETD reaction time 100 ms). 
 
Thermo Orbitrap Fusion  
nLC-ESI-MS/MS analysis of cell lysate samples was performed using an Orbitrap Fusion 
tribrid mass spectrometer (Thermo Scientific) attached to an UltiMate 3000 nano system 
(Dionex). Peptides were loaded onto the trapping column (Thermo Scientific, PepMap100, 
C18, 300 μm X 5 mm), using partial loop injection, for seven minutes at a flow rate of 
9 μL/min with 2% ACN 0.1% (v/v) TFA and then resolved on an analytical column (Easy-
Spray C18, 75 µm x 500 mm, 2 µm bead diameter) using a gradient of 96.2% A (0.1% formic 
acid in H2O) 3.8% B (0.1% formic acid in 80:20 ACN:H2O) to 50% B over 90 minutes at a flow 
rate of 300 nL/min.. A full scan mass spectrum was acquired over m/z 350-2000 in the 
Orbitrap (120K resolution at m/z 200) and data-dependent MS/MS analysis performed 
using a top speed approach (cycle time of 3 s), with HCD (collision energy 32%, max 
injection time 35 ms) and neutral loss triggered (Δ98) EThcD (ETD reaction time 50 ms, max 
ETD reagent injection time 200 ms, supplemental activation energy 25%, max injection time 
50 ms) for fragmentation. All product ions were detected in the ion trap (rapid mode). 
 
2.8 Data analysis  
 
2.8.1 CompassXport/MASCOT  
MS output files from the Bruker AmaZon instrument were converted to .mgf files using 
CompassXport software (Bruker Daltonic) and an in-house script. The resulting .mgf files 
were searched using the MASCOT search algorithm (version 2.6) against the Uniprot bovine 
and equine databases. Parameters were as follows: MS1 and MS2 mass tolerance of 0.6 Da; 
enzyme specificity set as trypsin with 2 missed cleavages allowed; carbamidomethylation of 
Cys set as a fixed modification; phosphorylation of Ser, Thr, Tyr and His set as variable 
modifications. Data was manually inspected using DataAnalysis software (Bruker Daltonic) 
for the presence of pHis-containing peptides, and to extract peak area values for 
(phospho)peptides. 
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2.8.2 PEAKS 7.5  
Label-free quantification of myoglobin peptides in SAX fractions (either with casein or 
spiked into U2OS lysate) was performed following analysis with the Orbitrap Fusion tribrid 
mass spectrometer. Raw files were searched using the PEAKS search engine against either 
an in-house database created by combining the Uniprot Bovine and Equine databases 
(2016.02.19) or the Uniprot human reviewed database (2015.12.02). Search parameters 
were as follows: parent mass error tolerance of 10 ppm; fragment mass error tolerance of 
0.6 Da; enzyme specificity set as trypsin with 2 missed cleavages allowed; 
carbamidomethylation of Cys set as a fixed modification; phosphorylation of Ser, Thr or Tyr, 
phosphorylation of His, Cys, Asp or Arg, and oxidation of Met set as variable modifications 
with the maximum number of variable modification per peptide set to 4. 
 
2.8.3 Proteome Discoverer 1.4  
Raw files acquired on the Thermo Fusion mass spectrometer (HCD-neutral loss triggered 
EThcD method) were converted to .mzML using ProteoWizard’s msconvert tool in order to 
perform MS2-level deisotoping. The resulting files were then processed using Proteome 
Discoverer. For each raw file scans were split into those arising from HCD and EThcD events 
using a collision energy filter (HCD: min CE 0, max CE 34; EThcD: min CE 35, max CE 1000) to 
generate 2 separate .mgf files. These were searched using the MASCOT search algorithm 
(version 2.6) against the Uniprot Human database (2015.12.02; 20,187 sequences). 
Parameters were set as follows: MS1 tolerance of 10 ppm; MS2 mass tolerance of 0.6 Da; 
enzyme specificity set to trypsin with 2 missed cleavages allowed; carbamidomethylation of 
Cys set as a fixed modification; phosphorylation of Ser, Thr, Tyr and His and oxidation of 
Met set as variable modifications; instrument type set as ESI-Quad-TOF for HCD files and 
CID+ETD for EThcD files. Phosphopeptides were additionally analysed using the ptmRS 
node, with the ‘treat all spectra as EThcD’ option selected for EThcD data. A peptide FDR 
filter of 5% was applied and all data files were exported to .csv for further processing. 
Peptides with rank >1 and those classified as ‘ambiguous’ or ‘rejected’ were removed. MS2 
spectra corresponding to phosphopeptides were assessed for the presence of 3 neutral loss 
peaks (Δ80, Δ98 and Δ116) with a mass tolerance of 0.5 Da and an intensity cut-off of 5% 
compared to the base peak ion and given a ‘Triplet’ score of 0, 1, 2 or 3 depending on the 
number of neutral loss peaks identified. 
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2.8.4 Bioinformatics 
DAVID functional annotation and clustering 
Function annotation and clustering was performed using DAVID (version 6.8). The list of pX 
proteins identified in each condition (NT siRNA and PHPT1 siRNA) was compared to a ‘user-
submitted’ background of all proteins identified by analysis of all samples. Default settings 
were used. Classification stringency: medium; similarity term overlap: 3; initial/final group 
membership: 3; EASE: 1.0. 
Enriched functional groups were classified according to P value: <0.05; <0.01 and <0.001. 
Groups with Benjamini adjusted P-values < 0.1 are also highlighted. The Benjamini-
Hochberg method is a strategy for correcting p-values to account for multiple hypothesis 
testing228. This method first ranks all items (e.g. genes/proteins) by P-value; the adjusted P-
value for a given item is then calculated by multiplying the original P-value by the total 
number of items divided by the rank of the given item. 
 
Motif-X 
Sequences for input into Motif-X were extracted from pX site/protein information to obtain 
the seven residues either side of the phosphorylated site. These ’15-mers’ were analysed 
using the Motif-X algorithm with significance set at 1E-5 (corresponds to P value of 3E-4 
with Bonferroni correction). The Bonferroni correction is a method of controlling for 
multiple comparisons; the P-value is divided by the number of statistical tests to determine 
a new, smaller P-value below which results are determined to be significant. 
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Chapter 3. Results I: Exploring strategies for the enrichment of 
phosphohistidine-containing peptides 
 
3.1 Introduction 
 
As previously discussed in Chapter 1. Introduction, the aim of this work was to develop 
strategies suitable for the analysis and identification of acid-labile pHis-containing peptides 
from complex biological samples. Phosphopeptide enrichment is a key stage in the 
phosphoproteomics workflow, yet techniques suitable for pHis-peptide enrichment are 
lacking. This chapter describes the generation and validation of a pHis protein standard, 
and its application in the characterisation of multiple phosphopeptide enrichment 
strategies for their suitability for the analysis of labile pHis-containing peptides. 
 
The phosphoproteins α- and β-casein are routinely used as standards to assess new and 
existing phosphopeptide enrichment strategies136, 155, 229 as they yield a number of well 
characterised pSer and phosphothreonine (pThr)-containing peptides upon tryptic 
digestion. However, there are currently no known analogous pHis-containing proteins 
which would provide multiple pHis-containing peptides upon enzymatic digestion. 
Additionally, pHis-containing peptides cannot be synthesised by typical solid-phase 
synthesis strategies due to the instability of the phosphoramidate bond. However, 
potassium phosphoramidate can be used to chemically phosphorylate His as a free amino 
acid, in synthetic peptides and also within proteins211, 217, 230, 231, and was therefore utilised 
to generate a pHis-containing protein which could be used as a standard for method 
development.  
 
The initial strategy for this work was to assess a number of published phosphopeptide 
enrichment strategies for their suitability for the analysis of pHis-containing peptides. 
Titanium dioxide (TiO2) enrichment is one of the most widely used techniques for 
phosphopeptide enrichment136, 147, 232, 233, although the acidic conditions used to enhance 
selectivity of enrichment may not necessarily be suitable for pHis. Another acid-labile 
modification, phosphoarginine, has previously been shown to be enriched using an 
alternative TiO2 based enrichment strategy at pH 4
234. Hydroxyapatite is known to bind 
particularly strongly to phosphoproteins and has therefore been used as a solid support to 
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perform phosphopeptide enrichment155, 156, 159. The non-acidic conditions make this 
particularly attractive for enrichment of peptides containing acid-labile pHis residues. A 
further strategy used for enrichment of phosphopeptides is based on their precipitation 
with calcium phosphate under basic conditions160, 161. All of these methods have previously 
been used to enrich pSer/pThr peptides in complex samples but thus far none of them have 
been assessed for pHis analysis. 
 
In addition to these potential enrichment strategies, chemical derivatisation approaches for 
analysis of pHis-containing peptides were also considered. The rationale for such an 
approach would be to chemically derivatise non-modified His residues, prior to actively 
inducing loss of phosphate from pHis residues. In this way, His-phosphorylated peptides 
could be inferred from their absence of chemical derivatisation. Diethylpyrocarbonate 
(DEPC) and 4-hydroxynonenal (HNE) are two possible candidates for selective His 
modification that were tested as part of this work235, 236. 
 
Finally, in response to the development of monoclonal 1- and 3-pHis antibodies227, an 
immunoprecipitation experiment was conducted. In contrast to the other techniques 
trialled, this enrichment is conducted at the protein level. Although this technique has been 
reported to recover pHis proteins from cell lysates, the ability of this method to identify His 
phosphorylated peptides is yet to be established. 
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3.2 Results 
 
3.2.1 Generation of a histidine-phosphorylated protein standard 
Potassium phosphoramidate was used to chemically phosphorylate the His residues of 
myoglobin. The specificity of the reaction is such that Ser, Thr or Tyr residues are not 
phosphorylated219 although reaction with potassium phosphoramidate can also be used to 
phosphorylate lysine residues237, 238. Myoglobin contains 11 His residues which upon 
phosphorylation and digestion can theoretically yield up to 6 pHis-containing tryptic 
peptides. Potassium phosphoramidate was synthesised in-house according to a previously 
reported reaction scheme (Figure 3.1). Phosphoryl chloride (POCl3) was reacted with 
ammonium hydroxide on ice to give ammonium hydrogen phosphoramidate 
(NH4HPO3HN2). This was subsequently reacted with potassium hydroxide (KOH) at 50 °C 
and acidified to produce potassium phosphoramidate (KHPO3NH2). Overall reaction yield 
was typically around 15%.  
 
Myoglobin was reacted with potassium phosphoramidate overnight (Figure 3.2); it is 
reported for free pHis that shorter reaction times yield the 1-pHis isomer whilst increasing 
the reaction time (to at least 16 hours) results in formation of the more thermodynamically 
stable 3-pHis isomer211.   Buffer exchange was performed to remove the large excess of 
potassium phosphoramidate and to ensure the protein was in a non-volatile solvent 
suitable for direct infusion into a mass spectrometer. 
 
The deconvoluted mass spectrum obtained following intact mass analysis of myoglobin that 
had been reacted overnight with potassium phosphoramidate is shown in Figure 3.3. 
Although a small amount of unreacted myoglobin can be observed, the vast majority of 
signal derives from phosphorylated forms of the protein. The most abundant 
phosphoisomers contain three phosphate groups, with up to five phosphoforms detected. 
The heme-bound form of myoglobin can also be observed, again with multiple 
phosphoforms, albeit in much lower abundance. 
 
Enzymatic digestion of phosphorylated myoglobin with trypsin was performed and the 
resulting peptides analysed by LC-MS/MS. Details of the His phosphorylated peptides 
detected following LC-MS/MS analysis with the Thermo Orbitrap Fusion are shown in Table 
3.1.  
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Figure 3.1 Reaction scheme for synthesis of potassium phosphoramidate (KHPO3NH2) via 
ammonium hydrogen phosphoramidate (NH4HPO3HN2) 
 
 
 
 
 
Figure 3.2 Reaction scheme for phosphorylation of histidine by potassium 
phosphoramidate. Reaction overnight yields the more thermodynamically stable 3-pHis 
isomer 
  
  
5
6 
Figure 3.3 Zero charge state mass spectrum of intact phosphorylated myoglobin following overnight reaction with potassium phosphoramidate, generated 
by direct infusion via nanoESI into a Synapt G2-Si mass spectrometer. The raw mass spectrum was deconvoluted using MaxEnt. Up to five phosphate groups 
per intact myoglobin molecule are observed, along with the heme-bound form of myoglobin containing up to four phosphate groups. 
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Table 3.1 Phosphohistidine-containing peptides of myoglobin generated by overnight 
reaction of myglobin with potassium phosphoramidate and identified following tryptic 
digestion and LC-MS/MS analysis with HCD or EThcD fragmentation. Phosphosite 
localisation was confirmed by manual annotation of the spectra. 
  
Sequence Site Observed m/z Charge 
VEADIAGpHGQEVLIR His25 845.42 2+ 
LFTGpHPETLEK His37 676.32 2+ 
pHGTVVLTALGGILK His65 730.41 2+ 
GpHHEAELKPLAQSHATK His81 645.31 3+ 
GHpHEAELKPLAQSHATK His82 645.31 3+ 
GHHEAELKPLAQSpHATK His94 645.31 3+ 
YLEFISDAIIpHVLHSK His114 983.50 2+ 
 
 
Tandem mass spectra were manually annotated in order to confirm the identity of each of 
the pHis-containing peptides (Figure 3.4.a-g). The five pHis-containing peptide sequences 
identified correspond to a total of seven pHis sites, i.e. one peptide 
(GHHEAELKPLAQSHATK) contains three possible His residues that could be phosphorylated.  
Figures 3.4.d, 3.4.e and 3.4.f indicate that there is evidence for any of the 3 possible sites of 
this peptide to be phosphorylated. There is no selectivity of the potassium 
phosphoramidate reaction in terms of which His residues can be phosphorylated, so any (or 
all) of these phosphoisomers could be present in the sample. Knowing which His residue is 
phosphorylated is not relevant for the assessment of various enrichment strategies.  No 
evidence has been found for the presence of this peptide in a multiply phosphorylated 
form. It is worth noting that the non-phosphorylated equivalents of these peptides are also 
observed by LC-MS/MS following tryptic digestion, due presumably to a combination of the 
fact that some myoglobin remained unphosphorylated after reaction with potassium 
phosphoramidate (as previously shown by intact mass analysis, Figure 3.3) and the 
potential for His residues to become dephosphorylated during LC-MS/MS analysis. 
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Figure 3.4 Product ion spectra of pHis-containing tryptic peptides of myoglobin generated 
by HCD or EThcD. a) doubly charged ion at m/z 845.42, HCD, pHis25; b) doubly charged ion 
at m/z 676.32, HCD, pHis37; c) doubly charged ion at m/z 730.41 HCD, pHis65; d) triply 
charged ion at m/z 645.31, HCD, pHis81; e) triply charged ion at m/z 645.31, EThcD, pHis82; 
f) triply charged ion at m/z 645.31, HCD, pHis94; g) doubly charged ion at m/z 983.50, HCD, 
pHis114. The sequence is displayed on the mass spectrum with the site of phosphorylation 
indicated as ‘pH’. 
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3.2.2 Stability of phosphohistidine-containing peptides 
Free pHis is known to be acid-labile211, 212 and it is also reported to have increased stability 
at basic pH compared to Ser and Thr phosphopeptides239. There is however no published 
evidence regarding the pH stability of His-phosphorylated peptides. The pH stability of the 
myoglobin pHis-containing peptides was therefore assessed at 25 °C over two hours at pH 
1, 4, 6 and 9. Acidic samples were neutralised at each time point by addition of ammonium 
hydroxide in an attempt to minimise additional de-phosphorylation which may have 
occurred between the time of collection and the point of analysis by mass spectrometry. 
The normalised intensity of two example pHis peptides is shown as a percentage compared 
to the amount at time = 0 (Figure 3.5). This data is an average of three technical replicates, 
where relative standard deviation between measurements is <20%. The results are 
representative of at least two independent experiments. 
  
  
6
3 
Figure 3.5 pH stability of pHis-containing tryptic peptides of myoglobin. Extracted ion chromatograms were used to determine the relative signal intensity 
of the pHis-containing peptides LFTGpHPETLEK at m/z 676.3 (dotted line) and VEADIAGpHGQEVLIR (solid line) at m/z 843.9 following incubation at pH 1, pH 
4, pH 6 and pH 9. Signal intensity was normalised against a non His-containing peptide and is presented as a percentage compared to the amount at time = 
0.   
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As expected the peptides show limited stability at pH 1. Both pHis peptides show rapid 
dephosphorylation, even after just 15 minutes, with the peptide VEADIAGpHGQEVLIR 
completely dephosphorylated by two hours, and the peptide LFTGpHPETLEK completely 
dephosphorylated by four hours. The t1/2 of these phosphopeptides is ~15 minutes at pH 1, 
meaning that any enrichment technique that requires peptides to be under extreme acidic 
conditions even for a few minutes is likely to greatly impact the recovery of pHis peptides. 
The stability of these pHis peptides at pH 4 and pH 6 is much greater, with almost 100% of 
the peptides remaining even after two hours. At pH 9 these pHis peptides exhibit greater 
instability than would have been expected, with only around 60% of the phosphorylated 
peptide remaining after two hours. Given that previous hydrolysis studies have been 
performed only on the free pHis it is possible that stability is affected by other residues in 
the peptide. These results therefore provide suitable pH and time-scales upon which it 
should be possible to conduct sample enrichment and preparation techniques without 
incurring significant pHis dephosphorylation. 
 
3.2.3 Titanium dioxide enrichment 
TiO2-based phosphopeptide enrichment is one of the most commonly used strategies in 
phosphoproteomics. The standard method employs acidic pH to improve specificity of 
binding136, which given the previously discussed pH stability would not necessarily be 
suitable for analysis of pHis. Alternative approaches were therefore considered, including 
performing the binding step at non-acidic pH and replicating a previously reported method 
for the analysis of phosphoarginine (pArg) which is performed using lactic and acetic acid at 
pH 4234.  A comparison of TiO2 enrichment with these three sets of binding and elution 
conditions was performed; the buffer compositions used for binding, wash and elution 
steps are shown in Table 3.2 for each of the methods.  
 
Enrichment efficiency was assessed by comparing the amount of each pHis-containing (and 
the corresponding non-phosphorylated) peptide in the un-enriched “start material”, the 
flow through and washes from the TiO2 matrix, and the eluate (Table 3.3). Two replicates 
were performed and percentage recovery calculated for each peptide at each stage of the 
experiment. Recovery was calculated by determining the peak area for each peptide 
(phosphorylated and non-phosphorylated) in the flow through, washes and eluate, and 
expressing this as a percentage compared to the peak area of the same peptide in the un-
enriched “start material”. The range of these calculated values across the five pHis peptides 
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is reported in Table 3.3. The large variability observed is due to differences in recovery 
between different peptides; typically variance between replicates for the same peptide was 
low. 
 
Table 3.2 Conditions evaluated for TiO2 enrichment of pHis (and other) phosphopeptides. 
Binding, sequential washing and sequential elution buffers for each of the three conditions 
(A, B and C) used to assess suitability of TiO2 enrichment specifically for pHis-containing 
peptides are detailed. All % are (v/v). 
  
 Binding Wash Steps Elution Steps 
A 65% ACN, 2% TFA, 
saturated with 
glutamic acid, pH 2 
1. 65% ACN, 0.5% TFA 
2. 65% CAN, 0.1% TFA 
1. 300 mM NH3, 50% ACN 
2. 500 mM NH3, 60% ACN 
B 65 mM NH4OAc, 
5% ACN,  
pH 7.5 
1. 65% ACN, 0.5% TFA 
2. 65% ACN, 0.1% TFA 
1. 300 mM NH3, 50% ACN 
2. 500 mM NH3, 60% ACN 
C 3 M lactic acid, 60% 
ACN, 12.5% AcOH,   
pH 4 
1. 2 M lactic acid, 75% ACN, 
2% TFA 
2. 2 M lactic acid, 75% ACN, 
10% AcOH, pH 4 
3. 80% ACN, 10% AcOH 
1% NH3, 30 mM (NH4)3PO4 
 
 
 
Table 3.3 Evaluation of TiO2 enrichment of tryptic pHis peptides of myoglobin under three 
different sets of conditions. Range of values for binding and elution/recovery represents 
analysis from five pHis peptides for two replicate experiments. Binding, washing and 
elution buffers for experiments A, B and C are detailed in Table 3.2.  
 
Enrichment 
conditions 
% Binding pHis 
peptides 
% Elution pHis 
peptides 
% Recovery non-
phosphorylated His peptides  
A. Acidic (pH 2) 
binding 
95 - 100 0 54 - 133 
B. Neutral (pH 
7.5) binding 
98 - 100 0 7 - 164 
C. Lactic/acetic 
acid (pH 4) 
binding 
96 - 100 0 18 - 109 
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All TiO2 binding conditions were compatible with efficient binding of pHis-containing 
peptides as demonstrated by very small amounts (maximum 5%) of any given pHis-
containing peptide being detected in the flow through and washes. However, this did not 
translate into successful enrichment as none of the pHis-containing peptides of myoglobin 
were detected following elution from the TiO2 material. It appears that under the acidic 
conditions of the binding /washing steps pHis peptides are dephosphorylated. This idea is 
supported by the fact that recovery of non-phosphorylated equivalents of the pHis 
peptides of myoglobin are greater than 100%. Extracted ion chromatograms (XICs) show 
that His-phosphorylated peptides are dephosphorylated during the enrichment process 
and therefore the amount of non-phosphorylated peptide recovered is greater than the 
amount in the “start material” (Figure 3.6).  
 
Given the previous pH stability data this result is not surprising for the experiment 
conducted under the typical TiO2 enrichment conditions (binding at pH 2) where rapid 
dephosphorylation would be expected. The pH stability data suggests that pHis peptides 
could be enriched at pH 4 and pH 7.5 without undergoing considerable dephosphorylation. 
However, these experiments still employ acidic wash steps which although were performed 
rapidly, appear to have significantly hindered the recovery of His-phosphorylated peptides.  
 
In all cases enrichment of non-pHis-containing phosphopeptides was shown to be 
successful by the efficient recovery of pSer/pThr peptides of α-/β-casein. The average 
recovery of four representative phosphopeptides from α-/β-casein following TiO2 
enrichment was 67%. 
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Figure 3.6 Representative XICs demonstrate dephosphorylation of pHis-containing 
peptides during TiO2 enrichment. Overlay of XICs for the non-phosphorylated counterpart 
of the pHis-containing myoglobin peptide VEADIAGHGQEVLIR at m/z 803.9 in the load (red) 
and flow through (green) for TiO2 enrichment performed under standard conditions. 
Greater than 100% recovery of the non-phosphorylated peptide indicates loss of the 
phosphate group from the corresponding pHis-containing peptide. 
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3.2.4. Hydroxyapatite enrichment 
Following on from its application in chromatography columns to separate phosphoproteins, 
hydroxyapatite has been used as a solid support to enable phosphopeptide enrichment150, 
240. The potential advantage of this technique for pHis analysis is that all binding, washing 
and elution steps are performed at non-acidic pH; binding to the solid support is performed 
at pH 7.2, and under standard conditions a phosphate salt at pH 7.8 competitively elutes 
phosphopeptides155, 156. Initial experiments were performed using these standard elution 
conditions, but poor recovery of both phosphorylated and non-phosphorylated His-
containing peptides was observed (Table 3.4). In an attempt to improve specificity of 
phosphopeptide binding and recovery of pHis peptides the elution step was also performed 
at pH 6 and pH 7. Phosphopeptide enrichment efficiency was assessed by calculating the 
percentage recovery of phosphorylated and non-phosphorylated peptides in the flow 
though, washes and eluate compared to un-enriched “start material”. Two replicates were 
performed and the values for % recovery displayed in Table 3.4 represent the range across 
five pHis peptides. As with the TiO2 experiments the observed variability is due to 
differences in recovery between different peptides.  
 
Table 3.4 Evaluation of hydroxyapatite enrichment of tryptic pHis peptides of myoglobin 
under three different sets of elution conditions. Range of values for binding and 
elution/recovery represents analysis from five pHis peptides for two replicate experiments.  
 
Enrichment 
conditions 
(elution pH) 
% binding pHis- 
containing 
peptides 
% elution pHis-  
containing 
peptides 
% recovery non-
phosphorylated His-
containing peptides 
pH 7.8 83 - 96 0 4 - 18 
pH 7.0 83 - 96 0 2 - 37 
pH 6.0 83 - 100 0 1 - 35 
 
 
Binding of pHis-containing peptides to the hydroxyapatite solid support was generally 
good, ranging from 83-100% across all experiments. However, none of the pHis-containing 
peptides from myoglobin were detected in the elution at any of the pH conditions trialled. 
Under the same conditions, pSer and pThr peptides from α-/β-casein were successfully 
enriched demonstrating that the column and conditions used were generally suitable for 
phosphopeptide enrichment. The average recovery of four representative α-/β-casein 
phosphopeptides was 43%. Unlike for the acidic TiO2 experiments the lack of detection of 
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these pHis peptides was not suspected to be a result of dephosphorylation. Indeed, the 
recovery of non-phosphorylated His-containing peptides was less than 40%, indicating that 
both phosphorylated and non-phosphorylated His-containing peptides were not being 
eluted from the hydroxyapatite. The degree of peptide recovery was impacted very little by 
the pH of the elution buffer.  
 
The results of the experiments performed here seem to demonstrate an exceptionally 
strong binding interaction between hydroxyapatite and these particular pHis peptides, and 
indeed their non-phosphorylated counterparts.  Perhaps other residues of the peptides are 
binding and thus increasing the strength of the interaction, or His itself exhibits a 
particularly strong binding interaction with hydroxyapatite. Additionally, the average 
recovery of seven representative non-phosphorylated peptides from α-/β-casein is only 
44% indicating that considerable non-specific binding could be causing poor overall 
recovery of peptides from hydroxyapatite. The results presented here for the attempted 
enrichment of pHis peptides of myoglobin using hydroxyapatite seem to suggest that it is 
not a suitable technique for analysis of pHis peptides. 
 
3.2.5. Calcium phosphate precipitation 
Another published method for phosphopeptide enrichment works by co-precipitation of 
phosphorylated peptides with calcium phosphate at basic pH160, 161. The non-acidic 
conditions, at least for the precipitation and wash steps, make this an appealing strategy 
for the analysis of pHis. The phosphopeptide recovery step is however performed under 
acidic conditions (5% TFA, ~pH 1) which may be expected to impact on the effectiveness of 
pHis-peptide recovery by this method. An attempt was made to rapidly re-solubilise the 
pellet with 0.1% TFA (~pH 3), in order to reduce potential dephosphorylation of pHis 
peptides. Re-solubilised samples were immediately loaded onto C18 desalting tips and 
desalted under neutral conditions. 
 
The amount of phosphorylated and non-phosphorylated peptides in the flow 
through/washes (not precipitated) and the sample following re-solubilisation of the 
precipitate was compared to un-enriched “start material” to determine the percentage 
recovery of (phospho)peptides. Three replicates were performed and the values for % 
recovery displayed in Table 3.5 represent the range across five pHis peptides. 
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Table 3.5 Evaluation of calcium phosphate precipitation for enrichment of tryptic pHis 
peptides of myoglobin under two different sets of re-solubilisation conditions. Range of 
values for capture and recovery represents analysis from five pHis peptides for three 
replicate experiments. 
 
Re-
solubilisation 
conditions 
% pHis- containing 
peptides captured 
in precipitate  
% pHis- containing 
peptides recovered 
after re-solubilisation 
% recovery (total) non-
phosphorylated His-
containing peptides 
5% TFA 80 – 100 1 – 9 0 – 51 
0.1% TFA 81 – 100 0 – 8 0 – 55  
 
 
The calcium phosphate precipitation step captures at least 80% of the pHis-containing 
peptides, however, recovery of these peptides following re-solubilisation of the precipitate 
is extremely low (maximum recovery of 9% for pHis peptides). With 5% TFA this could be 
due to the expected dephosphorylation that would occur at pH 1. Whilst recovery of non-
phosphorylated His-containing peptides didn’t exceed 100% (as was demonstrated for 
dephosphorylation during TiO2 enrichment) the non-phosphorylated His-containing 
peptides were detected in the sample following re-solubilisation. The recovery of pHis 
peptides at 0.1% TFA was potentially impacted by poor re-solubilisation at this pH; a pellet 
was still visible in the sample despite vigorous mixing, and this resulted in two of the 
peptides exhibiting 0% recovery in at least one replicate. This poor level of recovery was 
also seen for α-/β-casein peptides, whereby on average only 3% recovery was observed for 
four representative pSer/pThr peptides. Overall, the recovery of all peptides is lower than 
would be expected. A maximum of 55% of any non-phosphorylated His-containing peptide 
was recovered across the whole experiment and similarly recovery of α-/β-casein 
phosphopeptides (with 5% TFA) was only 48% on average.  Sample losses through the 
course of the experiment, perhaps during the C18 desalting step, could account for this low 
recovery. The acidic re-solubilisation step has proven to be unsuitable for analysis of pHis 
peptides, with even a modest decrease in acidity to aid pHis peptide stability dramatically 
reducing enrichment efficiency. 
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3.2.6 Subtractive approaches for phosphohistidine peptide enrichment 
Given the challenges associated with analysis of pHis-containing peptides using standard 
phosphopeptide enrichment strategies, an alternative approach was developed which 
would instead rely on indirect identification of pHis-peptides. A subtractive approach, as 
depicted in Figure 3.7, requires phosphopeptides to be bound to a solid support, such as 
TiO2 or hydroxyapatite, whilst all non-phosphorylated peptides are washed away. Selective 
dephosphorylation of pHis is then performed and the recovered peptides are inferred as 
having previously been phosphorylated on His. Any remaining phosphopeptides 
(pSer/pThr) can be recovered using the standard elution conditions for each of the solid 
supports. The first step in establishing this approach was to determine suitable conditions 
for pHis peptide dephosphorylation. Previously presented results regarding the pH stability 
of pHis peptides of myoglobin indicate that an acidic treatment step could be used to elicit 
the required dephosphorylation. 
 
As an alternative to acid, heat treatment may also be a viable option to selectively 
dephosphorylate pHis-peptides for the purposes of a subtractive workflow. Therefore, the 
stability of pHis-containing myoglobin peptides was assessed at elevated temperature. 
Myoglobin peptides were incubated in a neutral buffer at 80 °C and 95 °C for up to four 
hours. As for the pH stability studies, the normalised intensity of two example pHis 
peptides is shown as a percentage compared to the amount at time = 0 (Figure 3.8).   
  
7
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Figure 3.7 Workflow to show proposed subtractive strategy for pHis peptide analysis as an alternative to standard phosphopeptide enrichment 
workflows. Binding and wash steps should be performed at (near) neutral pH. Heat, acid and hydroxylamine treatment can be used to selectively 
dephosphorylate pHis-containing peptides with consideration given to compatibility with the proposed solid support. 
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Figure 3.8 Temperature stability of pHis-containing tryptic peptides of myoglobin. XICs were used to determine signal intensity of the pHis-containing 
peptides YLEFISDAIIpHVLHSK at m/z 655.6 and LFTGpHPETLEK at m/z 676.3 following incubation at 80 °C and 95 °C. Signal intensity was normalised against 
a non His-containing peptide and is presented as a percentage compared to the amount at time = 0. 
Chapter 3. Results I 
 
74 
 
Rapid dephosphorylation was observed for both pHis peptides with a greater loss of the 
phosphate group observed at the higher temperature, as would be expected. At 95 °C the 
t1/2 for both peptides is ~15 minutes, whilst at 80 °C the t1/2 is 45-60 minutes. Based on 
these results it should be possible to use 95 °C heat treatment for the selective 
dephosphorylation of pHis within a subtractive workflow. 
 
Another potential approach to elicit dephosphorylation of pHis-containing peptides is 
through the use of hydroxylamine, which has previously been shown to selectively 
dephosphorylate pHis239. The reduction in signal intensity of pHis-peptides of myoglobin 
following reaction for 1 hour with hydroxylamine is shown in Table 3.6. This data is from a 
single experiment. Although only four of the previously identified pHis peptides were 
observed in this experiment, presumably due to degradation of the pHis-myoglobin 
standard over time, this was deemed sufficient to assess the effects of hydroxylamine 
treatment. A representative XIC (Figure 3.9) for a single peptide pre-and post- 
hydroxylamine treatment indicates almost complete dephosphorylation of this peptide in 
solution. 
 
Table 3.6 Reduction in pHis-containing peptide signal following reaction for 1 hour with 
hydroxylamine. XICs were used to determine the signal intensity for each of the pHis-
containing peptides before and after the reaction, with the difference expressed as a 
percentage compared to the amount before the reaction. 
 
Sequence m/z % reduction in pHis 
peptide signal intensity 
LFTGpHPETLEK 676.3 93.6 
pHGTVVLTALGGILK 729.9 91.8 
VEADIAGpHGQEVLIR 843.9 95.1 
YLEFISDAIIpHVLHSK 655.6 86.9 
 
All pHis-containing peptides detected before the reaction exhibited at least an 86% 
reduction in signal intensity following treatment for 1 hour with hydroxylamine. Although 
the amount of dephosphorylation appears to be peptide dependent, with the amount of 
peptide remaining after the reaction ranging from 5-13%, this is nevertheless an effective 
method to dephosphorylate pHis peptides.  Hydroxylamine is comparable to elevated 
temperature (95 °C) for pHis dephosphorylation, where ~5% of the pHis peptides were 
remaining after 1 hour. Both techniques perform slightly better than acidic treatment (pH 
1) which after 1 hour exhibits a 70 – 85% reduction in pHis signal intensity. 
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Figure 3.9 Representative XICs to demonstrate loss of phosphate following reaction of 
histidine phosphorylated myoglobin peptides for 1 hour with hydroxylamine. Overlay of 
XICs of pHis-containing peptide VEADIAGpHGQEVLIR at m/z 843.9 before (blue) and after 
(red) reaction with hydroxylamine shows 95% reduction in signal intensity. 
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Following on from this evaluation of pHis dephosphorylation, the subtractive approach was 
applied to both a TiO2 and hydroxyapatite based strategy, according to the workflow 
previously depicted in Figure 3.7. Phosphopeptides were bound to the TiO2 or 
hydroxyapatite solid support under (near) neutral conditions. For the TiO2 experiment 
selective dephosphorylation was attempted using an acid treatment step, whilst for 
hydroxyapatite, which exhibits instability below pH 5.5, elevated temperature and 
hydroxylamine treatment were trialled. Percentage binding and recovery for pHis peptides 
and their non-phosphorylated equivalents was determined at each stage of the 
experiment. The range of these calculated values across the five pHis peptides is reported 
in Table 3.7.  
 
Table 3.7 Recovery of tryptic pHis peptides of myoglobin by subtractive approach using 
TiO2 or hydroxyapatite. Binding and recovery of pHis peptides (and non-phosphorylated 
equivalents) following a subtractive strategy for enrichment using acid to elicit selective 
dephosphorylation of pHis peptides bound to TiO2 and either heat or hydroxylamine for 
pHis peptides bound to hydroxyapatite. Range of values represents analysis of five pHis 
peptides. 
 
Solid support & 
dephosphorylation 
conditions 
% binding pHis- 
containing 
peptides 
% binding non-
phosphorylated His-  
containing peptides 
% recovery non-
phosphorylated His-
containing peptides 
after treatment 
TiO2: 
Acid (pH 1) 
89 - 100 0 - 94 0 
Hydroxyapatite: 
Heat  
(95 °C, 45 mins) 
78 – 93 18 – 68 0 – 2 
Hydroxyapatite: 
Hydroxylamine  
(1 hour) 
85 – 96 0 – 71 0 – 2 
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Under these conditions binding of pHis peptides to the TiO2 solid support was efficient (89-
100%) but a number of other problems were highlighted with the proposed method. 
Firstly, there was considerable binding of some of the non-phosphorylated His-containing 
peptides to the TiO2 solid support (up to 94%) when this was performed at neutral pH. 
Binding of non-phosphorylated peptides is undesirable as they could interfere with 
subsequent identification of His phosphorylated peptides. Secondly, there was no recovery 
of previously phosphorylated His-containing peptides following the acid treatment step, 
with a large portion of these peptides remaining unaccounted for in any stage of the 
experiment. The reasons for this are currently unexplained. Finally, following the acid 
treatment a few non-phosphorylated peptides of α-/β-casein are observed, suggesting this 
step can remove peptides from the TiO2 solid support. Elution of these non-phosphorylated 
peptides is detrimental in this type of subtractive strategy as such peptides could 
mistakenly be identified as having previously been phosphorylated on His in a more 
complex sample where sites of phosphorylation are unknown. 
 
Both hydroxyapatite based experiments demonstrate reasonable binding of pHis-
containing peptides to the hydroxyapatite resin, as was previously observed with this solid 
support, therefore highlighting that the binding stage of this experiment is robust. 
However, despite both elevated temperature and reaction with hydroxylamine proving 
effective for almost complete dephosphorylation of pHis peptides in solution (Figures 3.8 
and 3.9), these treatments did not facilitate recovery of peptides bound to hydroxyapatite. 
Neither incubation at 95 °C for 45 minutes or with hydroxylamine for 1 hour resulted in 
recovery of His-containing peptides from hydroxyapatite. An additional issue with this 
strategy is the incomplete removal of non-phosphorylated peptides from the resin prior to 
the dephosphorylation step; as little as 30% is recovered in flow through/washes in some 
cases. The apparently strong binding of non-phosphorylated peptides to hydroxyapatite 
resin in these experiments is perhaps not unexpected given the poor recovery of peptides 
previously observed for the hydroxyapatite enrichment strategy (Table 3.4). Binding of non-
phosphorylated peptides at this stage could hinder interpretation of results from more 
complex experiments with unknown phosphosites whereby pHis peptides would be 
inferred by their lack of a phosphate group.  
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3.2.7 Derivatisation of histidine residues 
An additional strategy for indirect identification of pHis residues was attempted based on 
chemical derivatisation of non-phosphorylated His residues. The general workflow for such 
a strategy is detailed in Figure 3.10. With this approach His residues would first be 
chemically modified then pHis peptides could either be subjected to selective 
dephosphorylation or standard sample preparation techniques which relied on acid could 
be used without the loss of the phosphate group hindering analysis. The absence of a 
phosphate group (alongside the lack of the chemical derivatisation) would be indicative of 
His phosphorylation. 
 
DEPC and HNE have both been previously shown to be capable of modifying His235, 236, 
according to the reactions displayed in Figure 3.11. Tryptic peptides of the phosphorylated 
myoglobin standard were reacted with both DEPC and HNE to observe the extent of 
modification of unphosphorylated His. Both reagents were shown to be capable of 
modifying His-containing peptides. The efficiency of the reaction is displayed as a 
percentage reduction in His-containing peptide signal intensity (Table 3.8), as this can be 
compared before and after the reaction.  Following the reactions chemically modified His-
containing peptides were identified by mass spectrometry by addition of 72 Da (DEPC) or 
156 Da (HNE) to the non-modified peptide mass, thus indicating that the observed 
reduction in His-containing peptide signal is a result of the expected modification having 
occurred. Peptides without a His residue remained unmodified by these reactions, as 
determined by comparable signal intensity before and after the reaction. 
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Figure 3.10 Workflow to show subtractive strategy based on chemical derivatisation of non-phosphorylated histidine residues. Dephosphorylation of 
pHis peptides following chemical derivatisation of non-phosphorylated His residues allows His phosphorylation to be inferred by lack of phosphate group or 
chemical modification. 
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Figure 3.11 Reaction scheme for chemical modification of histidine residues. Non-
phosphorylated His residues can be modified by reaction with a) 4-hydroxynonenal (HNE) 
or b) diethylpyrocarbonate (DEPC) 
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Table 3.8 Reduction in signal intensity of histidine-containing peptides following reaction 
with 4-hydroxynonenal (HNE) and diethylpyrocarbonate (DEPC). XICs were used to 
determine the signal intensity for each of the His-containing peptides before and after 
reaction, with the difference expressed as a percentage compared to the amount before 
the reaction. 
 
Peptide m/z 
% reduction in signal intensity 
HNE DEPC 
LFTGHPETLEK 636.3 47.3 68.8 
HPGDFGADAQGAMTK 751.8 36.9 69.6 
VEADIAGHGQEVLIR 803.9 61.5 42.6 
HGTVVLTALGGILK 689.9 99.4 3.8 
 
 
For both reactions the degree of modification of His-containing peptides is variable and 
incomplete. With HNE one peptide is almost completely modified (HGTVVLTALGGILK; 99%) 
although for others there is as little as 37% modification. For reaction with DEPC the degree 
of modification ranges from 4-70%, with this reaction performing better than HNE for some 
peptides but worse for others. For these reactions to be successfully incorporated into a 
subtractive strategy for pHis peptide identification, the degree of modification would need 
to approach 100% for all His-containing peptides to allow conclusions to be drawn that the 
now free His-peptides were previously phosphorylated. Further experiments may have 
revealed reaction conditions which facilitated complete reaction of all His residues, but this 
was not investigated any further. As it stands, chemical derivatisation of His-containing 
peptides with these reagents appears not to be suitable for use as part of a subtractive 
strategy for pHis peptide identification. 
 
3.2.8 Immunoprecipitation 
One of the most recent developments in the field of pHis analysis is the production of 
monoclonal antibodies for the 1- and 3- isomers of pHis227. These have been shown to be 
capable of enriching pHis proteins from cell lysate via an immunoprecipitation approach, 
although the published data does not give details about the His residues of these proteins 
that are phosphorylated. To determine effectiveness of these antibodies for pHis peptide 
analysis, an immunoprecipitation experiment was conducted using the 1- and 3-pHis 
antibodies to enrich for pHis-containing proteins in a U2OS lysate, which were 
subsequently digested and analysed by LC-MS/MS using the Orbitrap Fusion mass 
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spectrometer. Data was searched using MASCOT, with a peptide FDR of 1% and two 
peptides required per protein for identification.  
 
A total of 1002 proteins were identified following immunoprecipitation with the 3-pHis 
antibody, compared to 837 with the 1-pHis antibody. There are 684 proteins common to 
both IP experiments (Figure 3.12 a). Many of the proteins identifications shared with both 
samples are likely to be a result of non-specific interactions, resulting in a background of 
common contaminant proteins binding to the affinity resin241, 242. The data generated in 
these experiments was compared with previously published data for pHis 
immunoprecipitation (Figure 3.12 b, c and full list of overlapping proteins in Appendix). 
Proteins from the Fuhs et al. list were filtered to only include those which showed a greater 
than 2-fold difference compared to the control, with the aim of removing proteins that had 
bound non-specifically from this list. Overlap of protein IDs between this experiment and 
the previously published list was 24% for 3-pHis proteins and 28% for 1-pHis proteins. 
However, there were no pHis-containing peptides identified in either the 1- or 3-pHis 
immunoprecipitation experiments, and indeed very few phosphorylated peptides were 
identified in either sample. Without detection and identification of pHis peptides there is 
no way to validate, using only this type of enrichment, whether any of the identified 
proteins were actually phosphorylated on His. Despite enriching for pHis proteins, there are 
still a vast number of non-phosphorylated peptides present in the sample after tryptic 
digestion which will potentially result in the same ion-suppression effects evident in non-
enriched samples and stoichiometry is still likely to be low. In order for this 
immunoprecipitation approach to be used for identification of pHis-containing peptides an 
additional stage of enrichment may be required at the peptide level following enrichment 
of pHis proteins. 
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Figure 3.12 Immunoprecipitation with 1- and 3-pHis antibodies a) Overlap in protein IDs 
between 1-and 3-pHis IP experiments b) Overlap in protein IDs between this experiment 
and published IP data for 1-pHis c) Overlap in protein IDs between this experiment and 
published IP data for 3-pHis (List of overlapping protein IDs can be found in the Appendix)  
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3.3. Conclusions 
 
His-phosphorylated peptides have been generated by chemical phosphorylation of 
myoglobin with potassium phosphoramidate and subsequent tryptic digestion. MS/MS 
analysis was used to identify five tryptic pHis-containing peptides, and the sites of His 
phosphorylation were determined. As expected based on previously published studies 
regarding pH stability of the free pHis amino acid211, 212, these pHis-containing peptides 
exhibit considerable instability at acidic pH and high temperatures, which poses a number 
of challenges for their analysis by typical (phospho)proteomics strategies. It was also 
observed that these pHis peptides were less stable at pH 9 than was previously expected. 
 
None of the methods presented in this chapter have proven successful for the analysis of 
pHis-containing peptides. Attempts to enrich with either TiO2 or hydroxyapatite resulted in 
no recovery of pHis-containing peptides. In the case of TiO2, the primary reason for the 
failure of this method was the dephosphorylation of pHis over the course of the 
experiment, whilst the hydroxyapatite method appears to display considerable non-specific 
binding. Both methods were shown to enrich pSer/pThr-containing peptides meaning the 
aforementioned issues are specific to pHis. Calcium phosphate precipitation also proved 
unsuccessful for pHis peptide enrichment due to dephosphorylation of pHis peptides 
during acidic resolubilisation of the precipitation, and was further hindered by poor peptide 
recovery. 
 
Additional methods trialled were based around a subtractive approach, using TiO2 or 
hydroxyapatite for binding followed by selective dephosphorylation of pHis-containing 
peptides by reduction in pH, elevated temperature or hydroxylamine treatment. Again, 
problems associated with these methods, based on extremely poor recovery meant that 
they could not be used for pHis peptide analysis. A similar subtractive approach was tested 
based on the chemical derivatisation of non-phosphorylated His residues whereby His 
phosphorylation would be inferred by the absence of the chemical modification (or 
phosphorylation) following standard phosphoproteomics strategies. Neither DEPC nor HNE 
were capable of consistent and complete derivatisation of non-phosphorylated His residues 
which would be essential for such an approach to be feasible. 
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An attempt was also made to identify pHis-containing peptides and proteins via an 
immunoprecipitation approach using monoclonal 1- and 3-pHis antibodies. Despite a large 
number of proteins being identified, approximately 25% of which match with previously 
published data, there were no pHis-containing peptides identified in the dataset, meaning 
that the identity of these proteins as His phosphorylated can only be inferred. 
 
Overall, it would be preferable for any strategy for pHis analysis to be based upon the 
direct identification of pHis-containing peptides, therefore allowing the site of 
phosphorylation to be localized to a specific residue within the peptide. His is not the only 
labile phosphorylation suspected to be present in mammalian systems; Lys, Arg, Asp, Glu 
and Cys are also known to be phosphorylated in other systems, although there is little to no 
evidence currently for these modifications in higher eukaryotes, arguably largely because 
of difficulty in their identification. An indirect approach to phosphopeptide identification 
would ignore modification of other acid-labile residues, and peptides with other 
phosphorylated residues may be missed, or indeed mis-assigned as pHis. Ideally, an 
analytical strategy developed for characterisation of pHis would also be suitable for 
identification of other acid-labile phosphorylated residues, allowing for an unbiased 
approach to phosphopeptide analysis. 
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Chapter 4. Results II: Development of a strong anion exchange 
approach for analysis of phosphohistidine 
 
4.1 Introduction 
 
Following on from the unsuccessful attempts to adapt existing phosphopeptide strategies 
for enrichment and subsequent characterisation of pHis (Chapter 3. Results I) an alternative 
approach was sought. This chapter describes the development of a strong anion exchange 
(SAX) fractionation method suitable for analysis of pHis-containing peptides. Initial 
evaluation of the method with a simple peptide mixture is followed by validation for its 
suitability for analysis of a complex cell lysate. 
 
A fractionation strategy is different to enrichment in that all peptides are recovered and 
analysed, compared to enrichment whereby the aim is to remove non-phosphorylated 
peptides, as far as is possible, from the analysis. Fractionation is routinely used in 
proteomics studies to increase the depth of proteome coverage achieved, with strong 
cation exchange (SCX) and high pH reverse-phase chromatography being particularly 
attractive for whole proteome analysis84, 169, 173. Phosphoproteome analysis has also been 
conducted using SCX243 although more recent developments have seen SCX coupled to 
phosphopeptide enrichment techniques such as IMAC92, 127, or combined with an additional 
fractionation step such as anion exchange177. SAX has proven to be particularly effective for 
analysis of phosphopeptides, either as a strand alone fractionation strategy or coupled with 
enrichment steps or another dimension of separation such as high pH reversed phase 
chromatography to improve coverage178-180, 244, 245.  
 
All ion exchange, including SAX, enables separation of peptides based on their net 
accessible charge, which is dependent on the residues a given peptides possess and the pH 
at which the separation is conducted. A decrease in pH results in increased protonation of 
amino acid residues within the peptide whose side-chains possess an ionisable group, 
thereby reducing the ion-ion interaction these peptides have with a positively charged 
stationary phase and/or introducing a repulsive effect. Therefore, a decreasing pH gradient 
can be used to perform anion exchange separation of peptides. Alternatively, anion 
exchange can be conducted at a constant pH with elution brought about by an increasing 
salt gradient; peptides with a stronger interaction with the anion exchange column due to 
greater net negative charge require a higher concentration of salt to be eluted. In terms of 
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phosphopeptides, the negatively charged phosphate group will increase the interaction 
between these peptides and the SAX column, meaning they will elute later in the gradient, 
regardless of whether a pH or salt gradient is used.  A recently reported method by Alpert 
et al180 demonstrates that strong anion exchange based fractionation of phosphopeptides 
can be achieved using triethylammonium phosphate, with binding at high pH and elution 
by pH gradient. The work described in this chapter seeks to develop the SAX methodology 
to allow fractionation of pHis peptides using a salt gradient at non-acidic pH. 
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4.2 Results 
 
4.2.1. Optimal pH for SAX fractionation 
To help maintain pHis peptide stability, the SAX fractionation strategy must be conducted 
at non-acidic pH, using a salt gradient for peptide elution. The optimal conditions for 
fractionation of phosphopeptides are such that separation of phosphorylated and non-
phosphorylated peptides is maximised. Negatively charged phosphate groups ensure 
increased retention of phosphopeptides, which would be expected to result in SAX 
fractions at the end of the gradient containing a higher percentage of phosphopeptides 
compared to those at the beginning where the salt concentration is low. The pKa values of 
a phosphate group and amino acid side chains in peptides246 are given in Table 4.1.  
 
Table 4.1 pKa values of phosphate group and amino acid side chains. Phosphate has three 
pKa values as shown. Amino acid side chain pKa values measured in peptides246 
 
 pKa 
Phosphate 2.2, 7.2, 12.4 
Asp 3.9 
Glu 4.3 
His 6.5 
Cys 8.6 
Tyr 9.8 
Lys 10.4 
Arg 12.3 
C terminus 3.7 
N terminus 8.0 
 
Above pH 2 all phosphate groups will have one negative charge, whilst increasing the pH 
above ~7 will result in phosphopeptides gaining an additional charge and therefore 
exhibiting a stronger interaction with the SAX column. Above pH ~4 all Glu/Asp residues 
will be deprotonated, thus there is likely to be some interference in later fractions from 
peptides with multiple acidic residues when conducting SAX at non-acidic pH. Finally, given 
that histidine has a pKa of 6.5, non-phosphorylated His residues will carry a positive charge 
below pH 6.5, resulting in peptides containing His eluting earlier in the gradient when SAX 
is conducted at lower pH. The difference in charge between protonated and 
phosphorylated His residues will allow for a greater separation between these peptides and 
their phosphorylated equivalents than would be observed for other pairs of 
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phosphorylated (pSer/pThr) and non-phosphorylated peptides, where the non-
phosphorylated residue is uncharged. 
 
Initial method development and optimisation was conducted using a standard mixture of 
α-/β-casein and myoglobin tryptic peptides, containing non-phosphorylated, pSer/pThr and 
pHis peptides. SAX fractionation was tested at pH 6, 6.8 and 8. Fractions were collected 
every minute and pooled to give 16 fractions overall, which were subsequently analysed by 
LC-MS/MS. An equal volume of each fraction was loaded onto the trap column of the LC-
MS system at neutral pH, with the LC column then developed under standard conditions. 
The data was processed using PEAKS in order to perform label free quantification of each 
peptide and thus assess efficiency of peptide separation and recovery. The overall 
phosphopeptide recovery in each fraction was determined by summing all reported signal 
intensity for a given fraction, then calculating the percentage of this attributable to either 
phosphorylated or non-phosphorylated myoglobin and α-/β-casein peptides (Figure 4.1). 
 
Under all pH conditions it was observed that the initial fractions consist of predominantly 
non-phosphorylated peptides, whilst the latter fractions show up to 100% of signal 
attributable to phosphorylated peptides. The SAX fractionation approach separates 
phosphorylated peptides from non-phosphorylated peptides using a salt gradient elution, 
and results in a number of fractions towards the latter end of the column development that 
are considerably enriched for phosphopeptides. At pH 6.8 there is the greatest number of 
fractions containing more than 80% phosphopeptide signal; 7 fractions have 
phosphopeptide signal >80% at pH 6.8, compared to 3 and 4 fractions at pH 6 and 8 
respectively. 
 
All three analyses show fractions towards the middle of the gradient (fractions ~10-13) that 
appear to have a higher percentage of non-phosphorylated peptides than might be 
expected based on the otherwise observed trend of decreasing non-phosphorylated 
peptide signal as the gradient progresses. This apparent discrepancy can be explained as an 
artefact of the data processing strategy. Signal from one non-phosphorylated peptide in 
particular may dominate the fraction despite the total number of non-phosphorylated 
peptides being low. For example, the peptide FQSEEQQQTEDELQDK from β-casein 
generates the most intense ion signal by far in fraction 12 at pH 6, resulting in almost 80% 
of the total signal attributed to non-phosphorylated peptides. However, the percentage of 
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non-phosphorylated peptides identified in this fraction in terms of unique number of 
peptides is only ~50% (12 out of 22 peptides are non-phosphorylated). Despite this issue, 
representing phosphopeptide enrichment in terms of signal intensity is overall preferable 
for a simple mixture, as the observed enrichment is not diminished by detection of small 
amounts of non-phosphorylated peptides in later fractions, potentially due to carry-over on 
the LC column. Overall, using peptide signal intensity is appropriate for comparison 
between conditions as is required for this experiment.  
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Figure 4.1. Separation of phosphorylated and non-phosphorylated peptides is achieved 
by strong anion exchange (SAX) chromatography. Percentage of the total signal intensity 
attributed to phosphopeptides (blue) and non-phosphorylated peptides (grey) in each SAX 
fraction at pH 6, 6.8 and 8, following LC-MS/MS analysis and label free quantification using 
PEAKS, with later fractions consisting of up to 100% phosphopeptides. 
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The label free quantification data was also used to determine the fractions in which pHis 
peptides of myoglobin (and their non-phosphorylated equivalents) were observed. For any 
given peptide, the total signal intensity across all fractions was summed, and the amount in 
each individual fraction then displayed as a percentage of this total amount. The results for 
each pair of the pHis and equivalent non-phosphorylated peptide are compared at 
different pH values (Figure 4.2). 
 
At pH 8 (green lines), only two of the five pHis peptides (VEADIAGHGQEVLIR and 
LFTGHPETLEK, Figure 4.2 a and b) exhibit separation from their non-phosphorylated 
equivalent. The other three peptides (HGTVVLTALGGILK, GHHEAELKPLAQSHATK and 
YLEFISDAIIHVLHSK, Figure 4.2 c, d and e) elute in the same fraction as their non-
phosphorylated equivalents as shown by the overlapping solid and dashed lines. In general, 
non-phosphorylated peptides elute in later fractions at pH 8 compared to at pH 6.8 and 6. 
Later elution of non-phosphorylated His-containing peptides at higher pH can be explained 
by the fact that the imidazole side chain of histidine (pKa 6.5) will be deprotonated at pH 8, 
yielding an uncharged residue, and resulting in reduction of the repulsive interaction with 
the SAX column that is observed when the histidine side chain is positively charged. The 
effects of this repulsive interaction between positively charged histidine and the SAX 
column at lower pH is particularly apparent for peptides HGTVVLTALGGILK and 
GHHEAELKPLAQSHATK which are observed in fraction 1 at pH 6 and pH 6.8. 
  
The peptides VEADIAGHGQEVLIR and YLEFISDAIIHVLHSK show similar behaviour under all 
three pH conditions, with the pHis and non-pHis versions of YLEFISDAIIHVLHSK eluting in 
the same fractions and VEADIAGHGQEVLIR in adjacent fractions regardless of pH. As pH 
increases from pH 6 to pH 8, increased deprotonation of the phosphate group should result 
in greater retention of a given phosphorylated peptide and hence greater separation from 
the non-phosphorylated equivalent. In the case of these peptides other residues may be 
suppressing the effects of additional deprotonation, resulting in similar retention by the 
SAX column at pH 6, 6.8 and 8.  However, for HGTVVLTALGGILK, GHHEAELKPLAQSHATK and 
LFTGHPETLEK differential separation is observed. Although maximum separation is 
observed at pH 6 (red lines) for the LFTGHPETLEK peptide, separation is maximised for the 
other two peptides at pH 6.8 (blue lines). Additionally, at pH 6 the non-phosphorylated 
HGTVVLTALGGILK peptide (and to a lesser extent the GHHEAELKPLAQSHATK peptide) elute 
in two different fractions (HGTVVLTALGGILK in fractions 1 and 4 and GHHEAELKPLAQSHATK 
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in fractions 1 and 6) as shown by a second peak for the dashed lines, which could 
potentially indicate on-column dephosphorylation of the pHis peptide. Taking in to account 
peptide stability and separation of phosphorylated and non-phosphorylated peptides, pH 
6.8 appears to be optimal for separation of pHis peptides from their non-phosphorylated 
equivalents under conditions of pHis stability. 
 
  
 
9
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Figure 4.2 Differential elution of myoglobin pHis peptides and their non-phosphorylated equivalents at different pH values. Label free quantification of 
pHis-containing peptides (solid lines) and their non-phosphorylated equivalents (dashed lines) in individual SAX fractions, expressed as a percentage of the 
total ion current across all fractions, for separation at pH 6 (red square), pH 6.8 (blue triangle) and pH 8 (green circle)
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A similar assessment of peptide separation under the three pH conditions was carried out 
for the peptides of α-/β-casein. The amount of phosphorylated and non-phosphorylated 
peptide in each fraction is displayed as a percentage of the total amount across all fractions 
for four representative peptides (Figure 4.3).  
 
The phosphorylated peptides (YKVPQLEIVPNSAEER, VPQLEIVPNSAEER, TVDMESTEVFTK and 
FSSEEQQQTEDELQDK, Figure 4.3 a-d) and their non-phosphorylated counterparts elute in 
separate fractions under all pH conditions. A difference of at least two fractions in terms of 
where the majority of the phosphorylated and non-phosphorylated version of the peptide 
elutes is observed, as indicated by the non-overlapping dashed and solid lines of the same 
colour. The observation of non-phosphorylated FQSEEQQQTEDELQDK (Figure 4.3 d) in 
fractions 10 and 12 highlights the fact that peptides containing many acidic residues will 
elute in the later fractions along with phosphorylated peptides. Above pH 6 both Asp and 
Glu will be deprotonated (pKa 3.9 and 4.3 respectively) resulting in greater retention of 
peptides containing a high number of these residues compared to those without. The 
retention of acidic peptides could be minimised by lowering the pH, but this would have a 
detrimental effect on pHis peptide stability, hence their presence in the later fractions must 
be tolerated.  As sample complexity increases, interference from acidic peptides may 
become more apparent, but this is not expected to have an overall negative impact on 
analysis of pHis peptides.  
 
 
  
 
9
6 
Figure 4.3 Differential elution of phosphorylated and non-phosphorylated peptides of α-/β-casein at different pH. Label free quantification of 
phosphorylated peptides (solid lines) and their non-phosphorylated equivalents (dashed lines) in individual SAX fractions, expressed as a percentage of the 
total ion current across all fractions, for separation at pH 6 (red square), pH 6.8 (blue triangle) and pH 8 (green circle)
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4.2.2 Comparison of SAX with high pH reversed-phase fractionation 
High pH RP fractionation has been utilised for phosphoproteomics analysis of complex cell 
lysates, typically coupled to an additional dimension of separation or combined with a 
phosphopeptide enrichment step, such as titanium dioxide or IMAC174, 245, 247. A comparison 
of high pH RP fractionation and SAX was conducted in order to establish whether the 
phosphopeptide enriched fractions obtained following SAX were purely a result of sample 
fractionation or a specific feature of the SAX method. The same mixture of α-/β-casein and 
myoglobin peptides, containing pSer, pThr and pHis peptides as well as non-
phosphorylated peptides was fractionated by high pH RP chromatography. As for the SAX 
fractions, the high pH RP fractions were pooled and analysed by LC-MS/MS, followed by 
label free quantification with PEAKS. The ion current for all peptides in each fraction was 
summed and the percentage attributable to either phosphorylated or non-phosphorylated 
peptides was calculated (Figure 4.4 a). The total signal for a given peptide was summed 
across all fractions, and the percentage observed in each fraction plotted to compare 
fractions in which pHis peptides and their non-phosphorylated equivalents elute. Results 
for two representative peptides are shown (Figure 4.4 b and c). 
 
Unlike for SAX fractionation where the later fractions are enriched for phosphopeptides, 
high pH fractionation results in elution of phosphorylated peptides predominantly in the 
first three fractions. Elution of phosphopeptides at the start of the gradient is unsurprising 
given that the addition of a phosphate group makes a peptide more hydrophilic and 
therefore reduces its affinity to a C18 column. The percentage signal from 
phosphopeptides in these early fractions does not exceed 80%, whereas with SAX 
fractionation the later fractions exhibit up to 100% phosphopeptide signal. These data 
demonstrate that the phosphopeptide enriched fractions observed following SAX 
fractionation are not simply a result of fractionation, i.e. spreading out the peptides across 
multiple fractions, rather it is the charge-based separation inherent to SAX that results in 
the desired phosphopeptide enrichment effect.  
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Figure 4.4. High pH reversed-phase fractionation of tryptic peptides of α-/β-casein and 
myoglobin a) Percentage of the total signal intensity attributed to phosphopeptides (blue 
bars) and non-phosphorylated peptides (red line) in each fraction following LCMS/MS 
analysis and label free quantification using PEAKS, with phosphopeptide signal 
predominantly in first three fractions. b) and c) Label free quantification of two 
representative pHis peptides (solid lines) and their non-phosphorylated equivalents 
(dashed lines) in individual fractions, expressed as a percentage of the total ion current 
across all fractions.  
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Inspection of label free quantification data for individual pHis peptides and their non-
phosphorylated equivalents following high pH RP fractionation, highlights two main 
problems. Two out of the five pHis peptides of myoglobin eluted after the first three 
fractions, so are in fractions that predominantly consist of non-phosphorylated peptide 
signal. In the example shown the HGTVVLTALGGILK peptide (Figure 4.4 b) elutes in fraction 
9, which contains 99% signal intensity from non-phosphorylated peptides (Figure 4.4 a). 
Elution of pHis peptides in fractions containing predominantly non-phosphorylated 
peptides would become more problematic as sample complexity increases, as 
phosphopeptides in these fractions could result from the same ion suppression effects 
commonly observed for non-enriched samples, thus hindering the identification of 
phosphopeptides in these fractions. For two of the five pHis peptides of myoglobin it was 
additionally observed that both the phosphorylated and non-phosphorylated version 
eluted in the same fraction, as demonstrated by the example peptide 
GHHEAELKPLAQSHATK (Figure 4.4 c), indicating that this method was not able to separate 
the two forms. Again, poor separation of phosphorylated and non-phosphorylated peptides 
would undoubtedly hinder analysis of more complex samples. 
 
Despite high pH reversed-phase chromatography being proven to be effective for pre-
fractionation of samples, including prior to (or after) TiO2 enrichment for increased 
coverage of the phosphoproteome174, it is not suitable as a stand-alone strategy for 
fractionation where the goal is to obtain phosphopeptide enriched fractions. For the 
purpose of phosphopeptide enrichment, the SAX method developed in this work is far 
superior. 
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4.2.3 Peptide recovery by SAX fractionation 
An assessment was made regarding the recovery of pHis peptides throughout the sample 
preparation pipeline thus far developed, i.e. SAX fractionation, pooling and drying of 
fractions, and rapid C18 desalting (<10 minutes) prior to LC-MS/MS analysis. Recovery of 
(phospho)peptides was primarily assessed in order to determine the potential loss through 
dephosphorylation that could be occurring for pHis containing peptides, analogous to the 
assessment made of the efficiency of other phosphopeptide enrichment strategies 
(Chapter 3. Results I). It was also deemed important to establish the overall losses that may 
be incurred as a result of a procedure with multiple sample handling steps. Using the label 
free quantification data generated with PEAKS, the total signal across all fractions for a 
given peptide was compared to the signal for the same peptide in an unfractionated 
sample; the amount of unfractionated sample analysed by LC-MS/MS was equivalent to the 
total amount analysed across all 16 fractions. Peptide recovery is shown for a 
representative selection of pHis, pSer/pThr and non-phosphorylated peptides from α-/β-
casein and myoglobin (Table 4.2). 
 
 
Table 4.2 Recovery of tryptic peptides of myoglobin and α-/β-casein following SAX 
fractionation and C18 desalting. Recovery calculated by comparison of sum of peptide 
intensity across all fractions compared to signal intensity of peptide in unfractionated 
sample, following LC-MS/MS analysis and label free quantification using PEAKS. 
Phosphorylated residues are underlined. 
 
 Peptide Sequence m/z % recovery 
Myo (pHis) YLEFISDAIIpHVLHSK 655.6 16.4 
VEADIAGpHGQEVLIR 843.9 31.6 
LFTGpHPETLEK 676.3 35.1 
Myo (non-
phosphorylated) 
YLEFISDAIIHVLHSK 472.0 17.9 
VEADIAGHGQEVLIR 536.3 40.3 
LFTGHPETLEK 424.6 19.2 
Myo (no histidine) YKELGFQG 471.2 36.5 
Casein (pSer/Thr) VPQLEIVPNpSAEER 830.9 50.5 
TVDMESpTEVFTK 733.8 43.9 
FQpSEEQQQTEDELQDK 687.9 21.4 
Casein (non-
phosphorylated) 
VPQLEIVPNSAEER 790.9 75.4 
TVDMESTEVFTK 693.8 22.2 
FQSEEQQQTEDELQDK 991.4 101.1 
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Recovery is comparable between all peptides regardless of whether they are 
phosphorylated or not, or the residue of phosphorylation. Only one of the peptides 
analysed exhibited 100% recovery, with an average recovery of 39% across the 13 
representative peptides. Less than 100% recovery is perhaps to be expected given the 
number of sample preparation steps involved, each with the potential for samples losses to 
occur. However, encouragingly the recovery of pHis peptides is similar to that of other 
pSer/pThr phosphopeptides indicating that extensive dephosphorylation will not 
significantly hamper this analysis, as was the case for the previously trialled enrichment 
techniques where recovery of pHis peptides was often 0% (Chapter 3. Results I). The 
observed sample losses can be tolerated for the purposes of this work, although further 
consideration would be required if utilising this strategy for a quantitative rather than 
qualitative analysis. 
 
4.2.4 SAX fractionation of cell lysate 
Following on from the successful application of the SAX method for the analysis of model 
pHis peptides from myoglobin, the next step was to ensure compatibility of the method 
with analysis of more complex samples such as a whole cell lysate. Peptides of α-/β-casein 
and myoglobin were analysed by SAX at pH 6.8 following digestion in urea (8 M original 
concentration, diluted to 2 M prior to addition of trypsin), either as the simple peptide 
mixture alone or spiked into U2OS cell lysate. Each fraction was analysed by LC-MS/MS and 
label-free quantification performed as previously described using PEAKS. For any given 
peptide the total signal intensity across all fractions was summed, and the amount in each 
individual fraction then displayed as a percentage of this total amount. The elution of pHis 
peptides and their non-phosphorylated equivalents are compared across the various 
conditions (Figure 4.5). 
 
In the all cases the peptides elute in the same (or an adjacent) fraction regardless of the 
addition of the urea or the presence of peptides from a whole cell lysate. For the sample 
digested with urea and a whole cell lysate all pHis peptides are observed in different 
fractions to their non-phosphorylated equivalents. The effective separation of pHis and 
non-phosphorylated peptides indicates that the method is robust, and the sample 
preparation techniques proposed for use with whole cell lysate will be suitable for 
fractionation of these samples using the SAX method. 
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Figure 4.5 Comparison of pHis peptide separation by SAX at pH 6.8 following digestion under different conditions. Label free quantification of 
phosphohistidine containing peptides (solid lines) and their non-phosphorylated equivalents (dashed lines) in individual SAX fractions, expressed as a 
percentage of the total ion current across all fractions, following digestion in AmBic (blue triangle) digestion in urea (red square) and digestion in urea with 
U2OS lysate (green circle). YLEFISDAIIHVLHSK peptide (e) not detected in sample digested in urea.  
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Fractionation of a U2OS cell lysate (1 mg) was performed using the SAX method previously 
described. Sample loading for LC-MS/MS was optimised by increasing the amount of the 
later fractions analysed to achieve approximately equal base peak chromatogram 
intensities for all fractions.  LC-MS/MS data was generated on the Orbitrap Fusion mass 
spectrometer using a HCD with neutral loss triggered EThcD method. Data was searched 
using the MASCOT search engine with oxidation (M) and phosphorylation (ST, Y and H) as 
variable modifications. Peptides are reported at 1% FDR. An in-house perl script was used 
to determine unique peptide IDs across all fractions, where the highest scoring (MASCOT 
ion score) peptide was kept. The number of phosphorylated and non-phosphorylated 
peptides in each fraction was plotted to assess the extent of phosphopeptide enrichment 
across the SAX gradient (Figure 4.6). 
In the later SAX fractions the percentage of phosphopeptides approaches 45%. Indicating 
that these fractions are considerably enriched for phosphopeptides compared to a non-
fractionated sample; phosphopeptide IDs are typically <1% of total peptide IDs in non-
fractionated U2OS cell lysate digest analysed in the same way. An attempt was made to 
improve coverage of phosphopeptides by removing the fraction pooling step and instead 
analysing the 46 SAX fractions by LC-MS/MS individually. The average percentage of 
phosphopeptides in the later fractions (39-46, approximately corresponding to fractions 15 
and 16 of the pooled analysis) was 50% representing only a very modest improvement. A 
37% increase in phosphopeptide IDs was obtained by analysis of individual rather than 
pooled fractions, again representing a modest improvement. However, to achieve these 
improvements requires a vast increase in sample preparation and MS instrument time; LC-
MS/MS analysis of 46 samples with a 2 hour method approaches 4 days, which would soon 
become unfeasible for experiments with multiple biological conditions and replicates. 
For the data obtained by analysis of 16 pooled fractions, the number of unique 
phosphopeptides in each fraction was further separated into the different phosphosites, 
with localisation determined by MASCOT (Figure 4.7). Analysis of the 16 SAX fractions 
revealed 29 endogenous pHis containing peptides, 12 of which were phosphorylated only 
on histidine. A total of 2121 phosphopeptides were identified across all the fractions, the 
majority of which were phosphorylated on serine (1911, 90%). The SAX fractionation 
strategy was thus shown to be suitable for identification of pHis peptides alongside other 
sites of phosphorylation, representing a theoretically unbiased approach to 
phosphopeptide analysis.  
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Figure 4.6 Percentage of unique phosphorylated and non-phosphorylated peptides identified in each fraction following SAX fractionation of U2OS lysate 
at pH 6.8. Peptides from tryptic digest of U2OS lysate (1 mg) separated by SAX at pH 6.8, with 16 pooled fractions analysed by LC-MS/MS using the Orbitrap 
Fusion, then searched with MASCOT at 1% FDR. Later fractions show a considerable degree of enrichment, containing up to 45% phosphopeptides. 
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Figure 4.7 Number of unique phosphopeptides identified in each fraction following SAX fractionation of U2OS lysate at pH 6.8. Later fractions show 
increased numbers of phosphopeptides compared to early fractions. Site of phosphorylation determined by MASCOT, with the majority of sites identified as 
pSer and a total of 29 endogenous pHis peptides identified.  
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4.2.5 SAX fractionation using StageTips 
The SAX phosphopeptide separation method as it has been developed thus far uses 1 mg of 
digested cell lysate, which may become problematic if only limited sample amounts are 
available, for example from experiments involving biological tissue or primary cell lines.  
Utilising a StageTip format rather than a large chromatography column would enable 
smaller sample amounts to undergo SAX fractionation, as well as significantly reducing the 
time taken to fractionate each sample. A rapid SAX fractionation strategy would be 
especially beneficial for studies with many samples, as currently it requires at least a day to 
perform the fractionation and subsequent drying and desalting of the 16 fractions for a 
single sample. 
 
StageTips are routinely used as a simple method of sample clean-up and fractionation248, 
249. For this experiment the tips were packed with two discs of anion exchange material, 
and a step-elution fractionation performed. Based on preliminary experiments which 
revealed that all peptides (phosphorylated and non-phosphorylated) were eluting in early 
(low salt concentration) fractions, the concentration of triethylammonium phosphate was 
reduced such that the concentration in the final fraction was ~200 mM compared to 300 
mM in the column method. The method was tested with 40 µg of a simple mixture of pHis-
myoglobin and α-/β-casein peptides, a much lower amount than is required for SAX 
fractionation by the column method. Each fraction was desalted and analysed by LC-
MS/MS, using the Bruker AmaZon mass spectrometer. The low-resolution data generated 
by the Bruker Amazon mass spectrometer is not compatible with label-free quantification 
using PEAKS therefore assessment of fractionation efficiency is based on peptide numbers 
alone. The percentage of unique phosphorylated and non-phosphorylated peptides in each 
fraction was calculated, with the average across two technical replicates plotted in Figure 
4.8.  
 
A moderate degree of phosphopeptide enrichment is observed with the later fractions 
containing ~40% phosphopeptides. A direct comparison to the SAX column data is not 
possible due to different methods of LC-MS/MS analysis, but a greater degree of 
phosphopeptide enrichment using the StageTip method would be desirable, especially 
given that the degree of enrichment would be expected to drop further for a complex 
sample.  
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Inferior performance of the StageTip method compared to the SAX column based method 
may be expected as the larger packed column provides considerably better resolution than 
the StageTip format, meaning less interference in later fractions from non-phosphorylated 
peptides. It was observed in the StageTip data that the majority of peptides elute in at least 
two or more fractions, with a few being identified in up to six fractions. Perhaps performing 
multiple elution steps at the same salt concentration would reduce the likelihood of 
peptides spreading across multiple fractions. Additionally, using anion exchange resin 
packed into a small column, either home-made or a commercial product, rather than the 
discs of anion exchange material may provide improved performance on a smaller scale. 
Techniques to achieve comparable results to the SAX method developed using the large-
scale column but on a smaller scale still require further investigation.  
 
 
 
Figure 4.8. Percentage of unique phosphorylated and non-phosphorylated peptides 
identified in each fraction following SAX StageTip fractionation of α-/β-casein and 
myoglobin peptides at pH 6.8. Eight fractions were collected by step-elution with 
increasing salt concentration, desalted and analysed by LC-MS/MS using the Bruker 
AmaZon. Data searched with MASCOT at 1% FDR and unique peptides determined in each 
fraction. Later fractions (6 to 8) contain 30-40% phosphopeptides, compared to 2% for 
fraction 1.   
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4.3 Conclusions 
 
A SAX fractionation strategy for phosphopeptide enrichment based on salt gradient elution 
has been developed. Assessment of the elution of pHis peptides and their non-
phosphorylated equivalents with buffers at three different pH values (pH 6. 6.8 and 8) 
revealed pH 6.8 to be optimal for the analysis of pHis-containing peptides. For a simple 
mixture SAX fractions at the end of the gradient contain up to 100% phosphopeptide signal. 
The recovery of pHis peptides by this method is up to 35% which is comparable to recovery 
of other peptides (pSer/pThr and non-phosphorylated) using this workflow and much 
improved compared to other enrichment strategies previously assessed in Chapter 3. 
Results I. Unlike other enrichment strategies whereby the “unwanted” material is discarded 
and not analysed this SAX fractionation method allows for LC-MS/MS analysis of the whole 
sample. With this SAX method all sites of phosphorylation can be assessed, representing a 
novel unbiased approach to phosphopeptide analysis. The method has subsequently been 
termed UPAX (Unbiased Phosphopeptide enrichment by strong Anion Exchange). 
 
The ability of the UPAX method to identify pHis peptides in a complex cell lysate has been 
clearly demonstrated, with later fractions containing up to 45% phosphopeptides and 29 
endogenous pHis peptides identified following SAX fractionation of a U2OS cell lysate. The 
method will therefore be utilised in further studies to examine the extent of acid-labile 
phosphorylation in mammalian cells, and the types of proteins on which these 
modifications occur.  The fact that this method may not be applicable for studies where 
sample is limited has been addressed by modification of the technique for SAX 
fractionation in StageTips, using discs of anion exchange material packed into a pipette tip 
and a step-elution of increasing salt concentration. Although some degree of enrichment is 
observed in the later fractions, the method still requires further development in order to 
achieve a comparable performance to the large packed column with which the method was 
originally developed. 
 
The data analysis strategy used thus far has been relatively simple, using only MASCOT for 
phosphopeptide localisation, with no consideration given for confidence of the sites of 
modification, for example by application of a phosphosite localisation scoring strategy209. It 
will be important to develop a data analysis pipeline to complement the UPAX strategy, 
such that confident pHis peptide identifications can be reported.  Application of well-
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thought-out criteria for pHis site localisation will be crucial as further studies to 
characterise pHis sites and their possible functions are undertaken. 
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Chapter 5. Results III: Phosphohistidine in human cells 
 
5.1 Introduction 
 
This chapter describes the implementation of the successfully developed UPAX strategy for 
the separation and characterisation of pHis peptides, derived from HeLa cell lysates, at 
non-acidic pH. Whilst there is precedent for using pervanadate to inhibit Tyr phosphatases 
for global pTyr site mapping studies250, 251, no such inhibitors have yet been characterised 
for His phosphatases.  Instead, siRNA knockdown of PHPT1, one of two known His 
phosphatases, was conducted in HeLa cells with the intention of increasing the basal level 
of His phosphorylation.  
 
Phosphorylation of His was first reported in mammalian cells over 50 years ago10, and since 
then there has been growing evidence for the roles of pHis in mammalian signalling. 
Histone H4 kinases activity appears to be associated with cell growth and development41-43, 
and NME1 and NME2, the only reported His kinases to date, are implicated in cancer and 
tumour metastasis25-27. His phosphorylation has also been implicated in differentiation of 
PC12 neuronal cells23, T-cell signalling30, 34 and glycoprotein VI signalling in platelets and 
bone remodelling21, 22. However, widespread characterisation of His phosphorylated 
proteins and their functions in mammalian systems is still lacking. The work presented in 
this chapter thus aimed to address this issue by application of the UPAX strategy, enabling 
characterisation of hundreds of sites of His phosphorylation in human cells.  
 
As described in Chapter 1. Introduction, phosphosite localisation presents a significant 
challenge in phosphoproteomics experiments. Therefore, it was vital to implement a robust 
phosphosite localisation strategy into the pHis analysis pipeline, such that pHis sites could 
be reported with confidence. From the many available approaches for site localisation209, 
either integrated into search engines or available as post-search engine tools, ptmRS was 
chosen for this study. However, an additional strategy to confirm sites of His 
phosphorylation was also considered. Oslund et al.252 studied gas-phase fragmentation of 
pHis peptides and thus proposed that a characteristic neutral loss pattern was indicative of 
His as the site of phosphorylation. LC-MS/MS data was interrogated to determine whether 
the triplet neutral loss strategy could be utilised for high-throughput characterisation of 
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pHis peptides, by virtue of improving confidence in localisation of His as the site of 
phosphorylation, as opposed to another amino acid. 
 
The results presented in this chapter represent the largest number of localised pHis sites to 
be reported to date, which provided a unique opportunity to characterise motifs for His 
phosphorylation. Additionally, the pHis proteins identified in these samples were assessed 
in terms of functional annotation and enrichment analysis. Widespread His 
phosphorylation has been revealed in human cells, and novel biological roles for pHis were 
thus considered.  
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5.2 Results and Discussion 
 
5.2.1 siRNA knockdown of PHPT1 
PHPT1 knockdown was performed in HeLa cells with the aim of increasing levels of pHis. 
PHPT1 is ubiquitously expressed in mammalian cells253, and the HeLa cell line has been 
shown to contain pHis-containing proteins by western blotting and/or immunofluorescence 
staining with 1- and 3-pHis antibodies227. Additionally, PHPT1 has been shown to be 
elevated in other cancer cell lines; increased PHPT1 expression correlates with increased 
tumour size in renal cell carcinoma and increased cell migration and invasion in lung 
cancer254, 255.  
 
Knockdown of PHPT1 with siRNA was performed in triplicate, alongside a positive control 
Lamin A/C knockdown (Figure 5.1). All bioreplicates demonstrate successful knockdown of 
PHTP1 compared to control lysates treated with non-targeting (NT) siRNA.  The two 
conditions are hereby referred to as ‘PHPT1 siRNA’ and ‘NT siRNA’. 
 
 
 
Figure 5.1 Knockdown of PHPT1 in HeLa cells. In all three bioreplicates almost complete 
reduction in levels of PHPT1 (15 kDa) in cells treated with PHPT1 siRNA for 48 hours is 
observed, with GAPDH (37 kDa) loading control also shown. Levels of LaminA/C (75 kDa), 
which was used as knockdown control, are also reduced after 48-hour treatment. 
Chapter 5. Results III 
 
113 
 
5.2.2 Implementation of SAX fractionation strategy 
The UPAX strategy successfully developed for separation and characterisation of 
phosphopeptides in complex cell lysates (Chapter 4. Results II), was applied to the HeLa cell 
lysates collected following the siRNA knockdown experiment previously described. The 
general workflow implemented for this analysis is outlined in Figure 5.2.  
 
 
Figure 5.2. Workflow for PHPT1 knockdown and SAX experiment. Following treatment 
with PHPT1 or non-targeting siRNA for 48 hours cells were lysed and proteins digested with 
trypsin. Peptides were fractioned by SAX at pH 6.8 with salt gradient elution and the 
resulting 16 fractions were analysed by LC-MS/MS using the Thermo Orbitrap Fusion. 
 
 
Cells were lysed and digested with trypsin, under non-acidic conditions and without 
exposure to elevated temperature. Peptides were fractionated by SAX at pH 6.8, and 16 
fractions analysed by LC-MS/MS, using a Thermo Orbitrap Fusion mass spectrometer. 
Fragmentation was performed by HCD with neutral loss triggered EThcD. According to this 
fragmentation scheme a neutral loss of 98 Da from the precursor in the HCD fragment ion 
spectrum, triggers the precursor to undergo a second round of fragmentation by ETD with 
supplemental HCD activation to produce b/y and c/z ions. HCD-neutral loss triggered EThcD 
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provides a good balance between rapid analysis achieved using HCD and superior 
phosphosite localisation afforded by an ETD-based fragmentation method74, 200. 
Representative base peak chromatograms (Figure 5.3 a) indicate different profiles observed 
for LC-MS analysis of different fractions throughout the SAX gradient. Loading of each 
fraction onto the LC-MS/MS system was adjusted following estimation of peptide amount 
by Nanodrop and test injections, such that the base peak intensity of each fraction was 
approximately equivalent. 
 
Proteome Discoverer (PD) was used to implement a workflow for database searching and 
phosphosite localisation (Figure 5.3 b). Raw files were first processed using MSConvert to 
perform MS2 level de-isotoping, and the resulting mzML file then provided as the input for 
the PD workflow. Each file was split into spectra generated by HCD or EThcD, with each 
type processed separately due to the different settings required to search each type of 
data. For site localisation the ptmRS node was used. This is the most recent version of the 
PhosphoRS software developed by Taus et al206. The algorithm assesses all possible sites 
that can be phosphorylated and assigns a confidence score (between zero and 100) to each 
one, where the higher the score for a given site the more likely it is to be phosphorylated.  
Scores >99 indicate very high confidence in the phosphosite localisation, whilst sites with 
scores >75 are considered to be confidently localised, with this cut-off routinely used for 
phosphoproteomics studies94, 256.  
 
Protein and peptide level results were exported from PD for further interrogation using 
manual methods and/or in-house scripts. A 5% FDR at the peptide level was applied for all 
exported data. For proteins an additional criteria of ≥2 peptides per protein was applied. 
From peptide data only rank 1 peptides were considered for further analysis. For 
phosphopeptide identifications a 1% FLR was applied with ptmRS scores defined as 99.2 for 
HCD and 90.2 for EThcD data, according to the benchmarking study performed by Ferries et 
al200. 
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Figure 5.3   LC-MS/MS analysis of SAX fractions and data processing with Proteome Discoverer a) Base peak chromatograms shown for select SAX 
fractions (3- green; 6- red; 10- grey) following LC-MS/MS using an Orbitrap Fusion mass spectrometer; peptides fragmented by HCD with EThcD triggered by 
neutral loss of 98 Da from the precursor ion. b)  Proteome Discoverer data processing pipeline; tandem mass spectra are separated according to 
fragmentation type prior to searching with MASCOT and application of ptmRS for phosphosite localisation. 
a b 
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An initial assessment was made of the number of phosphorylated and non-phosphorylated 
peptides in each fraction to establish the extent of phosphopeptide enrichment achieved 
with the SAX fractionation strategy. Unique peptides and phosphopeptides were 
determined across all fractions, with the highest scoring (MASCOT ion score) peptide kept 
in the data set. The number of phosphorylated and non-phosphorylated peptides in each 
fraction is displayed as a percentage of total number of peptides identified. Data for one 
representative bioreplicate is shown in Figure 5.4, with graphs for all bioreplicates shown in 
the Appendix.  As previously observed for fractionation of a U2OS lysate (Chapter 4. Results 
II) the later fractions contain ~50% phosphorylated peptides, indicating a significant degree 
of enrichment compared to an unfractionated sample. All bioreplicates showed a similar 
trend for fractionation, with an average of 47% phosphorylated peptides in fraction 16 
across the six sets of fractions, thus demonstrating that the SAX fractionation has 
performed as expected for these samples. 
  
 
1
17
 
 
Figure 5.4 Percentage of unique phosphorylated and non-phosphorylated peptides identified in each fraction following SAX fractionation of HeLa lysate 
at pH 6.8. HeLa cells treated with non-targeting siRNA and analysed according to previously described workflow (Figure 5.2). Proteome Discoverer pipeline 
used to search data with MASCOT, with peptide IDs exported at 5% FDR and unique peptides determined using an in-house perl script. Later fractions show 
a considerable degree of enrichment, containing approximately 50% phosphopeptides. 
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5.2.3 Global effects of PHPT1 knockdown  
Protein identifications across the three bioreplicates for each condition show a high degree 
of overlap (Figure 5.5 a); for PHPT1 siRNA samples a maximum of 10% of the identified 
proteins were unique to any given individual bioreplicate (10.5%, 7.4%, 7.3%), and 62% of 
the 5232 proteins identified were common between the three replicates. Similarly, for the 
NT siRNA control samples, 63% of the 5353 proteins identified were common across the 
three bioreplicates, with a maximum of 11% (11%, 8%, 7%) being unique to any individual 
bioreplicate analysis. Overlap between bioreplicates was also considered for non-
phosphorylated peptides (Figure 5.5 b):  a maximum of 15% (of 90643) or 19% (of 96363) of 
peptides were unique to a single bioreplicate for the PHPT1 siRNA or NT siRNA treated 
sample respectively. For phosphopeptides (Figure 5.5 c), the numbers were a slightly more 
variable, with up to 27% (of 6574) or 26% (of 7111) of identified phosphopeptides being 
unique to a single bioreplicate for the PHPT1 siRNA or NT siRNA samples respectively.  
To assess common identifications between the PHPT1 siRNA and NT siRNA samples, 
proteins identified in two or more bioreplicates were considered. 83% of the 4580 unique 
proteins identified across the two conditions, were common, indicating a high degree of 
overlap. Additionally, 68% of peptides and 55% of phosphorylated peptides were common 
between the two conditions, considering only those peptides that were identified twice or 
more across the dataset. Independent of assessment criteria, greater numbers were 
identified in the NT siRNA compared to the PHPT1 siRNA sample. 
There are 340 and 417 protein identification unique to the PHPT1 siRNA or NT siRNA 
conditions, respectively. Gene ontology (GO) analysis of these proteins was performed 
using Panther257 (Figure 5.6). There are no discernible differences in GO terms with respect 
to biological processes, molecular function or protein class, revealing no significant insights 
into the global effects of PHPT1 knockdown in HeLa cells. 
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Figure 5.5 Overlap of protein, peptide and phosphopeptide IDs between bioreplicates 
and conditions a) Protein identifications show high degree of overlap between 
bioreplicates; 80% of proteins are identified in two or more bioreplicates with 83% overlap 
between the two treatment conditions b) For peptide IDs in two or more bioreplicates 
there is an overlap of 57% for PHPT1 siRNA samples and 59% for NT siRNA, with 68% 
overlap between conditions c) Overlap of  phosphopeptide IDs between conditions is 55%, 
with 35% of phosphopeptides identified in two or more bioreplicates for both the PHPT1 
and NT conditions. 
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Figure 5.6 GO term analysis of proteins unique to either PHPT1 siRNA or NT siRNA condition. Unique proteins for PHPT1 (340 proteins) and Non-T (417 
proteins) show no considerable differences in terms of molecular function, biological process or protein class when searched against the PANTHER 
classification system. 
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5.2.4 Evaluation of triplet neutral loss patterns for pHis peptide identification 
A crucial aspect of phosphoproteomics analysis is the confident localisation of the 
phosphate group to a specific residue within a peptide. The use of a tool such as ptmRS can 
aid in this by providing a confidence score for possible sites of phosphorylation. However, 
an additional diagnostic strategy to confirm the site of phosphorylation as His, as opposed 
to another amino acid, would provide an extra level of confidence to these identifications. 
 
It is known that pSer/pThr phosphopeptides can undergo neutral loss of phosphoric acid 
(Δ98 Da) from the precursor ion during fragmentation187, 188. This results in a predominant 
neutral loss ion in the fragment ion spectrum under CID, and to a lesser extent HCD, 
fragmentation regimes. In comparison, neutral loss from pTyr peptides is typically observed 
only at Δ80 Da. The loss of HPO3 upon fragmentation of the labile P-N bond of pHis 
phosphopeptides results in a neutral loss of 80 Da, whilst concomitant loss of water from 
elsewhere in the peptides results in neutral loss of 98 Da. Further loss of water from 
phosphopeptides undergoing fragmentation gives rise to a Δ116 Da neutral loss which can 
be observed in pHis, pThr and pSer peptides. It was proposed by Oslund et al.252 that the 
combination of neutral loss ions observed following fragmentation of a phosphopeptide 
could be indicative of the amino acid which is phosphorylated, specifically that the ‘triplet’ 
neutral loss pattern (Δ80, Δ98 and Δ116 Da) is characteristic of pHis phosphorylation, aiding 
in the identification of pHis peptides in a phosphoproteomics experiment.  
 
The triplet neutral loss strategy could be invaluable for increasing confidence in the 
localisation of phosphosites to His residues, particularly in cases where a peptide contains 
other residues that could be phosphorylated in addition to His. The triplet neutral loss 
pattern was observed in all fragment ion spectra (generated by HCD) of the pHis peptides 
of myoglobin (Chapter 3. Results I, Figure 3.4), suggesting this was a promising strategy to 
pursue. To assess the validity of implementing the triplet neutral loss strategy for high-
throughput characterisation of pHis-containing peptides, the prevalence of neutral loss ions 
in the tandem MS spectra of phosphopeptides was assessed using data obtained by 
fractionation of HeLa lysate and analysis of the 16 fractions by LC-MS/MS using the Thermo 
Orbitrap Fusion. Data was processed using MASCOT and Proteome Discover as previously 
described, and tandem MS spectra were subsequently inspected for the presence of 
product ions corresponding to the expected m/z values that would result from neutral 
losses of 80, 98 and 116 Da from the precursor ion. Each identified peptide was therefore 
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assigned a ‘triplet’ score (of 0, 1, 2 or 3) depending on the number of neutral loss ions 
observed following collisional dissociation. 
 
How does HCD vs CID affect triplet score? 
The original paper describing the triplet neutral loss strategy utilised CID fragmentation for 
the observation of the characteristic neutral loss patterns. Whilst neutral loss ions are a 
predominant feature of spectra resulting from CID fragmentation, under HCD 
fragmentation this is not necessarily the case. The higher energy dissociations associated 
with HCD compared to CID result in a wider range of fragmentation pathways, and thus 
neutral loss from the precursor is not necessarily dominant product ion258. A comparison 
was therefore made between the triplet scores of phosphopeptides identified in one SAX 
fraction, following fragmentation by HCD or CID (Figure 5.7). The proportion of 
phosphopeptides displaying each triplet score is broadly similar for both HCD and CID 
fragmentation. Crucially, this means that 27% of peptides identified following CID 
fragmentation do not display neutral loss ions, even when the intensity cut off is set at 2% 
compared to the base peak ion (as it is for the data shown). Considering each site of 
phosphorylation separately, CID still does not appear to offer any significant benefits in 
terms of generation of diagnostic fragment ions compared to HCD. The pattern of triplet 
scores for pSer/pThr peptides is almost identical for both fragmentation types, and whilst 
the proportion of pHis peptides displaying the triplet neutral loss is greater when CID 
fragmentation is used compared to HCD, so is the proportion of pHis peptides with no 
neutral loss ions at all. Further investigation of the triplet score was based on HCD data 
only, obtained by LC-MS/MS analysis of 16 SAX fractions. 
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Figure 5.7 Effect of fragmentation method on distribution of triplet scores for phosphopeptides, a) Comparison of triplet scores for all phosphopeptides 
identified in a single SAX fraction (SAX fraction 13) following fragmentation by either HCD or CID, b-c) Distribution of triplet scores for unique singly 
phosphorylated peptides with ptmRS score ≥75 as a function of site of phosphorylation (pHis, pSer/pThr and pTyr) following (b) HCD or (c) CID 
fragmentation. 
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Is triplet score related to ptmRS score? 
Given that ptmRS scores are a measure of confidence in site localisation it was expected 
that peptides with higher ptmRS scores would display closest adherence to the triplet 
theory, i.e. the most confidently assigned pHis peptides should exhibit the triplet neutral 
loss, whereas for low scoring sites there is greater ambiguity over the site of 
phosphorylation and therefore these peptides may not display the triplet neutral loss 
pattern, instead displaying a neutral loss pattern indicative of an alternative site of 
phopshorylation (pSer, pThr or pTyr).  The triplet score for all pHis-containing peptides 
identified across the 16 fractions was thus considered according to four categories of 
ptmRS score assigned according to different degrees of site localisation confidence (Figure 
5.8 a).  
 
Somewhat unexpectedly the number of pHis peptides exhibiting the triplet neutral loss 
pattern was extremely low, even for phosphopeptides with a ptmRS score greater than 99; 
only 3% of pHis peptides with ptmRS score >99 have a triplet score of 3. One reason for this 
could be that the number of phosphosites in the peptide is affecting the neutral loss 
pattern, i.e. doubly phosphorylated peptides may be more likely to display neutral loss of 
Δ196 Da (two losses of 98 Da) meaning the expected triplet pattern may not be observed 
for multiply phosphorylated pHis peptides. Triple score versus ptmRS score was therefore 
considered for singly, doubly and multiply (≥3) phosphorylated peptides separately (Figure 
5.8 b, c and d). For multiply phosphorylated peptides a triplet score of 0 is most likely; 70% 
of multiply phosphorylated peptides have triplet score of 0 across all ptmRS score 
categories. The trends for singly and doubly phosphorylated peptides are broadly similar, 
with higher ptmRS score not necessarily resulting in observation of the triplet pattern. For 
additional investigation of the triplet neutral loss pattern only singly phosphorylated 
peptides were considered. 
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Figure 5.8 Distribution of triplet scores for pHis peptides as a function of site localisation 
confidence. Data shown is for unique phosphopeptides identified across 16 SAX fractions, 
with site confidence determined by ptmRS score and neutral loss ions considered present if 
≥2% compared to the base peak ion. Triplet score of 3 indicates observation of all three 
neutral loss ions, 2 indicates any two neutral loss species and 1 indicates any one of the 
three possible neutral loss ions. a) all phosphopeptides containing a pHis site, b) singly 
phosphorylated pHis containing peptides, c) doubly phosphorylated pHis containing 
peptides c) multiply phosphorylated (≥3 phosphosites) pHis containing peptides 
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Is triplet score related to MASCOT score or precursor intensity? 
One possible reason for the failure of these potential pHis peptides to adhere to the triplet 
neutral loss pattern could be a result of poorer quality spectra. As a measure of this the 
MASCOT score was used, whereby higher MASCOT scores may generally indicate better 
quality spectra, and thus these higher quality spectra may be more likely to contain the 
indicative triplet neutral loss pattern for pHis (Figure 5.9 a). Additionally, it was proposed 
that spectra arising from peptides with higher signal intensity would be more likely to 
display the triplet neutral loss pattern; the neutral loss ions arising from low intensity 
peptides would be more likely to fall below the limits of detection. The triplet scores were 
considered for peptides in the top 10% and top 25% for precursor signal intensity, with 
peptides in the bottom 25% when ranked by signal intensity also shown for comparison 
(Figure 5.9 b). 
 
The highest number of pHis peptides with a triplet score of 3 are observed in the >40 
MASCOT score category; 13% of pHis peptides in the >40 category have a triplet score of 3, 
compared to 10%, 3% and 2% in the 30-40, 20-30 and <20 categories respectively. 
However, this category still contains a majority of peptides with a triplet score less than 3, 
and 20% of these peptides display no neutral loss ions. The trend is similar for the 30-40 
MASCOT score category. For peptides with a MASCOT score below 30 there is an even 
greater proportion of peptides (39%) with a triplet score of 0, whilst over half (57%) of the 
peptides with a MASCOT score below 20 have no neutral loss ions. However, MASCOT 
score still does not fully account for the observed triplet scores for these pHis peptides. 
 
When considering the relationship between signal intensity and triplet score, the top 10% 
most intense ions still only contain a small proportion of peptides (11%) with a triplet score 
of 3, with almost half (42%) of these peptides again not displaying any neutral loss. The 
trend is similar for peptides in the top 25%, whilst the least intense peptides seem to 
exhibit the highest proportion of one and two neutral losses, with 64% of peptides having 
triplet score of 1 or 2. Therefore, the failure of these pHis peptides to adhere to the triplet 
neutral loss pattern does not appear to be related to signal intensity. 
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Figure 5.9 Distribution of triplet scores for pHis peptides as a function of a) MASCOT 
score and b) signal intensity. Data shown is for unique singly phosphorylated peptides 
identified across 16 SAX fractions, with neutral loss ions considered present if ≥2% 
compared to the base peak ion. 
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Do triplet scores and observed neutral loss ions follow expected trends for other sites of 
phosphorylation? 
To establish whether the failure of pHis peptides to follow the expected neutral loss 
pattern was specific to these peptides, or a result of all phosphopeptides failing to exhibit 
the expected neutral losses, triplet scores were considered for all phosphopeptides across 
the 16 fractions. Based on expected neutral losses from phosphopeptides pSer/pThr should 
have triplet scores of 1 or 2 (relating to Δ98 Da and/or Δ116 Da) whilst pTyr peptides 
should exhibit only 1 neutral loss (Δ80 Da). None of these phosphopeptides should have 
the triplet neutral loss pattern. The triplet scores for each site of phosphorylation are 
shown in relation to the ptmRS score categories, with the expectation that more 
confidently localised sites may be more likely to exhibit the expected neutral losses.  Only 
singly phosphorylated peptides were considered, and the number of peptides with each 
triplet score has been converted to a percentage to allow for easier comparison when 
pSer/pThr peptides far outnumber pHis and pTyr (Figure 5.10). 
 
The expected pattern of triplet score is not clearly observed for any phosphopeptides. For 
all sites of phosphorylation peptides with a triplet score of 3 are observed in almost all of 
the score categories, with the greatest percentage of peptides displaying the triplet pattern 
actually observed for pSer/pThr peptides. In the >99 score category pSer/pThr peptides do 
predominantly have scores of 1 or 2 as would be expected, whilst close to 40% of pTyr 
peptides in this category have a score of 1, again in line with the expected neutral loss. 
These trends are lightly less clear as the ptmRS score decreases, and many peptides 
regardless of site of phosphorylation or ptmRS score have no neutral loss ions (triplet score 
of 0). 
 
The data was further interrogated to determine the actual neutral loss ions (Δ80, Δ98 
and/or Δ116 Da) rather than an overall triplet score, with the aim of revealing more clearly 
whether the expected mechanisms of neutral loss are occurring for each site of 
phosphorylation. For this analysis only phosphopeptides with ptmRS score ≥ 75 were 
considered, as there is a greater confidence in the assignment of these phosphosites so the 
neutral loss ions should match the proposed site (Figure 5.11). 
 
For pSer/pThr peptides with a triplet score of 1, the most common neutral loss is Δ98 Da, 
accounting for 54% of the peptides in this category. For a triplet score of 2 the predominant 
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combination of neutral losses, corresponding to 74% of peptides in this category, is Δ98 Da 
and Δ116 Da, suggesting these peptides are following the expected neutral loss behaviour 
to some degree. For pTyr 41% of the peptides have a triplet score of 1, as would be 
expected, but the type of neutral loss observed is fairly evenly split across Δ80, Δ98 and 
Δ116 Da. This even spilt of neutral loss ions is also observed for pHis peptides. 
 
 
 
 
 
 
 
 
 
Figure 5.10 Distribution of triplet scores for singly phosphorylated peptides (pHis, 
pSer/pThr and pTyr) as a function of site localisation confidence. Data shown is for unique 
phosphopeptides identified across 16 SAX fractions, with site confidence determined by 
ptmRS score and neutral loss ions considered present if ≥2% compared to the base peak 
ion. 
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Figure 5.11 Number of phosphopeptides exhibiting different combinations of neutral loss 
ions (Δ80, Δ98 and/or Δ116 Da). Neutral loss ions identified at ≥2% compared to base peak 
signal intensity for a) pHis, b) pSer/pThr, c) pTyr. Data is shown for unique singly 
phosphorylated peptides where the site localisation confident as determined by ptmRS is 
≥75. 
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Does relative intensity of neutral loss ions affect triplet scoring?  
Up to this point a neutral loss ion has been considered to be present if its intensity is ≥2% 
compared to the base peak ion in the spectrum. This threshold is fairly low, meaning that 
peaks which are just noise may be assigned as neutral loss ions, potentially explaining why 
pSer, pThr and pTyr peptides are observed to have more neutral loss ions than expected. 
Therefore, the threshold for determining a neutral loss ion was adjusted to 5% and 10% 
compared to the base peak intensity, then the number and nature of the neutral loss ions 
for each peptide was again determined. For the data with a 5% relative signal intensity cut-
off, the triplet score was also determined for non-phosphorylated peptides. As these 
peptides cannot undergo neutral loss (due to the absence of a phosphate group) any ions 
corresponding the expected m/z of a neutral loss are just background noise in the 
spectrum, thus providing an idea of the degree of false positives when considering neutral 
losses in this way (Figure 5.12). 
 
For pSer/pThr phosphopeptides increasing the intensity cut-off makes the expected trend 
of predominantly Δ98 Da and/or Δ116 Da neutral losses much more apparent. At a 10% cut 
off only 2% of pSer/pThr peptides exhibit the triplet neutral loss, and only a further 4% 
have a Δ80 Da neutral loss either alone or with another neutral loss ion. For pTyr peptides 
the number of Δ116 Da neutral loss ions reduces as the cut off is increased, meaning that 
Δ80 Da and Δ98 Da are the most common neutral loss ions observed; 23% of pTyr peptides 
exhibit one or both of these neutral losses when the 5% threshold is applied. Although the 
phosphorylated tyrosine itself should only give rise to a neutral loss of 80 Da, it appears 
that loss of water from elsewhere in the peptide results in Δ98 Da also being observed, 
with the number of peptides displaying one of these two neutral losses approximately 
equal when a 10% signal intensity cut-off is used. The observed neutral loss trends for pTyr 
are broadly similar to pHis peptides, meaning the mechanisms by which neutral loss occurs 
from these peptides is probably also similar. However, caution must be taken in drawing 
conclusions from these neutral loss patterns, as ions corresponding to neutral loss masses 
are also observed in the spectra of non-phosphorylated peptides; 26% of all non-
phosphorylated peptides display at least one ‘neutral loss’ ion when the 5% intensity 
threshold is applied. The proportion of ‘neutral loss’ containing spectra for non-
phosphorylated peptides compared to pHis and pTyr phosphopeptides is fairly similar (38% 
of pHis and 35% of pTyr peptide spectra contain at least one neutral loss peak), meaning 
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there could be a considerable number of false positives, masking the true trends in this 
data. 
 
One very clear observation in this data is the number of singly phosphorylated peptides (at 
5% FDR with ptmRS score ≥75) that do not exhibit any neutral loss ions (triplet score of 0). 
Although neutral loss from phosphopeptides is widely reported to occur following CID 
fragmentation, these neutral loss ions do not appear to be a dominant feature in HCD 
spectra. Whilst this may mean that the HCD spectra being generated are more useful for 
phosphopeptide identification and site localisation, by virtue of more complete backbone 
fragmentation which can otherwise be hindered by extensive neutral loss, it also means 
that using neutral loss ions as an additional tool to distinguish sites of His phosphorylation 
may be an unsuccessful strategy. 
 
Overall, it appears that the triplet neutral loss pattern cannot be used as a characteristic 
marker of pHis peptides. A number of high scoring and confidently localised pHis peptides 
(according to ptmRS score) did not display the expected triplet of neutral loss ions. Manual 
inspection of a few example spectra confirms that the absence of the triplet neutral loss is 
not detrimental to the identification of pHis peptides; confident site localisation can be 
achieved despite a triplet score of zero or one (Figure 5.13).  For future phosphopeptide 
analysis the triplet pattern was not considered, instead ptmRS scores were used as a 
measure of phosphosite confidence, with a 1% false localisation rate (FLR) applied. Based 
on work by Ferries et al.200 appropriate score cut-off values were chosen: 99.2 for HCD data 
and 90.2 for EThcD, reflecting the greater confidence in site localisation afforded by EThcD 
fragmentation.   
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Figure 5.12 Number of phosphopeptides exhibiting different combinations of neutral loss ions (Δ80, Δ98 and/or Δ116 Da) at 5% or 10% signal intensity 
cut-off a-d) Neutral loss ions identified at ≥5% compared to base peak signal intensity for a) pHis, b) pSer/pThr, c) pTyr and d) non-phosphorylated 
peptides, e-g) Neutral loss ions identified at ≥10% compared to base peak signal intensity for e) pHis, f) pSer/pTh and g) pTyr. Data is shown for unique 
singly phosphorylated peptides where the site localisation confidence as determined by ptmRS is ≥75. 
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Figure 5.13 Example pHis spectra demonstrate confident pHis localisation without triplet 
neutral loss a) HCD fragmentation of triply charged peptide ion QApHDLSPAAESSSTFSFSGR 
(m/z 721.31), exhibiting only one neutral loss ion (Δ116 Da), with ptmRS score H3:99.79 b) 
HCD fragmentation of doubly charged peptide ion EKEKVpHSEVVQIR (m/z 830.93), 
exhibiting no neutral loss ions, with ptmRS score H6:99.92.  
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5.2.5 Phosphoserine, threonine and tyrosine proteins 
 
In order to assess the unbiased nature of the SAX method presented in this work, the 
identified S/T/Y-phosphoproteins were compared to the phosphoproteins identified by an 
alternative enrichment strategy reported in the literature (Figure 5.14). The work by 
Sharma et al.251 describes the phosphoproteins identified from HeLa lysates that were first 
fractionated by SCX then enriched for phosphopeptides using TiO2. This two-stage 
fractionation and enrichment approach employed for deep phosphoproteome coverage 
results in a greater number of phosphoprotein IDs in the Sharma et al. dataset; 5545 
proteins compared to 2080. 
 
The proteins chosen for comparison were those identified in the control condition 
containing at least one ‘Class I’ S/T/Y-phosphosite, that is with a PTM Score >75 according 
to the MaxQuant phosphosite localisation algorithm. It is worth noting that the MaxQaunt 
software utilises the Andromeda search engine, whereas this work used MASCOT with 
ptmRS for phosphosite localisation, which may result in differences between identified 
phopshopeptides200.  Nevertheless, the majority (77%) of S/T/Y phosphoproteins identified 
by this SAX method (and the associated data analysis pipeline) are also present in the 
Sharma et al. dataset. This high degree of overlap indicates that the SAX method recovers 
an unbiased sub section of the phosphoproteome.  
 
Figure 5.14 Comparison of S/T/Y-phosphoprotein IDs in HeLa cells.  77% of the S/T/Y 
phosphoproteins identified by the method presented in this work (with at least one S/T/Y-
phosphosite above 1% FLR) are also present in the Sharma et al. dataset (phosphoproteins 
with Class I phosphosites (PTM score > 75) identified  following SCX fractionation and TiO2 
enrichment251).  
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5.2.6 Phosphohistidine-containing proteins 
Application of the previously described data analysis pipeline results in a total of 301 pHis 
peptides identified above the 1% FLR cut-off. 164 unique pHis peptides (corresponding to 
172 pHis sites) were identified in the PHPT1 siRNA samples, compared to 181 pHis peptides 
(186 pHis sites) in the NT siRNA sample (Figure 5.15). In both cases overlap between 
bioreplicates was fairly low with 88% and 84% of peptides identified in only one 
bioreplicate for PHPT1 siRNA and NT siRNA conditions respectively. Of the 164 peptides in 
the PHPT1 siRNA condition 27% (44 peptides) are also seen in the NT siRNA condition.  
Contrary to what was expected the number of pHis peptides is higher in the NT siRNA 
condition compared to PHPT1 siRNA treated samples. It was hypothesised that knockdown 
of a His phosphatase would increase levels of pHis. However, it is possible that some 
degree of negative feedback is occurring resulting in decreased pHis levels in the absence 
of PHPT1. Additionally, PHPT1 is not the only known His phosphatase35 and it is possible 
that here is redundancy in terms of their substrates. Indeed, it is also possible that other as 
yet unknown phosphatases could be acting to reduce overall pHis levels compared to the 
control sample. 
 
Analysis of PHPT1 siRNA and NT siRNA treated HeLa cells using the UPAX method has 
resulted in the identification of 296 pHis-containing proteins, which is largest number of 
pHis proteins identified in a single study where the site of phosphorylation is known. Only a 
small number of proteins identified in this work have previously been identified as 
phosphorylated on His. Interestingly, pHis peptides from well characterised pHis proteins 
such as histones and the NME1/2 kinases have not been identified, suggesting this is a far 
from complete analysis of the pHis proteome. A selection of pHis proteins/peptides are 
shown in Table 5.1 (the full list can be found in the Appendix). 
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Figure 5.15 Number of pHis peptides identified in PHPT1 siRNA and NT siRNA conditions with 1% FLR based on ptmRS localisation score. a)  Number of 
unique peptides, sites and proteins identified in each condition. b)  overlap in pHis peptide IDs between PHPT1 siRNA and NT siRNA conditions c) overlap in 
pHis peptides IDs between bioreplicates for PHPT1 siRNA d) overlap in pHis peptide IDs between bioreplicates for NT siRNA 
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 Table 5.1 A selection of pHis peptide/protein IDs that were observed at least twice across 3 bioreplicates; the highest scoring ID is shown. Localised pHis 
residue is indicated as ‘pH’, other phosphorylation sites in the peptide not indicated (further details in Appendix). 
Protein Description Protein 
Accession 
Peptide sequence Site 
(protein) 
ptmRS score 
(pHis site) 
Ion 
score 
Condition 
26S proteasome non-ATPase regulatory subunit 14a O00487 MLLNLpHK 221 100 25 Both 
ARF GTPase-activating protein GIT1  Q9Y2X7 pHGSGADSDYENTQSGDPLLGLEGK 590 99.89 53 Control 
CAD proteina P27708 MVVMpHPMPR 2183 100 24 PHPT1 
Calumenin  O43852 VpHNDAQSFDYDHDAFLGAEEAK 39 99.72 76 Both 
Cyclin-dependent kinase 19  Q9BWU1 ELKpHPNVIALQK 75 100 37 Both 
Cytoplasmic dynein 1 heavy chain 1a Q14204 KLMpHVAYEEFEK 403 100 20 Control 
E3 ubiquitin-protein ligase CHIP  Q9UNE7 KDIEEpHLQR 260 100 22 PHPT1 
Elongator complex protein 1  O95163 TPpHLEKRYK 481 99.72 21 Control 
FACT complex subunit SSRP1a Q08945 EGMNPSYDEYADSDEDQpHDAYLER 449 99.44 45 PHPT1 
Golgin subfamily A member 4a Q13439 LQKLpHEKELAR 485 100 19 Both 
PHD finger protein 6a Q8IWS0 TAHNSEADLEESFNEpHELEPSSPK 149 99.32 29 Control 
Pre-mRNA 3'-end-processing factor FIP1  Q6UN15 ERDpHSPTPSVFNSDEER 491 99.23 78 Both 
Protein RRP5 homologa Q14690 ALECLPSKEpHVDVIAK 1760 99.89 30 PHPT1 
Ribosomal L1 domain-containing protein 1a O76021 EQTPEpHGKK 343 100 28 Both 
RNA polymerase II elongation factor ELL2  O00472 VIpHLLALK 212 100 30 Both 
Serine/threonine-protein kinase PLK2  Q9NYY3 EIELpHRILHHK 134 100 26 Both 
T-box transcription factor TBX4  P57082 KFpHEAGTEMIITK 81 100 33 PHPT1 
T-complex protein 1 subunit alphaa P17987 DDKpHGSYEDAVHSGALND 542 99.94 46 Both 
Ubiquitin carboxyl-terminal hydrolase 43  Q70EL4 LSTLVKFPLSGLNMAPpHVAQR 618 100 22 Control 
a. identified as pHis proteins by Fuhs et al.227 
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5.2.7 Enrichment analysis and phosphohistidine motifs 
In order to reveal possible biological processes related to these pHis proteins, functional 
clustering and enrichment analysis was performed using DAVID259, 260 (version 6.8). The pHis 
proteins identified in each condition were compared to a background of all proteins 
identified in the samples to determine features that are enriched (Figure 5.16; full output in 
Appendix). For each cluster, the fold enrichment and associated P-value is shown. For this 
analysis only clusters containing >3 proteins were considered, with low protein counts 
tending to suggest weaker evidence for enrichment.   DAVID calculates P-values using a 
modified Fisher’s exact test, also called the EASE score, which is a more conservative 
method than a standard Fisher’s exact test. A Benjamini P-value is also calculated, which is 
a multiple testing correction technique used to globally correct P-values.  
 
Proteins in the NT siRNA condition are significantly enriched for motor protein (8 proteins, 
5.7 fold, P=4.58E-4) with cilium (7 proteins, 4.3 fold, P=5.43E-3), zinc finger, C2H2 (5 
proteins, 5 fold, P=1.75E-2) and heme binding (4 proteins, 6.9 fold, P=1.94E-3) also 
enriched. Upon treatment with PHPT1 siRNA only the zinc finger, C2H2 cluster is still found 
to be enriched amongst the identified proteins (6 proteins, 4.7 fold, P=8.57E-3). Enrichment 
is also reported for transducer (7 proteins, 4.6 fold, P=3.81E-3) and kinase activity (7 
proteins, 3.5 fold P=1.44E-2). There were no enriched KEGG pathways identified for either 
dataset. 
 
Analysis with DAVID incorporates terms from a variety of sources, utilising over 40 
annotation categories, including GO terms, protein functional domains and sequence 
features. This extended annotation coverage provides a comprehensive view of the data. 
Potential limitations of functional annotation and enrichment tools, such as DAVID, include 
incomplete annotation databases and the fact that only existing annotations are included, 
i.e. such informatics methods cannot discover previously unknown functions of any given 
protein cohort261. It is thus theoretically possible that the pHis-mediated regulation of any 
given protein identified in this study could be a moonlighting function in addition to the 
function already annotated and described in the various databases. 
  
 
1
40
 
 
 
Figure 5.16 Enrichment analysis of pHis proteins performed using DAVID. a) proteins identified in NT siRNA condition (b) proteins identified in PHPT1 
siRNA condition. P-value indicated by colour: yellow P<0.05, blue P<0.01, green P<0.001 with asterisks defining clusters where the Benjamini adjusted P-
value <0.1.  
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Given that this dataset reports the largest number of identified pHis peptides/sites to date, 
this presents a valuable opportunity to examine motifs surrounding these sites of His 
phosphorylation.  The seven residues either side of a confidently localised pHis site (1% 
FLR) were used to search for pHis motifs using the Motif-X tool262, 263 (Figure 5.17). A search 
with all pHis sites revealed two distinct motifs, both of which were Lys directed. Lys is 
enriched at either the -1 (2.84 fold) or +3 position (2.63 fold) in these motifs. Additionally, 
there appears to be a preference for Lys, Glu and Leu in the nearby residues either side of a 
phosphorylated His. Given the charge directed nature of the SAX separation it was 
suspected that there could be a bias in the motifs observed in the early compared to the 
later fractions. Motifs for fractions 1-8 are again all Lys directed: -1 position (3.9 fold), +3 
position (3.62 fold) and -3 position (3.90 fold), whilst the later eluting fractions (9-16) 
exhibit a preference for Glu at +5 (3.17 fold).  
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Figure 5.17 Extracted motifs from pHis peptide data. a) Motifs from pHis peptides in all 16 
SAX fractions b) Motifs from pHis peptides in SAX fractions 1-8 c) Motif from pHis peptides 
in SAX fractions 9-16. A higher score indicates a more significant/more specific motif. Fold 
increase compared to background of all sequences in the human proteome. Significance set 
at 1E-5 (not corrected for multiple hypotheses, corresponds to P value of 3E-4 with 
Bonferroni correction). 
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5.2.8 A potential role for phosphohistidine in kinases 
Reversible phosphorylation of proteins by protein kinases is a vital mechanism for 
eukaryotic signalling. Of the ~300 pHis peptides identified in this analysis, 12 were from 
protein kinases, which represents ~4% of all pHis peptide identifications. A sequence 
alignment (performed by P. Eyers, University of Liverpool) revealed that three of these pHis 
sites map to the identical region of the protein kinase catalytic domain, specifically   the 
HxN-His position of the αC-β4 loop. Furthermore, the pHis site is conserved in >65% of 
human protein kinases. Annotated spectra for the peptides derived from Ser/Thr kinases 
CDK19 and PLK2 and the tyrosine kinase Ephrin A1 are shown in Figure 5.18.  
 
For both CDK19 and PLK2 multiple instances of the same pHis peptide were identified 
across bioreplicates and across the two conditions. The highest scoring identification for 
each of these peptides is displayed in Table 5.1, with further details in the Appendix. The 
PLK2 peptide EIELHRILHHK is doubly phosphorylated with one phosphorylation confidently 
localised to H5 (above the 1% FLR threshold) whilst the other phosphorylation could be on 
one of a further two possible His residues in the peptide (H9, H10). The conserved residue 
maps to H10 in the peptide, although unfortunately there is no definitive evidence to 
localise the phosphorylation to this residue over the adjacent H9. The CDK19 peptide 
ELKHPNVIALQK is singly phosphorylated; the site of phosphorylation is localised to the H4 
residue with a ptmRS score of 100. The Ephrin A1 peptide EATIMGQFSHPHILHLEGVVTKR 
contains four sites of phosphorylation. The pHis site which maps to the conserved residue 
(H10) has a ptmRS score of 96.87, which is below the 1% FLR threshold but still above the 
cut-off of 75 many phosphoproteomics studies use to confidently assign phosphosites. 
 
The αC-β4 loop, to which these pHis sites map, is implicated in positioning of the αC-helix 
and Hsp90 mediated kinase maturation264-266. Additionally, PTMs of the αC-β4 loop have 
been observed in multiple kinases and are proposed to regulate the position of the 
preceding αC-helix267, 268. Therefore, phosphorylation of the HxN-His residue might act as a 
general mechanism for regulating kinase activity by altering kinase dynamics. To further 
investigate this hypothesis, molecular dynamics (MD) simulations have been performed (by 
N. Kannan & Z. Ruan, University of Georgia) (Figure 5.19). They used PLK2 as the model 
system; His139 maps to the conserved HxN-His position and corresponds to H10 in the 
observed peptide sequence (EIELHRILHHK). MD simulations were carried out on four 
possible pHis139 states, based on the protonation state and the attachment of the 
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phosphate group on the His residue. Specifically, pHis139-N1-H1D is the 1-pHis isomer with 
a singly protonated phosphate group, pHis139-N1-H2D is the 1-pHis isomer with an 
unprotonated phosphate group, pHis139-N3-H1E is the 3-pHis isomer with a singly 
protonated phosphate group, and pHis139-N3-H2E is the 3-pHis isomer with an 
unprotonated phosphate group. Comparison of these simulations showed increased 
flexibility in the phosphorylated compared to the unphosphorylated form (Figure 5.19 b). In 
particular the 3-pHis (N3) form displays increased flexibility in the activation segment, the 
regulatory αC-helix and the catalytic HRD motif (Figure 5.19 b, c), whilst the regulatory 
spine residue His134 also undergoes a conformational change upon phosphorylation of the 
His139 residue at the 3-position (Figure 5.19 d). 
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Figure 5.18 Annotated spectra for pHis peptides that map to HxN motif of protein kinases 
a) CDK19 peptide ELKpHPNVIALQK (m/z 735.40, ptmRS score H4:100) b) PLK2 peptide 
EIELpHRILHpHK (m/z 729.89, ptmRS scores H5:100, H9:50, H10:50) c) Ephrin A1 peptide 
EATIMGQFpSpHPpHILpHLEGVVTKR (m/z 974.09, ptmRS scores S9: 96.87, H10: 96.87, H12: 
76.11, H15: 99.79) 
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Figure 5.19 Molecular dynamics simulations of PLK2 with H139 phosphorylation a) Alignment of selected human kinases highlighting the HxN motif  
b) Root mean square fluctuation (RMSF) plot of unphosphorylated PLK2, pHis139-N1-H1D, pHis139-N1-H2D, pHis139-N3-H1E and pHis139-N3-H2E (see 
main text for explanation of pHis139 states). Key regions that display differential fluctuations are shown. c) Free energy landscape through root mean 
square deviation (RMSD) of αC-helix and the activation segment. d) Representative snapshot of unphosphorylated PLK2 (upper panel) and pHis139-N3-H1E 
(lower panel).  
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5.3 Conclusions 
 
A novel SAX strategy for unbiased analysis of phosphopeptides has been applied to HeLa 
cell lysates before and after siRNA knockdown of PHPT1, a known His phosphatase. This 
method enables partial separation of phosphorylated from non-phosphorylated peptides, 
resulting in SAX fractions that are considerably enriched for phosphopeptides, an effect 
which was observed in all three bioreplicates across both experimental conditions.  
 
Given the challenges associated with phosphosite localisation, an attempt was made to 
improve identification of pHis peptides based on a characteristic pattern of neutral loss 
from the precursor ion. However, the strategy did not prove diagnostic for pHis peptides. 
The triplet neutral loss pattern was not consistently observed for peptides where the site of 
phosphorylation was confidently assigned as His by the ptmRS site localisation tool and/or 
manual annotation of spectra. Additionally, many phosphopeptides modified on residues 
other than His exhibited the triplet neutral loss pattern, whilst a vast proportion of 
phosphorylated peptides did not show any neutral loss under the HCD fragmentation 
conditions employed in this experiment. The data analysis pipeline implemented for 
characterisation of pHis peptides therefore used ptmRS for site localisation, with a score 
threshold applied to achieve 1% FLR.  
 
Characterisation of phosphopeptides in both the NT siRNA and PHPT1 siRNA conditions 
(across all three bioreplicates) revealed a total of 301 pHis peptides, corresponding to 314 
unique pHis sites localised above the 1% FLR threshold. It was anticipated that PHPT1 siRNA 
treatment would increase the levels of His phosphorylation compared to the NT siRNA 
control. However, an increase in pHis was not observed under these conditions. Given the 
widespread differences between the pHis proteins identified in the two conditions it is 
likely that complex signalling mechanisms are involved to bring about the 
phosphorylation/dephosphorylation of many of these proteins, as opposed to them being 
direct targets for dephosphorylation by PHPT1. Hence over the time scale of the siRNA 
treatment more extensive effects are observed than just a rapid build-up of the pHis 
phosphorylation that is targeted by PHPT1 phosphatase activity. 
 
Functional analysis of the pHis proteins identified in each of the two conditions did not 
identify any clear functions or localisation to a particular sub-cellular compartment, which 
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may suggest pHis has a more generalised role in human cells. Additionally, it should be 
noted that many previously identified pHis-containing proteins were not observed in this 
analysis, which suggests the coverage of the pHis proteome represented by this dataset is 
incomplete. For example, peptides from neither NME1/2 (known His kinases) or histone H4 
were identified. Furthermore, there were few similarities between the pHis proteins 
identified in this dataset compared to the previously published pHis proteins derived from 
IP experiments with 1- and 3-pHis antibodies, which indicates that neither of these analyses 
were able to access the entire pHis proteome alone.  A combination of strategies will 
clearly be required to enable further exploration of this much-understudied area of the 
human phosphoproteome. 
 
Nevertheless, the dataset generated here still contains a wealth of useful information. The 
~300 sites of His phosphorylation have provided the first opportunity to examine amino 
acid motifs surrounding the site of modification. Consequently, two Lys-directed motifs 
have been revealed. The sequence of amino acids surrounding a phosphorylation site are 
crucial for kinase specificity. Hence, establishing such motifs can go some way to 
understanding the kinase-substrate interactions that modulate the network of 
phosphorylation in signal transduction pathways. 
 
Within this dataset a total of 12 pHis peptides derived from kinases were identified. Three 
of these pHis peptides map to the identical region of the αC-β4 loop within the kinase 
catalytic domain, which is implicated in positioning of the αC-helix and thus catalytic 
activity. His phosphorylation of the HxN-His position could therefore act as a general 
regulatory mechanism of eukaryotic protein kinases. Further studies to establish the effects 
of this phosphorylation on kinase activity will however be required.  
 
Given that His has a near neutral pKa and is thus partially protonated at physiological pH, 
the addition of a negatively charged phosphate group could result in a reversal of local net 
charge. This switch from positive to negative charge could conceivably cause a substantial 
conformational change within the protein, and will almost undoubtedly change the 
potential for local electrostatic interactions, thus regulating binding of the protein to other 
substrates. A positive to negative switch may also help regulate binding of proteins to 
nucleic acids, whereby phosphorylation of a His residue would inhibit binding of negatively 
charged nucleic acids. The identification of a number of RNA/DNA binding proteins in this 
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analysis, such as T-box transcription factor TBX4, RNA-binding protein 8A, Protein RRP5 
homolog (also known as NFκB-binding protein) and Ribosomal L1 domain-containing 
protein 1, hints at this being a possible role for pHis in human cells. As a further 
consequence of the near neutral pKa of His, these residues can exhibit catalytically 
important transitions from a charged to uncharged side chain. Reversible His 
phosphorylation could therefore have a major impact on catalysis. 
 
The identification of widespread His phosphorylation in human cells highlights the pressing 
need to identify the kinases and phosphatases involved in modulation of pHis in cellular 
signalling events. Biochemical evaluation and genomic annotation will be vital in this 
endeavour to refine the current understanding of eukaryotic signalling. Furthermore, 
identification of specific kinase-substrate interactions responsible for His phosphorylation 
may reveal druggable targets to modulate this activity. Given that pHis is known to be 
involved in cancer and tumour metastasis, identification of such targets may have 
therapeutic benefits, akin to the protein kinase inhibitors currently used in cancer 
treatments. As it is unlikely that pHis functions independently from pSer, pThr and pTyr, 
the effect of clinical inhibitors of protein kinases on global pHis in human cells, particularly 
those derived from disease models, may also provide an interesting avenue to establish the 
roles of pHis in human health and disease. 
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Chapter 6. Results IV: Analysis of the unexplored human 
phosphoproteome 
 
6.1 Introduction 
 
Besides the well-known phosphorylation of Ser, Thr and Tyr, and the previously discussed 
phosphorylation of acid-labile His, a number of other amino acid residues are known to be 
phosphorylated in biological systems. Phosphorylated Lys, Arg, Asp, Glu and Cys have all 
been reported, although very little is known about the extent of these phosphorylated 
residues in human systems, and what their roles might be6-8. The structures of these 
phosphorylated amino acids are shown in Figure 6.1. 
 
Similarly to pHis, the phosphoramidate bond of pLys and pArg makes them acid-labile, 
which significantly hinders their analysis. Despite the fact that phosphorylation of lysine 
was first observed in rat liver cells 50 years ago269, very little is known about this 
modification. There is evidence for in vivo phosphorylation of histone H1 on lysine41, 
although the kinases responsible are unknown, with only partial purification of a possible 
candidate achieved40.  There are also a few examples of pLys phosphatases isolated from 
mammalian systems, and the phosphatase PHPT1 has also been shown to dephosphorylate 
pLys in vitro270-272. Much of the current research regarding pArg is focused on bacteria, with 
the first protein arginine kinase identified less than 10 years ago273, and recent roles being 
discovered for pArg in bacterial stress response234. However, there are also several older 
reports of pArg kinase and phosphatase activity in vertebrates274-278. In general, reported 
pArg kinases are isolated from nuclear tissue, whilst the few known substrates tend to be 
basic proteins such as histones and myelin.  
 
The phosphorylation of Asp and Glu to form phosphoanhydrides increases their 
susceptibility to hydrolysis, and as such they are reported to be very unstable, at least in 
their free forms7. The role of pAsp in the two-component signalling system is well 
established; pAsp relays a signal from a sensor histidine kinase to a response regulator, 
which modulates a cellular response, for example transcription16. The two-component 
signalling system is well known in microorganisms and plants, although an analogous 
system is not thought to function in mammals. However, in human cells pAsp is known to 
occur as an enzymatic intermediate in a number of enzyme catalysed reactions279, 280, as 
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well as pAsp proteins having previously been identified in the study of human prostate 
cancer cell lines218. According to the literature, pGlu is best known for its free form gamma 
glutamyl phosphate, which is an important intermediate in the synthesis of the amino acids 
glutamine and proline281, 282, as well as being involved in the reaction to form glutathione283.  
In terms of its currently known roles in protein phosphorylation, pGlu is found in the 
nuclear protein prothymosin, where it is reportedly involved in production, processing or 
export of RNA284, 285, and has also been reported to occur in α2 chains of collagen286.  
 
It was hypothesised that given the UPAX method had proven to be successful for pHis 
analysis, it may also have preserved other acid-labile phosphate groups, which could be 
identified through additional interrogation of the data. This chapter describes the 
identification and bioinformatics characterisation of non-canonical sites of phosphorylation 
from the data acquired following treatment of HeLa cells with PHPT1 siRNA and NT siRNA 
with subsequent SAX fractionation and analysis by LC-MS/MS (as detailed in Chapter 5. 
Results III).  
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Figure 6.1 Phosphorylated amino acid structures a) phospholysine b) phosphoarginine c) 
phosphoaspartate and d) phosphoglutamate 
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6.2 Results and Discussion 
 
6.2.1 Identification of non-canonical sites of phosphorylation 
To perform a MASCOT search with all possible sites of phosphorylation considered as 
variable modifications would result in a massively increased theoretical search space, 
making the search very slow and causing a huge increase in false discovery rates, and thus 
decreasing the number of (phospho)peptides identified. Therefore, it was decided that a 
better approach was to perform searches with phosphorylated Ser, Thr, Tyr and one 
additional site of modification at a time. The inclusion of Ser, Thr and Tyr phosphorylation 
was important as a large number of these sites had previously been identified in the 
MASCOT searches for pHis, with the additional observation that numerous pHis-containing 
peptides were co-phosphorylated on Ser, Thr or Tyr.  
 
MASCOT searches were performed in the same way as they had been for pHis but with the 
other phosphosites. An initial evaluation of the extent of non-canonical phosphorylation 
was carried out by performing MASCOT searches for each site of phosphorylation (pLys, 
pArg, pAsp, pGlu and pCys) for one set of SAX fractions. There was no evidence for pCys in 
these samples, but the other four sites of phosphorylation warranted further investigation. 
For pLys, pArg, pAsp and pGlu MASCOT searches were subsequently carried out for all 
three bioreplicates across the two conditions (PHPT1 siRNA and NT siRNA). Phosphosite 
localisation confidence was assessed using the ptmRS node in Proteome Discoverer, with a 
1% FLR cut-off used as previously described. The number of non-canonical phosphosites 
identified in each of these searches is shown in Table 6.1, with the number of pSer, pThr 
and pTyr sites (identified in the search including pHis) shown for comparison. 
 
A surprisingly large number of pLys, pArg, pAsp and pGlu sites are identified in these 
searches, with the number of all of these sites exceeding the number of pHis and pTyr sites 
identified. Interestingly, for all sites except pLys there are a greater number of 
phosphosites identified in the NT siRNA condition compared to PHPT1 siRNA. The increase 
in pLys sites upon treatment with PHPT1 siRNA aligns with the previously published 
observation of dephosphorylation of pLys by PHPT1 in vitro272, suggesting that PHPT1 
phosphatase activity towards pLys may also be relevant in vivo, and perhaps PHPT1 
regulation of pLys is more prevalent than regulation of pHis. 
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Table 6.1 Number of phospho-sites, peptides and proteins identified following MASCOT 
searches for modification of acid-labile residues. MASCOT searches of all 16 SAX fractions 
for each of the three bioreplicates in both conditions (PHPT1 siRNA and NT siRNA) were 
conducted using Proteome Discoverer with 5% FDR.  Searches for pHis, pArg, pLys, pAsp 
and pGlu were conducted separately with pSer, pThr and pTyr additionally included as 
variable modifications for each pX. Numbers for pSer, pThr and pTyr are taken from the 
search with pHis. All sites meet the 1% FLR cut-off based on ptmRS score. 
 
Phosphosite 
Condition 
(siRNA) 
Unique pX 
peptides 
Unique pX 
sites 
Unique pX 
proteins 
pHis 
PHPT1 164 172 164 
NT 181 186 176 
pArg 
PHPT1 305 324 329 
NT 323 345 333 
pLys 
PHPT1 572 618 555 
NT 543 592 533 
pAsp 
PHPT1 276 287 264 
NT 284 294 274 
pGlu 
PHPT1 315 334 304 
NT 347 374 324 
pSer 
PHPT1 2655 2889 1575 
NT 3024 3321 1745 
pThr 
PHPT1 626 681 560 
NT 666 707 573 
pTyr 
PHPT1 152 159 148 
NT 169 175 165 
 
 
The degree of overlap for phosphopeptide IDs between the PHPT1 siRNA and NT siRNA 
conditions is similar for all non-canonical sites (Figure 6.2 a-d), ranging between 13 and 
17%. For pSer, pThr and pTyr phosphopeptides (identified in the search including pHis) 
overlap between the two conditions is 42%, 22% and 13% respectively. The greater degree 
of overlap between the pSer and pThr peptides is perhaps unsurprising given that many 
pSer/pThr mediated signalling events would not be expected to change between the two 
treatment conditions. The overlap in phosphopeptides IDs between bioreplicates for non-
canonical sites (pLys, pArg, pAsp and pGlu) and pTyr is fairly low, with the majority of 
phosphopeptides identified in only one bioreplicate. This is probably due to the stochastic 
nature of MS analysis, with low abundance phosphopeptides less likely to be identified in 
all samples, i.e. these phosphopeptides may not be selected for MS2 in some samples if 
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they are below the required intensity threshold. The highest confidence identifications will 
be those observed in more than sample, but for the purposes of this work all identifications 
were kept for further bioinformatics analysis. It would be wise to assess the number of 
times a given pX peptide of interest has been observed in these experiments as part of the 
criteria for selecting pX proteins that warrant further biochemical investigation. The results 
of each of the searches are discussed in more detail in the subsequence sections of this 
chapter. The full list of peptide and protein IDs for each site of phosphorylation can be 
found in the Appendix, along with example tandem MS spectra for peptides bearing each 
type of phosphorylation. 
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Figure 6.2 Overlap in phosphopeptide IDs between bioreplicates for each condition 
(PHPT1 siRNA and NT siRNA) and between conditions, shown for each site of 
phosphorylation. a) pLys, b) pArg, c) pAsp, d) pGlu, e) pSer, f) pThr and g) pTyr. Numbers 
for pSer, pThr and pTyr are taken from the search with pHis. Overlap for pHis peptides 
shown in Chapter 5. Results III: Figure 5.15 b.  
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6.2.2 Phospholysine 
Contrary to the trend observed for all other phosphosites, a greater number of pLys 
peptides are observed from proteins extracted from the PHPT1 siRNA treated samples (572 
peptides, 618 sites) compared to the NT siRNA treated samples (543 peptides, 592 sites). 
This corresponds to 555 and 533 pLys proteins identified in the PHPT1 siRNA and NT siRNA 
conditions respectively. Of the non-canonical phosphosites searched for in the data, pLys 
peptides are the most prevalent, with over 3 times as many pLys peptides compared to 
pHis. Of the 572 peptides identified in the PHPT1 siRNA condition 28% (159 peptides) are 
also identified in the NT siRNA condition (Figure 6.2 a). 
 
The increase in the number of pLys peptides (and proteins) identified following PHPT1 
siRNA treatment suggest that PHPT1 is acting as a pLys phosphatase. This aligns with 
previous evidence for dephosphorylation of pLys by PHPT1 in vitro272, and thus suggests 
that the phosphatase activity of PHPT1 towards pLys is also relevant in vivo. Histone H1 has 
previously been reported to be phosphorylated on Lys, by as yet unknown kinases40, 41. 
Interestingly, there are 3 pLys peptides identified in this study that belong to histones (H1x, 
H2A.J and H2B).  
 
Functional annotation clustering was performed using DAVID to assess enrichment of pLys 
proteins identified in each of the two conditions compared to the background of all 
proteins identified in these studies (Figure 6.3). Significant enrichment for pLys was 
observed in motor protein (18 proteins, 3.1 fold, P=5.21E-5), cell junction (35 proteins, 1.9 
fold, P=5.13E-4), calponin homology domain (7 proteins, 6.2 fold, P=6.52E-4) and ATPase 
activity (19 proteins, 2.4 fold, P=7.78E-4). PDZ domain (15 proteins, 2.5 fold, P=2.76E-3), 
leucine-rich repeat (11 proteins, 3 fold, P=3.17E-3) and myosin (8 proteins, 3.9 fold, 
P=3.47E-3) are also enriched, with a small but significant enrichment also observed in ATP 
binding (51 proteins, 1.5 fold, P=3.6E-3). 
 
Following treatment with PHPT1 siRNA IQ motif with EF-hand binding site shows significant 
enrichment (15 proteins, 4.9 fold, P=1.10E-6), which was not observed in the NT siRNA 
condition. Additionally, there is increased significance associated with ATP binding (69 
proteins, 1.7 fold, P=1.22E-5) and leucine-rich repeat (12 proteins, 4 fold, P=1.63E-4) 
compared to the NT siRNA condition. Calponin homology domain (7 proteins, 5.9 fold, 
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P=8.44 E-4), pleckstrin homology domain (23 proteins, 2.2 fold, P=8.61E-4) and PDZ domain 
(15 proteins, 2.4 fold, P=3.53E-3) are also enriched. 
 
There were eight KEGG pathways significantly enriched under NT siRNA conditions 
(P<5E-2). Most notable were tight junction (12 proteins including myosins, P=1.73E-3) and 
oxytocin signalling pathway (11 proteins, P=6.52E-3). The tight junction is one of ten KEGG 
pathways enriched following PHPT1 knockdown (13 proteins, P=1.04E-3), although the 
oxytocin signalling pathway enriched under control conditions was not observed following 
PHPT1 depletion. However, there was a 3-fold enrichment of the prostate cancer pathway 
(P=6.92E-3), represented by 9 proteins. 
 
All sequences identified across the two conditions were assessed using the Motif-X 
software (Figure 6.4). There appears to be a strong preference for the hydrophobic 
residues Leu or Ile at the -2 or -7 positions with respect to the phosphorylated Lys residue; 
the top scoring motifs have Leu in the -2 position (score 14.45, fold enrichment 1.80) and 
Leu in the -7 position (score 10.84, fold enrichment 1.81). The positions surrounding the 
phosphorylated Lys seem to favour hydrophobic residues, particularly Leu and Val, along 
with Glu. Leu directed motifs also emerge for peptides identified in the first eight fractions, 
with Leu in the -2 position having a particularly high score (score 15.95, fold enrichment 
2.17). For sequences identified in the last eight fractions the motif is Glu directed (Glu -1, 
score 7.81, fold enrichment 1.92), reflecting a possible bias due to the charge-based 
separation which result in later fractions containing peptides with more acidic residues. 
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Figure 6.3 Enrichment analysis of pLys proteins performed using DAVID a) proteins identified in NT siRNA condition, with enriched KEGG pathways shown 
in the table b) proteins identified in PHPT1 siRNA condition, with enriched KEGG pathways shown in the table. P value indicated by colour: yellow P<0.05, 
blue P<0.01, green P<0.001 with asterisks defining clusters where the Benjamini adjusted P-value <0.1  
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Figure 6.4 Extracted motifs from pLys peptide data a) Motifs from pLys peptides in all 16 SAX fractions b) Motifs from pLys peptides in SAX fractions 1-8 c) 
Motif from pLys peptides in SAX fractions 9-16. A higher score indicates a more significant/more specific motif. Fold increase compared to background of all 
sequences in the human proteome. Significance set at 1E-5 (not corrected for multiple hypotheses, corresponds to P value of 3E-4 with Bonferroni 
correction).
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6.2.3 Phosphoarginine 
A total of 551 pArg containing peptides were identified across both conditions, 
corresponding to 585 pArg proteins. Of the 323 pArg peptides identified in the NT siRNA 
condition 24% (77 peptides) were also identified in the PHPT1 siRNA condition. The very 
few examples of pArg on protein substrates in mammalian systems occur on histones or 
myelin; in this analysis one pArg-containing peptide derived from Histone H2A was 
identified. 
 
Functional annotation clustering (Figure 6.5) of the proteins identified in the NT siRNA 
condition revealed only clusters in the lowest category of significance (5E-2>P>1E-2). These 
clusters included voltage gated channel (5 proteins, P=2.33E-2), collagen (5 proteins, 
P=2.57E-2) and tetratricopeptide repeat (6 proteins, P=2.58E-2). However, following 
treatment with PHPT1 siRNA a number of significant enrichments are observed. Most 
notable is ATP binding (48 proteins, 1.6 fold, P=6.99E4), with spectrin/alpha-actin (5 
proteins, 8.5 fold, P=2.42E-3) and ATPase, dynein related, AAA domain (4 proteins, 11.6 
fold, P=4.29E-3) also enriched, although the latter two are based on a relatively small 
number of proteins. 
 
In both conditions three KEGG pathways were enriched (P<5E-2), although they were 
different pathways for each condition. The mTor signalling pathway (5 proteins, 4.14 fold, 
P=3.06E-2) and PI3K-Akt signalling pathway (11 proteins, 2.08 fold, P=3.52E-2) are enriched 
in the NT siRNA conditions, whilst focal adhesion (9 proteins, 2.37 fold, P=3.32E-2) is the 
most significantly enriched pathway in the PHPT1 siRNA condition. 
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Figure 6.5 Enrichment analysis of pArg proteins performed using DAVID a) proteins identified in NT siRNA condition, with enriched KEGG pathways shown 
in the table b) proteins identified in PHPT1 siRNA condition, with enriched KEGG pathways shown in the table. P value indicated by colour: yellow P<0.05, 
blue P<0.01, green P<0.001. 
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Motif-X analysis (Figure 6.6) of all sequences reveals two motifs: Glu in the +1 position 
(score 6.49, fold increase 1.85) and Leu in the -2 position (score 6.70, fold enrichment 
1.73). There also appears to be a general preference for Glu, Leu, Ile, and Ala in the 
positions surrounding the phosphorylated residue. When sequences from the first or last 
eight fractions are analysed separately no motifs are found, indicating that neither of these 
identified motifs are being biased as a result of the charge-based SAX fractionation 
strategy. 
 
 
Figure 6.6 Extracted motifs from pArg peptide data for peptides identified across all SAX 
fractions. A higher score indicates a more significant/more specific motif. Fold increase 
compared to background of all sequences in the human proteome. Significance set at 1E-5 
(not corrected for multiple hypotheses, corresponds to P value of 3E-4 with Bonferroni 
correction).  
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6.2.4 Phosphoaspartate 
In this analysis, a total of 496 pAsp peptides (corresponding to 474 proteins) were 
identified. This is over 1.5 times the number of pHis-peptides/proteins identified, which 
aligns with previous LC-MS/MS analysis of pHis/pAsp in a human prostate cancer cell line 
where a greater number of pAsp peptides were detected compared to pHis (75 pAsp 
proteins compared to 20 pHis proteins218). Of these previously identified pAsp proteins, 
seven were identified in this experiment (Table 6.2). There is however, disagreement in all 
cases over the phosphorylated Asp residue within these proteins, with different pAsp 
peptides identified in this experiment compared to the Lapek et al. data for each of the 
proteins. Of all of the pAsp peptides identified by Lapek et al. only one is identified in this 
data, with the phosphorylation site localised to a Ser residue in this analysis: 
SLSSpSLDDTEVKK from VAMP-associated protein with a ptmRS score of 76.69 for residue 
S5. The discrepancies between these two data sets highlights the difficulty in obtaining 
comprehensive and confident coverage of this unexplored area of the phosphoproteome. 
 
Table 6.2 Previously identified pAsp proteins. Proteins previously identified by Lapek et al.  
in human prostate cancer cell lines that are also observed in this analysis with at least one 
pAsp site. The pAsp sites observed in this analysis are not the same as those previously 
identified. 
Protein Description Accession pAsp residue Condition (siRNA) 
26S proteasome non-ATPase regulatory 
subunit 2 
Q13200 784 PHPT1 
Calumenin O43852 41; 250; 256 Both 
Eukaryotic translation initiation factor 2 P20042 4 NT 
Exportin 1 O14980 681 PHPT1 
Nesprin 1 Q8NF91 8307 PHPT1 
Neuroblast differentiation-associated 
protein AHNAK 
Q09666 4432; 4563; 
4990; 5742 
Both 
Stress induced phosphoprotein 1 P31948 70 Both 
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Interestingly, a peptide from PHPT1 was identified in three out of the six bioreplicates as 
being phosphorylated on an Asp residue. The same peptide is also observed in the 
remaining three bioreplicates but the ptmRS scores are below the 1% FLR cut-off (although 
the Asp site is still the most likely position of phosphorylation in all cases). Figure 6.7 shows 
a representative MS/MS spectrum for the pAsp peptide (AVApDLALIPDVDIDSDGVFK, m/z 
718.35), with the pAsp site localised to position 4. This pAsp site corresponds to residue D5 
in the protein sequence, which has not previously been identified as a modified site.  
 
Analysis with DAVID (Figure 6.8) for proteins identified in the NT siRNA condition revealed 
significant enrichment for tetratricopeptide repeat (12 proteins, 7.8 fold, P=2.93E-7) and 
cilium (11 proteins, 3.3 fold P=1.88E-3), with enrichment also observed for cell junction (20 
proteins, 2.1 fold, P=2.63E-3), cell cycle arrest (9 proteins, 3.7 fold, P=2.79E-3) and 
microtubule (14 proteins, 2.3 fold, P=7.09E-3). Proteins identified in the PHPT1 siRNA 
condition also show significant enrichment for tetratricopeptide repeat (7 protein, 9.6 fold, 
P=6.74E-5). Treatment with PHPT1 siRNA also results in significant enrichment of ATP 
binding (36 proteins, 2.1 fold, P=2.40E-5) and ATPase activity (13 proteins, 3.3 fold, 
P=5.53E-4), with motor protein (9 proteins, 3.2 fold P=6.60E-3), helicase (10 proteins, 2.9 
fold, P=6.73E-3) and disulphide bond (32 proteins, 1.6 fold, P=6.78E-3) also enriched. There 
were no significantly enriched KEGG pathways identified for proteins in either condition 
 
Motif-X analysis using all sequences did not reveal any motifs, however, when only the 
sequences identified in fractions 1-8 were used, one motif does emerge (Figure 6.8 c). The 
identified motif has Lys in the +4 position (score 6.64, fold increase 2.85). Additionally, 
there appears to be a preference for Lys and hydrophobic residues Leu, Ile and Ala in the 
positions surrounding the phosphorylated Asp residue. Motif analysis of the small number 
of pAsp peptides previously identified also highlighted a preference for Asp, Lys and 
hydrophobic residues in close proximity to pAsp218. 
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Figure 6.7 Tandem mass spectrum of triply charged pAsp peptide from PHPT1. Spectrum 
generated by HCD of peptide ion at m/z 718.35 (AVApDLALIPDVDIDSDGVFK); LC-MS/MS 
analysis with Orbitrap Fusion of SAX fraction 8 of NT siRNA treated sample. MASCOT ion 
score: 32, ptmRS score for residue D4: 99.94.  
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Figure 6.8 Enrichment analysis of pAsp proteins performed with DAVID and a pAsp motif a) Enrichment analysis for proteins identified in NT siRNA 
condition b) Enrichment analysis for proteins identified in PHPT1 siRNA condition. P value indicated by colour: yellow P<0.05, blue P<0.01, green P<0.001 
with asterisks defining clusters where the Benjamini adjusted P-value <0.1 c) Motif analysis for sequences in fractions 1-8 (no motifs found when all 
sequences searched). Significance set at 1E-5 (not corrected for multiple hypotheses, corresponds to P value of 3E-4 with Bonferroni correction). 
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6.2.5 Phosphoglutamate 
A total of 585 pGlu-containing peptides were identified across the two conditions, 
corresponding to 551 pGlu-containing proteins.  Of the 347 pGlu peptides identified in the 
NT siRNA condition 22% (77 peptides) were also identified in the PHPT1 condition, which is 
a similar degree of overlap as is observed for the other non-canonical phosphorylation 
sites. One of the few currently known examples of pGlu protein phosphorylation occurs on 
α2 chains of collagen286.  In this data set one pGlu peptide is observed from α2 collagen, 
with a further four pGlu peptides from other α1 and α4 collagen chains. 
 
Functional annotation clustering was performed using DAVID (Figure 6.9). Proteins 
identified in the NT siRNA condition are significantly enriched for dynein heavy chain (5 
proteins, 18.5 fold, P=8.79E-5). Also enriched are GTPase activation (13 proteins, 3 fold, 
P=1.34E-3), fibronectin type-III (8 proteins, 4.4 fold, P=2.11E-3) and microtubule motor 
activity (8 proteins, 4.1 fold, P=3.35E-3). Following treatment with PHPT1 siRNA, ATPase 
activity is significantly enriched (15 proteins, 3.3 fold, P=1.84E-4). Pleckstrin homology 
domain exhibits a similar degree of enrichment in both the PHPT1 siRNA and NT siRNA 
samples (PHPT1 siRNA: 15 proteins, 2.9 fold, P=3.38E-4; NT siRNA: 14 proteins, 2.3 fold, 
P=6.79E-3) as does ATP binding (PHPT1 siRNA: 32 proteins, 1.7 fold, P=5.10E-3; NT siRNA: 
32 proteins, 1.6 fold, P=8.03E-3). Proteins in the PHPT1 siRNA condition are also enriched 
for actin-binding (5 proteins, 10 fold, P=1.23E-3), Src homology-3 domain (10 proteins, 2.9 
fold, P=7.32E-3) and Myosin-like IQ motif-containing domain (4 proteins, 9.2 fold, 
P=8.47E-3). 
 
There are no KEGG pathways enriched in the NT siRNA condition, however pGlu proteins in 
the PHPT1 siRNA sample map to a number of enriched KEGG pathways. There are 27 
significantly enriched KEGG pathways with P<0.01, with a further 20 with P<0.05. The 
pathways with highest significance and represented by more than eight proteins are shown 
in Figure 6.9 b. Most notable are platelet activation (11 proteins, 4.7 fold, P=7.81E-3), 
insulin signalling pathway (11 proteins, 3.8 fold, P=4.67E-3) and AMPK signalling pathway 
(10 proteins, 4 fold, P=7.38 E-4). 
 
Motif-X analysis (Figure 6.10) of all sequences across the two conditions reveals a strong 
preference for Lys in the +1 position (score 12.78, fold increase 2.22), with a second motif 
where the preference is for Lys in the -3 position (score 6.09, fold increase 1.91).  
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Performing the analysis with only peptides in the first eight SAX fractions also reveals the 
motif with Lys in the +1 position (score 10.63, fold increase 2.73), plus a second different 
motif with Lys in the +2 position (score 6.17, fold increase 2.61). There is also a general 
trend towards Leu and Ile in the positions surrounding the pGlu residue. 
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Figure 6.9 Enrichment analysis of pGlu proteins performed with DAVID a) proteins identified in NT siRNA condition b) proteins identified in PHPT1 siRNA 
condition, with enriched KEGG pathways shown in the table. P value indicated by colour: yellow P<0.05, blue P<0.01, green P<0.001 with asterisks defining 
clusters where the Benjamini adjusted P-value <0.1   
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Figure 6.10 Extracted motifs from pGlu peptide data a) Motifs from pGlu peptides in all 16 SAX fractions b) Motifs from pGlu peptides in SAX fractions 1-8 
(no motifs found for peptides in fractions 9-16). A higher score indicates a more significant/more specific motif. Fold increase compared to background of 
all sequences in the human proteome. Significance set at 1E-5 (not corrected for multiple hypotheses, corresponds to P value of 3E-4 with Bonferroni 
correction).
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6.3 Conclusions 
 
The original aim of this work was to develop phosphopeptide enrichment strategies for 
pHis analysis, but the unbiased SAX approach at non-acidic pH also lends itself to 
separation and characterisation of other acid-labile modifications. Additional MASCOT 
searches of this data revealed a vast number of previously unknown phosphorylation sites 
on Lys, Arg, Asp and Glu. The numbers of pLys, pArg, pAsp and pGlu peptides far exceed the 
number of pHis and pTyr peptides identified in these samples, meaning this unexplored 
area of the human phosphoproteome is perhaps more expansive than previously thought. 
 
Interestingly, pLys phosphorylation was found to be increased in PHPT1 siRNA samples 
compared to NT siRNA treated controls, which is in direct contrast to the trend observed 
for all other sites of phosphorylation. Increased levels of pLys upon PHPT1 knockdown 
suggests that the pLys phosphatase activity of PHPT1 that was previously only observed in 
vitro272, may also occur in vivo. The side chains of Lys and Arg are fully protonated at 
physiological pH (with pKa values of 10.4 and 12.3 respectively), resulting in these basic 
side chains carrying a net positive charge. The reversal of this charge upon addition of a 
negatively charged phosphate group will potentially enable switch-like functions, which 
may include regulation of catalytic outputs or protein binding activity.  
 
Lys and Arg residues are also known to undergo various other PTMs287, most notably 
methylation and acetylation, and phosphorylation of these residues may therefore provide 
a novel mechanism of competitive regulation. Given that Lys and Arg residues of histones 
are known to be phosphorylated6, 41, and indeed three pLys peptides and one pArg peptide 
derived from histones were identified in this analysis, the balance between these 
modifications may have significant implications for understanding combinatorial signalling 
and epigenetics. 
 
Glu and Asp residues possess a single negative charge at physiological pH, with side chain 
pKa values of 4.3 and 3.9 respectively. Addition of a phosphate group will result in a net 
negative charge >1 and a large hydrated ‘shell’ associated with the mixed anhydride 
structure. This marked increase in both the degree and directionality of the negative charge 
may have significant consequences for protein function, perhaps through induction of 
conformational changes to the protein structure. 
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Of particular interest in the pAsp data is the phosphorylation of PHPT1 on an Asp residue, 
with the same phosphopeptide identified in multiple samples. Further investigation of this 
pAsp site may reveal a possible mechanism by which the activity of PHPT1 is regulated. The 
phosphatase activity of PHPT1 has been reported to target both His and Lys, and indeed in 
this analysis the Lys phosphatase activity of PHPT1 seems particularly relevant.  Therefore, 
it is conceivable that pAsp phosphorylation of PHPT1 may regulate levels of both pLys and 
pHis in human cells, hinting at the possibility of interplay between these non-canonical 
phosphorylation sites in cellular signalling events. To assess this hypothesis, in the first 
instance recombinant PHPT1 with or without mutation of this Asp residue to a non-
phosphorylatable Asn, can be tested for pHis and pLys phosphatase activity in vitro.  
 
Excitingly, this work highlights the prevalence of phosphorylation on residues other than 
Ser, Thr and Tyr, with insights already being revealed about their possible biological roles in 
human cells. Until now pLys, pArg, pAsp and pGlu were largely viewed as catalytic 
intermediates, but they also appear to occur as dynamic, stable PTMs in human cells. There 
is now a pressing need for new biochemical tools, such as phosphospecific antibodies, to 
further investigate these sites and build a more comprehensive picture of how they may 
function as part of signalling networks in mammalian systems. 
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The work in this thesis describes the characterisation of pHis and other acid-labile 
phosphorylated residues, using a workflow which incorporates a novel method termed 
UPAX (Unbiased Phosphopeptide enrichment by strong Anion Exchange). Implementation 
of the UPAX method combined with a comprehensive data analysis strategy for the 
identification and confident localisation of sites of phosphorylation, has revealed the vast 
extent of this previously unexplored area of the human phosphoproteome. 
 
The first set of results presented in this thesis (Chapter 3. Results I) describes the 
assessment of various existing phosphopeptide enrichment techniques in terms of their 
suitability for recovery of phosphopeptides containing acid-labile pHis. A model protein, 
generated by chemical phosphorylation of myoglobin with potassium phosphoramidate, 
was digested with trypsin to yield five pHis-containing peptides. The stability of the pHis-
containing peptides was assessed across a range of pH values and at elevated temperature, 
with t1/2 defined under different conditions. At both pH 1 and 95 °C, t1/2 of two 
representative pHis peptides was only 15 minutes, whilst at pH 4 and pH 6 pHis peptides 
remained phosphorylated for at least 2 hours.  Given the acid-labile nature of pHis it was 
perhaps unsurprising that TiO2 based enrichment which utilised acidic binding conditions 
was unsuccessful for pHis peptide enrichment. However, even with less acidic or near 
neutral buffers, recovery of pHis peptides from TiO2 was still not achieved. The pH ~7 
conditions utilised for hydroxyapatite enrichment were theoretically the most promising of 
all the techniques trialled, yet none of the model pHis peptides were recovered by this 
method. Furthermore, significant binding of non-phosphorylated peptides to the 
hydroxyapatite material was observed which is detrimental to overall enrichment of 
phosphopeptides. In summary, none of the peptide based enrichment methods tested for 
this work that had previously been used for phosphopeptide enrichment enabled recovery 
of pHis peptides. 
 
In line with the most recent development in the field of pHis analysis, an 
immunoprecipitation method using 1- and 3-pHis monoclonal antibodies was utilised for 
protein level enrichment. Despite previously published work reporting selective enrichment 
of pHis proteins with the 1- and 3-pHis antibodies, neither that experiment or the one 
conducted for this work enabled detection of any pHis-containing peptides in the absence 
Chapter 7. Discussion and Future Perspectives 
176 
 
of further peptide-based enrichment. Without observation of the relevant pHis peptide it is 
not possible to confirm that a protein is indeed phosphorylated. Furthermore, knowledge 
of specific pHis sites within a protein may reveal insight into possible functions which will 
not be gained by identification only at the protein level. It will be interesting in the future 
to perform the immunoprecipitation enrichment at the peptide level, a method which has 
proven successful for pTyr peptide enrichment using pTyr antibodies166, or to combine the 
protein level enrichment with an additional peptide level enrichment step such as UPAX. It 
is likely that the reason pHis peptides are not detected following protein level 
immunoprecipitation is that digestion of these protein results in a complex mixture which 
contains a majority of non-phosphorylated peptides. Thus, an additional step to enrich 
and/or fractionate peptide samples may enable successful identification of pHis peptides 
by LC-MS/MS. 
 
Following on from the unsuccessful attempts to enrich pHis-containing peptides using 
existing phosphopeptide enrichment strategies, the second results chapter (Chapter 4. 
Results II) describes the development of an alternative approach for separation and 
characterisation of pHis peptides based on SAX fractionation. A salt gradient elution using 
triethylammonium phosphate at pH 6.8 enabled separation of model pHis peptides from 
their non-phosphorylated equivalents. Phosphopeptides are more strongly retained by SAX 
as a result of their increased net negative charge, therefore fractions later in the gradient 
are enriched for phosphopeptides. For a simple mixture of peptides enrichment in later 
fractions reaches 100%, whilst for a complex cell lysate the fractions latest in gradient 
contain up to 50% phosphopeptides, representing a significant enrichment of 
phosphopeptides compared to an un-fractionated sample. Most importantly, the recovery 
of pHis-containing peptides by this SAX fractionation method was shown to be comparable 
to the level of recovery for other phosphorylated and non-phosphorylated peptides. Thus, 
the suitability of the UPAX method for characterisation of acid-labile pHis-containing 
peptides, even from complex mixtures, was established. 
 
A key aspect of phosphopeptide characterisation is the confident localisation of the 
phosphate group to a specific site within the peptide sequence. Therefore, before 
embarking on further analysis of cell lysate samples this part of the data analysis pipeline 
was carefully considered. As detailed in Chapter 5. Results III, a potential diagnostic tool for 
confirming phosphorylation of His residues based on observation of characteristic neutral 
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loss ions in tandem MS spectra was evaluated. Essentially, the strategy proposed that 
triplet neutral loss of 80, 98 and 116 Da is characteristic of a pHis residue and thus could be 
used to confirm that a peptide is phosphorylated on His as opposed to another amino acid. 
However, the triplet neutral loss pattern was not consistently observed for peptides with 
confidently assigned pHis sites according to the ptmRS site localisation tool and/or manual 
annotation of spectra. Additionally, many phosphopeptides modified on other residues 
(Ser, Thr, Tyr) exhibited the triplet neutral loss, whilst an even greater number of 
phosphopeptide spectra did not contain any neutral loss ions following HCD fragmentation. 
Under the MS/MS conditions employed in these experiments, the triplet neutral loss 
strategy did not appear to be diagnostic for pHis peptides, and thus was not implemented 
for further data analysis. 
 
The culmination of the method development was application of the UPAX strategy to HeLa 
cell lysate following treatment with PHPT1 siRNA or NT siRNA, and the subsequent 
identification of pHis and other acid-labile phosphorylation sites (pLys, pArg, pAsp and 
pGlu) from human cells (Chapter 5. Results III and Chapter 6. Results IV). PHPT1 is a known 
histidine phosphatase and therefore it was hypothesised that a global increase in pHis 
levels would be observed following treatment of HeLa cells with PHPT1 siRNA. Contrary to 
this expectation, the number of phosphopeptides identified with each site of 
phosphorylation was increased in the NT siRNA treated samples compared to those treated 
with PHPT1 siRNA, with the exception of pLys-containing peptides. The increased level of 
pLys in PHPT1 siRNA treated cells aligns with the previously reported in vitro phosphatase 
activity of PHPT1 towards pLys272, indicating that this Lys phosphatase activity may also be 
relevant in vivo. Additionally, the number of pLys, pArg, pAsp and pGlu sites identified 
across the two conditions far exceeds the number of pHis and pTyr sites identified in these 
samples, suggesting that this unexplored area of the phosphoproteome is far more 
extensive than previously understood.  
 
One of the most exciting insights to be revealed by the results generated in this thesis is the 
phosphorylation of a conserved His residue within the catalytic domain of eukaryotic 
protein kinases. The relevant pHis site was observed in a number of peptides isolated from 
three different kinases, and was subsequently shown to map to a His residue conserved in 
65% of eukaryotic protein kinases. The location of the HxN motif within the αC-β4 loop, 
which is implicated in positing of the αC-helix and thus catalytic activity, suggests 
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phosphorylation of the conserved His residue could serve as a general mechanism for 
kinase regulation, with results of MD simulations using the catalytic domain of PLK2 as a 
model system supporting this hypothesis. MD simulations suggest that addition of the 3-
pHis isomer to His139 (the residue which maps to the HxN-His position) of PLK2 has a more 
pronounced effect than the 1-pHis isomer on structural changes within the activation 
segment, so a logical next step would be to determine which pHis isomer is present in 
PLK2. Fortunately, the availability of isomer specific monoclonal antibodies makes this 
feasible. PLK2 could be purified from cell extracts by immunoprecipitation with PLK2 
antibodies, and subsequently immunoblotted with the 1- and 3-pHis antibodies, with the 
expectation that histidine phosphorylated PLK2 would only be detected by the antibody 
specific to either 1- or 3-pHis. Loss of immunoreactivity upon heat treatment will validate 
the presence of histidine phosphorylation, as opposed to phosphorylation of a heat stable 
residue or other non-specific binding of the antibody.  
 
Further investigations into the consequences of phosphorylation of the H139 site in PLK2 
may focus on mutation of the His reside to a residue that cannot be phosphorylated and 
does not carry a net charge, for example alanine. Comparison of the in vitro kinase activity 
of recombinantly expressed PLK2 and a H139A mutant, for example by radioactive kinase 
assay with [32P]ATP and a known PLK2 substrate, may reveal how this pHis site is implicated 
in the catalytic activity of PLK2. Given the proposed destabilising effect of phosphorylation 
at the H139 site upon the αC-helix region, it might be expected that phosphorylation of the 
His residue will reduce (or perhaps completely abolish) kinase activity. Such studies using 
PLK2 as a model kinase will enable inferences to be made regarding a general mechanism 
of kinase regulation which is potentially relevant to the significant proportion of eukaryotic 
protein kinases containing this conserved His residue.  
 
Given that PHPT1 is known to act as a histidine phosphatase, with activity demonstrated 
against ATP citrate lyase and the K+ channels KCa3.1 and TRPV529-31, it was somewhat 
surprising that the expected reduction in pHis peptides upon treatment of HeLa cells with 
PHPT1 siRNA was not observed. It would therefore be interesting to understand which 
proteins, if any, of the ones identified in this work are direct targets for dephosphorylation 
by PHPT1. The difference in pHis peptide identifications between both conditions was quite 
pronounced, with a large portion of identifications unique to each one of the conditions, 
making identification of potential substrates of PHPT1 somewhat challenging based on this 
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data alone. Setting criteria to narrow down confidently identified pHis proteins from the 
PHPT1 siRNA treated samples, based on MASCOT and ptmRS scores for the pHis peptide, 
identification of other peptides from the protein, and observation across more than one 
bioreplicate, would be a good place to start in identifying potential substrates.  To start to 
test for PHPT1 activity in vitro, phosphatase assays using recombinant PHPT1 against 
suspected protein substrates could be performed. Probing these samples with 1- and 3-
pHis antibodies before and after treatment with PHPT1 would enable changes in histidine 
phosphorylation to be detected, thus identifying which substrates can be targeted for 
dephosphorylation by PHPT1.  
 
PHPT1 has also been reported to act as a pLys phosphatase in vitro, and the increase in 
pLys peptides observed in this analysis upon treatment of HeLa cells with PHPT1 siRNA 
compared to NT siRNA, suggests that this activity may also be relevant in vivo. However, 
gaining insight into the pLys phosphatase activity of PHPT1 will be more challenging as 
there are no pLys antibodies, analogous to the monoclonal 1- and 3-pHis antibodies, 
currently reported. Understanding PHPT1 activity is further complicated by identification of 
a novel pAsp residue on PHPT1, which was observed across bioreplicates and has been 
confidently assigned by ptmRS score and manual annotation of tandem mass spectra. 
Unravelling how phosphorylation of both His and Lys may be regulated by pAsp presents an 
interesting direction for further study. The lack of appropriate biochemical tools to validate 
and further study non-canonical sites of phosphorylation may however be a significant 
impediment to the progression of this field of research. Although perhaps the 
unprecedented number of non-canonical phosphosites revealed by this work to be present 
in human cells will expedite development of new analytical strategies which will enable 
investigation of their roles in mammalian systems. 
 
Alongside the potential development of new analytical approaches, increased certainty 
regarding the characterisation by LC-MS/MS of non-canonical sites of phosphorylation in 
human cells could be obtained by generation of high-resolution MS2 data, using the 
Orbitrap for mass analysis. The MS/MS method used for this work performed MS1 analysis 
in the Orbitrap and MS2 in the ion trap, with the rationale that the increased speed of MS2 
ion trap analysis compared to the Orbitrap would result in more MS2 events and therefore 
more comprehensive coverage of peptides in the sample. This parallelization of MS1 and 
MS2 analysis has been reported to give the highest number of phosphopeptide 
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identifications, compared to methods which use the Orbitrap for both stages of MS 
analysis. However, in the same benchmarking study which was undertaken by someone 
else in the group while this data was being generated, optimal phosphosite localisation was 
achieved with Orbitrap MS2 analysis, with high mass accuracy increasing confidence in 
phosphopeptide identification and localisation compared to low resolution ion trap MS2 
measurements200. Therefore, high resolution data generated by analysis of these samples 
using an Orbitrap for both MS1 and MS2 would increase the confidence associated with the 
assigned phosphosites, which is especially important when so many novel sites have been 
reported.  Unfortunately, the samples generated for these experiments could not be re-
analysed using an alternative LC-MS/MS method due to time limitations and problems of 
phosphopeptide instability upon even short-term storage. To enable further LC-MS/MS 
analysis repeat sample preparation would be required, including cell lysis, SAX fractionation 
and desalting. Based on the benchmarking study, high-resolution MS2 analysis would 
undoubtedly be a clear improvement to the analytical strategy presented in this thesis, 
should it be applied to future studies concerned with characterisation of the ‘complete’ 
phosphoproteome. 
 
The data analysis pipeline used in this work to identify sites of non-canonical 
phosphorylation is arguably not the optimal approach. Searching each site of non-canonical 
phosphorylation separately does not take into account that some peptides may be 
phosphorylated on more than one of these non-canonical sites, and when considering only 
a single non-canonical pX at any one time there is potential for incorrect site assignment. It 
was observed that ~20% of all peptide spectrum matches (PSMs) containing non-canonical 
phosphorylation across all searches were derived from the same MS/MS scan, with a 
different pX site assigned as the site of phosphorylation at 1% FLR for the same peptide 
sequence. It is likely that the site of phosphorylation is incorrectly assigned in these 
peptides as the correct pX site was not offered as a potential site of modification. In the 
majority of cases where the site was differentially localised in different searches the 
possible sites of phosphorylation were within a few residues (<3) of each other within the 
peptide sequence, indicating that there are perhaps insufficient site-determining product 
ions to unambiguously localise the phosphosite. 
 
A possible strategy to address the problem of the same MS/MS scans corresponding to 
different pX site assignments in different searches may be to extract these scans from the 
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data file and re-search them in MASCOT and ptmRS with all pX modifications considered, 
thus allowing the localisation algorithm to consider more than one non-canonical 
phosphorylation site for these peptides. The primary reason for not searching all of the 
data with all possible pX modifications is that by specifying many variable modifications for 
a MASCOT search, multiple versions of each peptide are created in the database, thus 
causing an exponential growth of the search space. Hence, not only is the run time of the 
search increased, but critically, the false discovery rate associated with the results alters 
dramatically. One potential way to include all pX modifications without drastically 
increasing the search space would be to reduce the protein database size. For example, an 
initial search of the data with just S, T and Y phosphorylation could be performed with 
proteins identified in this first search filtered at a stringent 1% protein FDR. The set of 
proteins that are confidently identified as being present in the sample would be much 
smaller than the entire UniProt database and thus would provide the database against 
which the data could be re-searched with all possible pX modifications included. The 
second search would produce a list of peptides for which all pX sites had been considered, 
for proteins that are most likely to be present in the sample, and thus a confident list of pX-
containing peptides and proteins could be obtained. 
 
There are also a number of software tools available for searching for many variable 
modifications, such as InsPecT288, ModifiComb289, and PeaksPTM290, which perform 
unbiased PTM searches by a variety of different methods. These tools will search for 
multiple, undefined modifications, for example PeaksPTM searches the data with all 
modifications in the Uniprot database, not just the eight phosphosites of interest to this 
work. Although preliminary searching was attempted with PeaksPTM, it struggled to handle 
the mixed mode fragmentation workflow employed in these studies and total numbers of 
identified peptides (irrespective of phosphorylation) were low. Furthermore, site 
localisation confidence for the identified phosphosites is extremely important, meaning 
incorporation of results from unbiased searches into ptmRS would also require 
investigation. Attempting to implement alternative tools for PTM searching into the 
workflow for characterisation of non-canonical sites of phosphorylation would be a key 
step in the development of the data analysis pipeline for future applications. Indeed, there 
may be a requirement to develop new search strategies to assess the increased level of 
complexity within phosphoproteomics data afforded by the presence of so many possible 
sites of phosphorylation. 
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The combined UPAX, LC-MS/MS and data analysis strategy presented in this thesis has 
revealed widespread phosphorylation on a diverse range of amino acid residues other than 
Ser, Thr and Tyr in human systems. It appears that as well as the reported roles of these 
non-canonical phosphorylated residues as catalytic intermediates, they may also function 
as reversibly regulated PTMs in cellular signalling pathways. Further understanding of the 
possible roles of these non-canonical phosphorylation sites in cellular signalling will require 
the kinases and phosphatases responsible for their modulation to be ascertained, which is 
a considerable biochemical challenge. The regulation of these phosphosites as part of 
complex signalling networks may also be understood by revealing common protein 
domains on which these sites are observed. Molecular biology and chemical genetics 
strategies will further aid in elucidation of the mechanisms by which these phosphosites 
are implicated in cellular functions, whilst evaluation of non-canonical phosphorylation in 
the context of the cell cycle, ageing, disease models and drug treatments will all contribute 
to the understanding of the roles of these phosphorylated residues in global cell biology. 
Furthermore, the strategy presented in this thesis will also be applicable to analysis of non-
canonical phosphorylation in other systems, perhaps enabling large-scale characterisation 
of these sites in bacteria, plants and other eukaryotes, which are already known to use 
pHis, pAsp and pArg for signal transduction11, 12, 16, 234. The relative ease with which the 
UPAX strategy alongside LC-MS/MS analysis can be utilised for characterisation of these 
non-canonical phosphorylation sites in a complex mixture will undoubtedly be instrumental 
in enabling their extent and functional relevance in a wide variety of biological systems to 
be revealed, thus facilitating significant changes in the way we currently understand 
phosphorylation-mediated signalling. 
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The following excel files/tables are provided in electronic format: 
 
Table 9.1 Protein IDs shared with Fuhs et al. 
Proteins identified by LC-MS/MS following immunoprecipitation (IP) with 1- and 3-pHis 
antibodies (2 or more peptides required for protein ID), that were previously identified by a 
similar IP experiment. Proteins from the Fuhs et al. list were filtered to only include those 
which showed a greater than 2-fold difference compared to the control. 317 (28%) and 295 
(24%) proteins were shared between this analysis and the previously published data for the 
1- and 3-pHis IP experiments respectively. 
 
Table 9.2 pHis_1% FLR  
Table 9.3 pLys_1% FLR 
Table 9.4 pArg_1% FLR 
Table 9.5 pAsp_1% FLR 
Table 9.6 pGlu_1% FLR 
List of pX peptides/proteins identified in each of the two conditions (PHPT1 siRNA and NT 
siRNA). Where a peptide was identified more than once the highest scoring instance is 
shown, with a column to indicate those peptides with more than one observation. The ‘pX 
site’ column indicates the site(s) that are above the 1% FLR score cut-off, with all other 
phosphosites (below the score cut-off and/or not the residue of interest) shown in a 
separate column. For pHis peptides, the triplet score is shown. 
 
Table 9.7 DAVID_pHis 
Table 9.8 DAVID_pLys 
Table 9.9 DAVID_pArg 
Table 9.10 DAVID_pAsp 
Table 9.11 DAVID_pGlu 
Output from functional annotation clustering using DAVID (version 6.8). List of pX proteins 
identified in each condition (NT siRNA and PHPT1 siRNA) compared to background of all 
proteins identified by analysis of these samples. Classification stringency: medium; 
similarity term overlap: 3; initial/final group membership: 3; EASE: 1.0 
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Figure 9.1 Percentage of unique phosphorylated and non-phosphorylated peptides in 
each fraction following SAX fractionation of HeLa lysate at pH 6.8, for all six bioreplicates 
a) PHPT1 siRNA biorep 1, b) PHPT1 siRNA biorep 2, c) PHPT1 siRNA biorep 3, d) NT siRNA 
biorep 1 (also shown in main part of thesis: Chapter 5. Results III, Figure 5.4), e) NT siRNA 
biorep 2 and f) NT siRNA biorep  
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Figure 9.2 Example tandem MS spectra for each site of phosphorylation, following either 
HCD or EThcD fragmentation. a) pLys peptide: RLpSSASTGpKPPLSVEDDFEK, m/z 775.01, 
EThcD, ptmRS scores S3: 99.1, K9: 96.37; b) pLys peptide: ADpKEAAFDDAVEER, m/z 823.33, 
HCD, ptmRS score K3: 100; c) pArg peptide: TTpRTPEEGGYSYDISEK, m/z 671.62, HCD, 
ptmRS score R3: 99.93; d) pArg peptide: KPIDSLRDpSpRSLpSYSPVER, m/z 815.69, EThcD, 
ptmRS scores S9: 100, R10: 99.44, S13: 84.84; e) pAsp peptide: IYHLPpDAESDEDEDFKEQTR, 
m/z 839.69, EThcD, ptmRS score D6: 99.87; f) pAsp peptide: VVPGQFDDApDSSDSENR, m/z 
959.37, HCD, ptmRS score D10: 99.66; g) pGlu peptide: KIKNENTEGSPQpEDGVELEGLK, m/z 
832.06, EThcD, ptmRS score E13: 97.93; h) pGlu peptide: QDKPMDTSVLSpEEGGEPFQK, m/z 
768.00, HCD, ptmRS score E12: 99.37. Phosphorylated residue(s) are underlined. 
 
